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Abstract 
Breast cancer is the most common malignancy affecting women worldwide with an average 
lifetime risk of 12%. Risk is affected by age, family history, genetics, reproductive factors and 
environmental exposures, however many unknown risk factors may exist. Regular 
screening, lifestyle advice and preventative therapy may be offered to women at highest risk; 
however in the absence of high-penetrance mutations, personal breast cancer risk cannot be 
accurately estimated. Risk biomarkers are therefore required to help improve current risk 
prediction models. Epigenetic mechanisms control gene expression and genome function, 
and are influenced by both heritable and environmental factors. DNA methylation, the most 
widely studied epigenetic mark, is widely deregulated in cancer and cancer precursor 
lesions; however the contribution to disease risk of DNA methylation variability in normal 
tissue prior to disease is poorly understood. Several blood DNA methylation markers 
associated with cancer have been reported, including genome-wide hypomethylation and 
hypermethylation of the ATM gene associated with breast cancer, however, validation of 
these associations in samples collected prior to diagnosis (prospectively collected) are 
required to determine association with breast cancer risk.  
The aims of this thesis were to 1) validate ATM methylation as a breast cancer risk marker in 
three nested case-control studies from prospective cohorts; 2) To investigate 
hypomethylation of LINE1 in the same prospective cohorts and compare this in a meta-
analysis with all other published LINE1 data; 3) To investigate potential mechanisms or 
modifiers of ATM methylation; 4) To perform discovery microarray studies to identify novel 
DNA methylation markers of breast cancer risk. Herein, we show that ATM hypermethylation 
showed a 1.9 fold increased risk of breast cancer limited to women in the highest quintile of 
methylation (OR =1.89 (1.36-2.64), p= 1.64x10-4). There was no evidence of LINE1 
methylation associated with cancer risk in the prospective cohort studies. The meta-analysis 
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of LINE1 and other global methylation markers showed little evidence of association with 
cancer risk for surrogate assays of repetitive elements, but relatively consistent association 
with cancer risk using HPLC based total methyl-cytosine levels. Investigation of potential 
modifiers of ATM methylation revealed that methylation was independent of genetic 
haplotype, but independently associated with age, genotype of the one-carbon metabolism 
enzyme MTHFR, and serum levels of serum kynurenic acid levels in controls (p=0.02). 
Surprisingly, ATM methylation was reduced in controls (p= 5.707e-06) and cases (p= 0.008) 
that had fasted compared to those that had not. The effect of fasting on ATM methylation 
could be recapitulated by glucose restriction in ex-vivo PBMCs (p=0.046), independent of 
cell proliferation. Discovery studies to identify novel DNA methylation risk markers were 
conducted using differential methylation hybridisation and Illumina Infinium 
HumanMethylayion450 BeadChip microarrays; however, significant associations were not 
reproducible in validation sample sets. Discussed are prospects and caveats for epigenetics 
association studies, including the implications of temporal alteration of DNA methylation by 
environmental exposures, biases associated with genetic influences on DNA methylation, 
and the potential for investigation of these interactions to better understand the contribution 
of epigenetics to gene expression and cancer risk.  
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Chapter 1 
 
GENERAL INTRODUCTION  
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1.1 Breast Cancer 
Breast cancer is the most common malignancy affecting women worldwide with an average 
lifetime risk of 12% (Amir et al., 2010; McPherson et al., 2000). Incidence is highest in 
western countries and is increasing worldwide, especially in developing countries, and is 
predicted to increase in the coming decades (Cuzick et al., 2011). However, mortality rates 
have decreased substantially in recent years, due to earlier diagnosis and improved 
treatment (Collins and Politopoulos, 2011; Colston, 2008; Cuzick et al., 2011; Umar et al., 
2012). Most breast cancers are initially responsive to treatment, however 20-30% of breast 
cancer patients eventually develop incurable metastatic diseases (Eroles et al., 2012).  
Breast cancers are mainly classified based on expression of the estrogen receptor (ER), as  
ER+ and ER- breast cancers are considered distinct diseases with different etiologies, gene 
expression signatures and prognosis (Keller et al., 2012), and may have different risk factors 
(Tamimi et al., 2012). Further treatment stratification is based on expression of the 
progesterone receptor (PR) and amplification of the epidermal growth factor receptor 2 
(HER2) gene (Dawson et al., 2013). Breast cancers may also be classified by histological 
features, mutation profiles and mRNA expression profiles, and a recent classification based 
on genomic and gene expression data identified ten reproducible subtypes with distinct 
pathological features (Curtis et al., 2012). 
Ductal carcinomas make up ~80% of breast cancers (Keller et al., 2012), and the majority 
are thought to derive from luminal epithelial cells, though rare breast cancer subtypes may 
derive from basal cells (Keller et al., 2012). 
Common features of breast cancer include impaired DNA damage repair (DDR) resulting in 
genomic instability, mutations and chromosome rearrangements (Eroles et al., 2012; 
O'Donovan and Livingston, 2010), angiogenesis (Vona-Davis and Rose, 2009), and up-
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regulation of signalling pathways that promote cellular growth and proliferation, including the 
RAS/RAF/MAPK, JAK/STAT or PI3K/AKT/mTOR pathways (Eroles et al., 2012).  
 
1.1.1 Breast cancer risk 
Breast cancer mortality and disease burden are reduced with diagnosis at earlier disease 
stage (Nickson et al., 2012). Frequent breast cancer screening with magnetic resonance 
imaging (MRI) is offered to women at known high risk including women carrying mutations in 
the BRCA1 and BRCA2 breast cancer susceptibility genes, and women with a personal 
history or strong family history of cancer (Pashayan and Pharoah, 2012). Less sensitive 
mammographic screening is offered less frequently to women over 50 who are not known to 
be at high risk (Autier et al., 2010). Whereas Individual studies and meta-analysis reveal that 
mammographic breast screening is associated with decreased mortality from breast cancer 
(2012; Nickson et al., 2012), the current screening approach is limited by our current inability 
to accurately predict breast cancer risk.  
Breast cancer is considered one of the most preventable cancers, and a significant 
proportion of breast cancers could be prevented though weight loss, physical exercise and 
chemoprevention (Colditz and Wei, 2012), therefore, lifestyle advice and preventative 
therapy may be offered to women at known high risk (Colditz and Wei, 2012; Cuzick et al., 
2011; Umar et al., 2012). Preventative chemotherapy may benefit women at highest risk, as 
epidemiological studies  and assessment of breast cancer relapse prevention has identified 
several potential chemopreventative agents including anti-estrogens such as Tamoxifen and 
Raloxifene, and Aromatase inhibitors for ER+ disease, and bisphonates, metformin, statins 
and anti-inflammatory drugs such as aspirin for all breast cancer prevention (Cuzick et al., 
2011). Conversely, as regular mammographic screening is thought to also result in over-
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diagnosis (2012), the current screening measures may be reduced for some women at low 
disease risk (2012).  
Several breast cancer risk prediction models have been developed to predict breast cancer 
incidence (reviewed in (Evans and Howell, 2007) and (Amir et al., 2010). The current models 
predict cancer risk based on age, family history, reproductive factors and genetic data.  Such 
models are useful for predicting likelihood of having a breast cancer susceptibility mutation 
based on family history, and are used for selection of candidates for genetic screening for 
BRCA1/BRCA2 genetic screening (Parmigiani et al., 2007). The most accurate risk models, 
such as the Cuzick-Tyrer model, incorporate multiple risk factors, including genetics and 
non-genetic factors such as parity, and may be improved by incorporating additional genetic 
loci and breast density (Amir et al., 2010). However, many non-genetic factors such as body 
mass index, alcohol consumption and circulating hormone levels are not included. 
Furthermore, the current models have very limited ability to predict individual risk in the 
absence of high penetrance mutations or strong family history of cancer (Parmigiani et al., 
2007). Given that most breast cancers are sporadic, novel breast cancer risk markers are 
required to improve risk model performance for the general population (Cuzick et al., 2011; 
Prado et al., 2010). 
 
1.1.2 Breast cancer genetics 
Breast cancer displays familial clustering, and having relatives with early onset breast cancer 
is a strong risk factor for disease. Ethnicity also affects breast cancer risk in a subtype-
specific manner, independent of geographic location and socioeconomic factors (Carey et 
al., 2006). These factors are indicative of a strong genetic component to disease risk 
(Mavaddat et al., 2010). However, only 5-10% of breast cancers are associated with high-
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penetrance mutations in one of the known BRCA1 and BRCA2 breast cancer susceptibility 
genes (Armes et al., 1997; Collins and Politopoulos, 2011; Stadler et al., 2010), and many 
families displaying familial clustering of breast cancer lack known susceptibility mutations. 
Furthermore, linkage studies suggest that no more high-penetrance breast cancer 
susceptibility genes are likely to exist (Smith et al., 2006). It has been estimated that 20-25% 
of familial breast cancer risk is accounted for by mutations in breast cancer susceptibility 
genes (Mavaddat et al., 2010). These include mutations in TP53, PTEN and STK11, 
associated with the familial breast cancer susceptibility syndromes Li Fraumeni syndrome, 
Cowden syndrome and Peutz-Jegher syndrome respectively (Mavaddat et al., 2010). 
Germline mutations in E-cadherin (CDH1) are associated with susceptibility to breast, gastric 
and colorectal cancers (Pharoah et al., 2001). Moderate-penetrance mutations occur in the 
CHEK2, ATM, BRIP1 and PALB2 genes, and are associated with roughly 2-fold greater 
breast cancer incidence (Easton et al., 2007; van der Groep et al., 2011).  
Whereas mutations in known susceptibility genes are important risk factors for affected 
families, they are rare, explain only a minor proportion of breast cancer heritability, and offer 
little risk prediction value for the general population (Mavaddat et al., 2010; Salhab et al., 
2010). Genome-wide association studies (GWAS) studies have attempted to identify 
additional loci associated with breast cancer risk. ~68  low penetrance (OR 1.1-1.3) 
significant loci have been found to date, bringing up to ~30%, the percentage of breast 
cancer heritability explained by all genetic loci identified so far (Michailidou et al., 2013; 
Southey et al., 2013). 
GWAS studies support the theory that common complex diseases such as sporadic breast 
cancer are ‘polygenic’ in nature; are caused by multiple common risk factors rather than 
single rare lesions (Pharoah et al., 2002). The low penetrance of GWAS SNPs limits their 
suitability as biomarkers (Manolio et al., 2009; Politopoulos et al., 2011), however, combining 
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multiple SNPs into risk prediction models may help to improve model performance (Dite et 
al., 2013). This also presents a paradigm for including other information, such as epigenetic 
markers, into these prediction models. 
 
1.1.3 Other breast cancer risk factors 
Many well-established breast cancer risk factors, in addition to known genetic loci, exist. Age 
is the strongest breast cancer risk factor, with doubling of risk with every decade until 
menopause, after which risk increases more gradually with age (McPherson et al., 2000). 
Age may contribute to cancer risk through increased rate or accumulation of somatic 
mutations, or through association with other risk factors such as menopausal status and 
obesity. Having a prior personal history of benign breast disease is associated with 
increased breast cancer risk (Hartmann et al., 2005). Anthropometric measures such as size 
at birth (Lof et al., 2007), stature (Kabat et al., 2013), body mass index (Cheraghi et al., 
2012) and breast density (Boyd et al., 2007) are all associated with breast cancer risk. 
While, anthropometric factors have both genetic and environmental underpinnings, the role 
of these factors in cancer risk is poorly understood (Kabat et al., 2013). 
Levels of circulating sex hormones are associated with increased breast cancer risk in 
postmenopausal (Key et al., 2003) and premenopausal women (2013). Reproductive factors 
which modulate endogenous estrogen levels, including parity, age at menarche, age at first 
birth, age at menopause, and breast-feeding (He et al., 2012; Li et al., 2003), all affect breast 
cancer risk. Exposures to exogenous estrogens (Li et al., 2003), including oral 
contraceptives, hormone replacement therapy, and in utero exposure to synthetic estrogens 
also increase breast cancer risk (Parkin, 2011; Yager and Davidson, 2006).  
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Other lifestyle-associated breast cancer risk factors include alcohol consumption (Key et al., 
2006), physical exercise (Lynch et al., 2011), smoking (Luo et al., 2011), night-shift work 
(Megdal et al., 2005) and socioeconomic status (Webster et al., 2008). Many lifestyle risk 
factors for breast cancer relate to diet and metabolism (Thomson, 2012). Levels of glucose 
(Sieri et al., 2012), folate (Maruti et al., 2009) and vitamin D (Colston, 2008) have been 
reported to be associated with breast cancer risk.  
Lastly, interactions between genetic and environmental breast cancer risk factors may be 
frequent, as a recent consortium effort has successfully identified two examples, including an 
interaction between LSP1-rs3817198 and parity and CASP8-rs17468277 and alcohol 
consumption (Nickels et al., 2013), and risk associated with dietary factors may be modified 
by genetic variability in genes encoding enzymes in metabolism (Kaklamani et al., 2011; Liu 
et al., 2013).  
Less well studied to date is the possibility that epigenetic factors contribute to cancer 
susceptibility, whether as an innate epigenetic variability between individuals, akin to SNPs, 
or as a mediator of other genetic, environmental or lifestyle factors. 
 
1.2 Epigenetics 
Epigenetics refers to the cellular mechanisms that control gene expression and genome 
function independent of alterations in genome sequence (Feinberg and Tycko, 2004; 
Richards, 2006), and accounts for the phenotypic variability between genetically identical cell 
types that is introduced through cellular differentiation (Goldberg et al., 2007).  
Within the nucleus of mammalian cells, DNA is wrapped around octamers of histone proteins 
to form nucleosomes, the building blocks of chromatin. Gene expression is regulated by 
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chromatin structure, where open euchromatin is associated with gene transcription and 
access to gene regulatory elements of transcription factors and DNA binding factors, 
whereas dense heterochromatin is associated with gene repression (Hon et al., 2009). 
Chromatin structure and gene expression are regulated in part through changes in 
nucleosome occupancy (Struhl and Segal, 2013), incorporation of histone variants (Ooi et 
al., 2009), and post-translational modifications of N-terminal histone tails, including histone 
acetylation, methylation, phosphorylation, ubiquitylation, sumoylation and ribosylation 
(Kouzarides, 2007). Complex chromatin signatures are associated with gene expression 
across the genome, for example, active gene promoters are characterised by enrichment of 
histone 3 lysine 4 trimethylation (H3K4me3) whereas histone 3 lysine 27 trimethylation 
(H3K27me3) is enriched at inactive gene promoters (Hon et al., 2009). Histone modifications 
are catalysed by enzymes such as histone methyltransferases (HMTs) and histone 
acetlytransferases (HATs), and removed by enzymes such as histone demethylase(HDMs) 
and histone-deacetylases (HDACs).  
MicroRNAs (miRNA) are short RNA molecules that bind to messenger RNA molecules and 
regulate their stability and translation, and are an example of post-transcriptional epigenetic 
regulation of gene expression. (Baylin and Jones, 2011; You and Jones, 2012). Many other 
types on non-coding RNA regulate gene expression, including long intergenic non-coding 
RNAS (lincRNAs), that are implicated in regulation of chromatin structure, PIWI-interacting 
RNAs (piRNAs) that regulate transposable element transcripts, and small nucleolar RNAs 
(snoRNAs) that regulate ribosomal RNA function (Esteller, 2011). 
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1.2.1 DNA methylation 
DNA methylation is the addition of a methyl group to cytosine nucleotides at the 5-carbon 
position of the cytosine pyrimidine ring to form 5-methylcytosine (5meC), occurring primarily 
at cytosines within CpG dinucleotides in mammals (Chiacchiera et al., 2013).  
Among epigenetic marks, DNA methylation is the most frequently studied and well 
understood, largely due to its stability and the ability to measure methylation quantitatively 
and at  high resolution using PCR-based techniques, enabling methylation analysis of stored 
DNA and tissue samples (Rakyan et al., 2011; Robertson, 2005). Whereas DNA methylation 
is frequently studied in isolation, DNA methylation and chromatin modifications function 
cooperatively to regulate transcriptional regulation (Cameron et al., 1999; Jones, 2012; Nan 
et al., 1998), and emerging evidence suggests that DNA methylation patterns are 
determined by pre-existing chromatin marks (Ooi et al., 2009; Ooi et al., 2007).  
CpG dinucleotides occur at just 25% of their expected frequency within the human genome, 
due to high propensity for spontaneous deamination to thymine of methylated CpG site 
(Deaton and Bird, 2011; You and Jones, 2012). CpG sites are depleted at intergenic regions, 
and concentrated at CpG islands, regions of high CpG density found at the 5’-regions of 
~60% of human genes (Deaton and Bird, 2011). CpG islands are usually protected from 
DNA methylation by an unknown mechanism, therefore, only ~2% of human DNA 
methylation occurs at CpG islands compared with 34% found at gene bodies (Maunakea et 
al., 2010).  
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1.2.1.1 Establishment and loss of DNA methylation 
DNA methylation is catalysed by the DNA methyltransferase (DNMT) enzymes, of which 
there are five in mammals (Jurkowska et al., 2011). DNMT3a and DNMT3b, the ‘de novo’ 
DNMTs, have high affinity for unmethylated DNA, and are responsible for establishing the 
first patterns of DNA methylation during early development (Jurkowska et al., 2011). DNMT1 
has highest affinity for hemi-methylated (methylated on one DNA strand) DNA, and is 
described as the ‘maintenance’ DNA methyltransferase responsible for methylation of newly 
synthesised daughter DNA strands following DNA replication (Song et al., 2012). However, 
there is overlap between the roles of DNMT1 and de novo DNA methyltransferases (Ooi et 
al., 2009). The function of DNMT2 is poorly understood, however it appears to methylate 
tRNA rather than DNA (Goll et al., 2006).  DNMT3L is required for regulation of de novo 
methylation of maternally imprinted regions during oocyte development (Bourc'his et al., 
2001).  
DNA methylation is erased and re-established within the mammalian germline, and within 
the preimplantation embryo, allowing epigenetic reprogramming within each generation 
(Chen et al., 2003). There is some evidence suggesting that some epigenetic patterns can 
escape erasure during reprogramming and undergo transgenerational inheritance (de Assis 
et al., 2012; Hitchins et al., 2007a), however, this idea remains controversial (Chong et al., 
2007; Daxinger and Whitelaw, 2012). 
Relatively little is known about the mechanism by which DNA methylation is removed. 
Demethylation may simply occur passively, through the failure or prevention of maintenance 
DNA methylation during mitosis. Active demethylation, independent of cell division, occurs 
rapidly across the entire paternal genome paternal genome during embryonic 
preimplantation, and is thought to occur though oxidation of 5meC to 5-
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hydroxymethylcytosine (5hmC) by the ten-eleven-translocase (TET) enzymes followed by a 
base-excision repair mechanism (Bhutani et al., 2011; Chiacchiera et al., 2013). 
 
1.2.1.2 Function of DNA methylation 
The complete function of DNA methylation across the genome remains unclear, with 
different functions ascribed to different genomic contexts. DNA methylation at gene 
promoters is well established as having a transcriptionally repressive role (Appanah et al., 
2007; Jones, 2012). DNA methylation is indispensable for genomic imprinting, the 
phenomenon by which gene expression occurs on either the paternal or maternal allele, 
whilst the other allele is epigenetically silenced (Ferguson-Smith, 2011). Silencing of the 
inactive X chromosome in female mammals is associated with antisense RNA-induced DNA 
hypermethylation and heterochromatin formation (Wutz, 2011). Promoter hypermethylation 
plays a role in cellular differentiation, and is required for silencing of developmentally 
expressed genes in adult tissues, and genes that display tissue-specific expression (Pujadas 
and Feinberg, 2012). Curiously, intragenic DNA methylation appears to be associated with 
increased transcriptional activity, especially at intragenic CpG islands (Deaton et al., 2011; 
Maunakea et al., 2010). Recent research has implicated DNA methylation in alternative 
splicing, as DNA methylation is enriched at genes that undergo alternative splicing (Flores et 
al., 2012; Maunakea et al., 2013; Wan et al., 2013). Lastly, transposable elements are 
usually heavily methylated, consistent with an evolutionary role of DNA methylation in 
preventing transcription of endogenous parasitic DNA and maintaining genomic stability 
(Cordaux and Batzer, 2009; Ito et al., 2011; Munoz-Lopez et al., 2011). 
Also elusive is the mechanism by which DNA methylation induces transcriptional change. 
Methylation of some transcription factor binding sites, such as the MYC binding site, directly 
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prevents binding (Jones, 2012; Prendergast and Ziff, 1991). Recruitment of methyl-CpG 
binding domain proteins MBD1, MBD2, MBD4 and MECP2 may also contribute to 
transcriptional silencing (Bogdanovic and Veenstra, 2009; Deaton and Bird, 2011). Whereas 
it is unclear whether DNA methylation is the causative mechanism of transcriptional silencing 
of hypermethylated transcription start sites, methylation may stabilise silencing induced by 
formation of a repressive chromatin state (Jones, 2012). DNA methylation patterns vary 
greatly between tissues (Christensen et al., 2009; Koestler et al., 2012; Meissner et al., 
2008). Tissue-specific differential methylation is enriched at gene bodies, and within 
development genes and transcription factors (Eckhardt et al., 2006; Flanagan et al., 2009b; 
Illingworth et al., 2008; Kaminsky et al., 2009; Rakyan et al., 2008; Reinius et al., 2012).  
 
1.2.1.3 Factors affecting DNA methylation variability 
Considerable research efforts have been made to classify the factors that define DNA 
methylation patterns that may contribute to phenotype and health outcomes. Genetic factors 
play a strong role, as the epigenomes of monozygotic twin-pairs are more similar than those 
of dizygotic twin-pairs (Gordon et al., 2012; Kaminsky et al., 2009). In vitro studies have 
further helped to classify the genetic motifs that define DNA methylation pattern (Lienert et 
al., 2011). Twin studies also demonstrate the profound influence of age and environmental 
exposures on the epigenome, as epigenetic signatures within monozygotic twin pairs diverge 
with age and exposure to different environments (Fraga et al., 2005; Gordon et al., 2012; 
Kaminsky et al., 2009).  
Age-associated changes in DNA methylation include sporadic hypermethylation of tumour 
suppressor genes, sometimes associated with transcriptional silencing, and genome wide 
reduction of 5meC (genome-wide hypomethylation) associated with genomic instability and 
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increased mutation rate (Chen et al., 1998; Cho et al., 2010; Eden et al., 2003; Wilson et al., 
2007). Age-associated DNA methylated loci are also enriched at bivalent chromatin 
domains, i.e. regions at which both active and repressive chromatin marks are co-exist, 
implying a novel mechanism for age-associated epigenetic dysregulation in tumorigenesis, 
as bivalent chromatin domains are frequently abnormally methylated in cancer (Rakyan et 
al., 2010). Therefore age-associated DNA methylation changes may contribute to ageing 
and etiology of age-related diseases (Calvanese et al., 2009; Chen et al., 1998; Gonzalo, 
2010).  
The epigenome is thought to be especially sensitive to alteration by environmental 
exposures and stressors during specific developmental windows such as the periconceptual 
period during which epigenetic programming occurs (Feinberg, 2007; Heijmans et al., 2009). 
The ‘foetal origin of human disease’ hypothesis postulates that stable alterations of 
epigenetic states during prenatal development, caused by environmental, endogenous, and 
stochastic factors, may contribute to risk of adult onset disease (Feinberg, 2004). Evidence 
for this ‘epigenetic progenitor origin’ of human disease includes the identification of abnormal 
DNA methylation patterns with periconceptual exposure to famine, detectable in blood of 
exposed adults several decades later (Tobi et al., 2009), and in vitro epigenetic alteration by 
treatment with diethylstilbestrol (Hsu et al., 2009), a teratogenic synthetic estrogen 
associated with increased risk of  breast and reproductive organ cancers in prenatally 
exposed individuals (Reed and Fenton, 2013). Epidemiological and animal studies support a 
role of other in utero exposures, such as maternal diet, alcohol consumption and 
environmental toxin exposure (Burdge et al., 2009; Dolinoy et al., 2006; Fei et al., 2013; 
Haggarty, 2013; Hilakivi-Clarke and de Assis, 2006; Pilsner et al., 2009; Waterland et al., 
2006; Xu and Du, 2010). DNA methylation patterns in adult tissues are also susceptible to 
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alteration by diet (Li et al., 2011; Milagro et al., 2011; Weisenberger et al., 2005; Zhang et 
al., 2011b) and smoking (Shenker et al., 2012; Shenker et al., 2013).  
An emerging field of study, termed ‘epigenetic epidemiology’ explores the potential role of 
epigenetic mechanisms in mediating the effects of environmental exposures on disease risk. 
Associations of DNA methylation with exposure to environmental carcinogens such as lead 
(Wright et al., 2010), arsenic (Reichard et al., 2007) and benzene (Bollati et al., 2007) have 
been reported. Recently, Shenker et al identified an intergenic CpG site independently 
associated with both smoking and breast cancer risk (Shenker et al., 2012).  
DNA methylation dysregulation plays an etiological role in several disorders, such as fragile-
X syndrome, through hypermethylation-mediated silencing of the FMR1 gene (Dobrovic and 
Kristensen, 2009), and imprinting disorders, in which loss of allele-specific epigenetic 
regulation leads to gene-dosage alterations, resulting in pleiotropic phenotypes including 
increased susceptibility to several cancers (Robertson, 2005).  
In summary, emerging research indicates that DNA methylation is susceptible to alteration 
by multiple developmental, innate and environmental cancer risk factors, suggesting that 
DNA methylation variability in normal tissues may represent an ‘archive’ of lifetime 
exposures that may be exploited for development of cancer risk biomarkers. Furthermore, 
the possibility that epigenetic regulation may partially mediate the carcinogenic effects of 
some cancer risk factors warrants further attention.    
 
1.2.2 Epigenetics in tumours 
Epigenetic dysregulation is a hallmark of cancer, and is thought to contribute to 
tumorigenesis and disease progression at least as much as genetic abnormalities (Baylin 
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and Jones, 2011; You and Jones, 2012). Several epigenetic events, including loss of 
acetylation and methylation of histone 4, and loss and gain of expression of tumour 
suppressor miRNAs and oncogenic miRNAs, respectively, are characteristic of cancer cells. 
The gain or loss in cancer of conserved transcriptional enhancers represents a novel 
epigenetic mechanism of cancer initiation (Akhtar-Zaidi et al., 2012). The most widely 
studies epigenetic event in cancer is the widespread abnormal DNA methylation patterns 
displayed in virtually all cancers (Feinberg and Tycko, 2004).  
Genes encoding epigenetic modifying enzymes are some of the most frequently mutated in 
cancers, often resulting in epigenetic dysregulation (You and Jones, 2012). For example, 
gain-of-functions mutations in Isocitrate dehydrogenase1 and 2, found in acute myeloid 
leukemia are associated with genome-wide and locus specific hypermethylation (Figueroa et 
al., 2010). Conversely, DNA methylation represents an endogenous mutagen, as methylated 
cytosines are prone to deamination to thymine, therefore a high proportion of SNPs, 
including 30% of disease associated germline SNPs, occur at CpG sites, and methylated 
gene bodies are highly prone to somatic mutation (Rideout et al., 1990; You and Jones, 
2012). 
DNA methylation variability is increased in cancers compared with their respective normal 
tissues, indicating a general loss of control of DNA methylation (Hansen et al., 2011). 
However, breast cancer associated methylation patterns display spatial clustering, indicating 
a non-random process (Novak et al., 2008). Furthermore, transcriptional inactivation by 
promoter hypermethylation of specific genes represents a key pathogenic mechanism 
analogous to somatic mutation. For example, hypermethylation of BRCA1 and MLH1 
represents an alternative inactivating mechanism in tumours lacking somatic mutations in 
these genes, whereas other genes that are rarely mutated, such as  MGMT, CDKN2B and 
RASFF1A, are frequently silenced by promoter hypermethylation in many cancers (You and 
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Jones, 2012).  Over 100 genes have been reported to be hypermethylated in breast cancer, 
including genes involved in DNA repair, cell cycle regulation, apoptosis, cellular invasion and 
cellular homeostasis (Jovanovic et al., 2010; Widschwendter et al., 2008). Abnormal DNA 
methylation patterns, including hypermethylation of some genes, including FOXC1 and 
RARB1, is apparent in breast cancer precursor lesions and low grade disease (Fackler et al., 
2003; Muggerud et al., 2010) indicating that epigenetic inactivation represents an early, and 
potentially causative lesion in tumorigenesis (Faryna et al., 2012; Feinberg et al., 2006; 
Tycko, 2003). 
Promoter hypomethylation of some oncogenes, including CDH3 and NAT1, occurs in breast 
cancer, potentially leading to spurious activation (Jovanovic et al., 2010). Interestingly, many 
loci are differentially methylated between breast cancers of different hormone receptor 
expression status (Li et al., 2010a). 
Most solid tumour types, including breast cancer, display genome-wide hypomethylation 
compared with normal adjacent tissue and benign lesions (Soares et al., 1999). Genome-
wide hypomethylation is an early tumorigenic event, detectable in precursor lesion and 
normal adjacent tissues associated with some cancers (Flatley et al., 2009; Suter et al., 
2004). However, hypomethylation is correlated with breast cancer stage, suggesting that 
hypomethylation may also be a consequence of disease progression (Wild and Flanagan, 
2010). 
1.2.3 DNA methylation and cancer risk 
Whereas abnormal epigenetic dysregulation in cancer and precursor lesions are well 
studied, little is known about the potential contribution to disease risk of epigenetic variability 
in normal tissue prior to disease. Several studies have identified DNA methylation marks in 
blood that are associated with cancer, suggesting systemic epigenetic dysregulation that 
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may precede disease and contribute to susceptibility, representing an epigenetic disease 
precursor state.  
Blood is frequently used as a ‘surrogate tissue’ for investigation of epigenetic patterns in 
relation to cancer risk, as many cancer risk factors, such as age, genetics, and 
environmental exposures are known to affect blood DNA methylation (Milagro et al., 2011; 
Shenker et al., 2012), and as blood is relevant to cancer-related physiological factors such 
as inflammation and metabolism (Koestler et al., 2012; Xu et al., 2013a). Furthermore, blood 
is easily sampled, and the most widely collected tissue sample in population study cohorts. 
Lastly, blood DNA methylation would be ideal for biomarker development and population 
screening, due to ease of sampling and measurement.  
The only blood epigenetic markers with a known causative role in disease susceptibility are 
rare constitutional (soma-wide) promoter hypermethylation events, known as ‘epimutations’ 
associated with silencing of the DNA mismatch repair genes MLH1 and MSH2 in Lynch 
syndrome, a familial colorectal cancer syndrome  (Chan et al., 2006; Hesson et al., 2010). 
Underlying genetic mutations associated with the MSH2 epimutations, and some MLH1 
epimutations, have been identified, explaining their heritable nature (Hitchins et al., 2011; 
Ligtenberg et al., 2012). No genetic lesions has yet been found to explain the non-mendelian 
heritability of some MLH1 epimutation cases (Hesson et al., 2010; Hitchins and Ward, 2009; 
Hitchins et al., 2007b), however MLH1 methylation is subject to germline erasure and re-
establishment, at least within the male germline (Hitchins and Ward, 2007b), indicating that 
the DNA methylation pattern is not heritable per se (Hitchins, 2013).  
Genome-wide hypomethylation is by far the most widely studied epigenetic marker in blood 
in studies relating to cancer (see chapter 3). The experimental question being addressed, 
and the outcomes, vary widely between studies, depending on the assay used to measure 
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genome-wide DNA methylation, and various aspects of the study design (Brennan and 
Flanagan, 2012b; Nelson et al., 2011) . Therefore, it remains unclear whether blood 
genome-wide hypomethylation contributes to cancer risk. 
Four studies have reported the occurrence of subtle BRCA1 promoter hypermethylation in 
blood of breast cancer patients (Hansmann et al., 2012; Iwamoto et al., 2010; Snell et al., 
2008; Wong et al., 2010). BRCA1 hypermethylation in blood was significantly more frequent 
in breast cancer patients displaying tumour BRCA1 hypermethylation, than in healthy 
controls in two studies (Iwamoto et al., 2010; Wong et al., 2010), perhaps suggesting that 
increased propensity for BRCA1 hypermethylation in normal tissue increases breast cancer 
risk. Another study, however, failed to confirm this finding (Kontorovich et al., 2009). A recent 
study (Hansmann et al., 2012) confirmed the presence of allele-specific BRCA1 promoter 
hypermethylation in a small proportion (0.015%) of familial breast and ovarian cancer 
patients, suggesting that BRCA1 hypermethylation may represent a rare epimutation, 
however, given that only 10 healthy controls were included in the study (compared with 641 
cases) it is not clear whether blood BRCA1 hypermethylation is associated with cancer risk. 
Whereas it appears that BRCA1 hypermethylation does occur in some normal cells in blood, 
prospective studies are required to further investigate the implications for cancer risk.  
Previous research from our laboratory (Flanagan et al., 2009b) identified a region within the 
Ataxia telangiectasia mutated (ATM) gene that displaying high DNA methylation variability 
(methylation variable position (MVP)), and that displayed significantly higher DNA 
methylation in blood of bilateral breast cancer patients (n=190) compared with healthy 
controls (n=190). As bilaterality is considered an indicator of constitutional breast cancer 
susceptibility (Weitzel et al., 2005), it was hypothesized that ATM hypermethylation may 
have contributed to disease risk prior to cancer incidence,  however, a prospective 
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investigation of DNA methylation at this locus was required to exclude the possibility of 
reverse causality.  
Analogous to GWAS studies, the first epigenome-wide association studies (EWAS) have 
been conducted in order to identify epigenetic loci associated with various different cancers 
including bladder (Marsit et al., 2011), head and neck (Langevin et al., 2012) and nerve 
sheath tumours (Feber et al., 2011). A smaller study (Widschwendter et al., 2008), using a 
candidate gene approach, identified 5 loci that were differentially methylated between blood 
samples of breast cancer cases and controls. Methylation at the loci identified may reflect 
the presence of active disease, and may be suitable for diagnostic biomarker development 
(Teschendorff et al., 2009), or may be associated with cancer risk, confirmation of which 
would require prospective investigation.   
EWAS studies will be greatly assisted by availability of reference ‘normal’ epigenotypes for 
peripheral blood mononuclear cells (PBMCs) and individual blood cell types, which have 
been, and are being generated by large international collaborations including the 
International Human Epigenome Consortium (IHEC), BLUEPRINT (http://www.blueprint-
epigenome.eu/), ENCODE (http://genome.ucsc.edu/ENCODE/) and Road-map 
epigenenomics project (http://www.roadmapepigenomics.org/) (Langevin and Kelsey, 2013; 
Reinius et al., 2012). A full peripheral blood mononuclear cell (PBMC) DNA methylome from 
a healthy male individual is already publicly available (Li et al., 2010c). 
1.2.4 Epigenetic Biomarkers in Clinical Use 
There has been great interest in development of DNA methylation-based non-invasive 
biomarkers for various different cancer outcomes, including diagnosis (Warren et al., 2011), 
prognosis, survival, treatment response, and treatment toxicity, recurrence (Brock et al., 
2008; Heyn and Esteller, 2012). The most well established biomarkers to date include 
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hypermethylation of MGMT in serum, which has been validated for use for diagnosis, 
prognosis-prediction and treatment stratification in glioblastoma (Esteller et al., 2000; Heyn 
and Esteller, 2012), and hypermethylation of GSTP1, detectable in serum and urine, which 
may be used for prostate cancer diagnosis (Esteller et al., 1998; Van Neste et al., 2012).  
For several cancer types, tissues and bodily fluids that derive from the cancer affected 
tissue, and that may be easily and non-invasively collected, may provide the most relevant 
source of nucleic acids for development of cancer biomarkers. For example, DNA derived 
from buccal cells may be utilised for development of biomarkers for head and neck cancer, 
hair follicles may be useful for melanoma, sputum for lung cancers, urine for bladder cancer, 
semen and urine for prostate cancer, and stool samples may be for development of 
colorectal cancers biomarkers (Rakyan et al., 2011). For other cancers however, including 
breast, ovarian and pancreatic cancers, blood represents the most relevant, non–invasively 
collectable tissue for investigation (Hanash et al., 2011). Future studies of breast cancer 
biomarkers will likely benefit from availability of breast epithelial DNA samples, as bio-
banking of breast epithelium biopsies is increasing, and other non-invasive sources of breast 
epithelial cells such as nipple aspirate fluid and ductal lavage fluid, and breast milk are being 
developed  (Ljung et al., 2004; Twelves et al., 2013). In the meantime, blood represents the 
most relevant tissue for breast cancer, for which large cohorts of prospectively collected 
tissue samples are available (Hanash et al., 2011). 
 
1.3 Hypothesis and Aims 
We hypothesised that breast cancer susceptibility may be influenced by systemic and gene-
specific DNA methylation patterns that may be detectable in blood prior to breast cancer 
diagnosis. Such cancer-associated DNA methylation patterns may be determined by genetic 
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variability, age, environmental exposures, or other factors, therefore epigenetic patterns may 
mediate the effects of risk factors on disease susceptibility, likely through gene-expression 
changes. Blood DNA methylation may therefore provide molecular biomarkers for breast 
cancer risk prediction.  
We aimed to investigate the relationship between blood DNA methylation and breast cancer 
risk in prospective studies, and to assess the suitability of blood DNA methylation for breast 
cancer risk biomarker development. Candidate risk markers of interest included the ATM 
and LINE1 markers previously associated with disease in retrospective studies. Next we 
aimed to investigate potential mechanisms defining methylation variability at the ATM gene 
locus. Lastly, we aimed to discover novel epigenetic breast cancer risk markers using 
microarray approaches.  
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CHAPTER 2 
 
INTRAGENIC ATM METHYLATION AS A BREAST CANCER 
RISK FACTOR 
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2.1 Introduction 
In a previous report (Flanagan et al., 2009b), Flanagan et al identified regions within the 
ATM gene that displayed increased DNA methylation variability in blood compared with other 
gene regions, which they termed methylation variable position (MVPs). Furthermore they 
showed, using bisulphite-pyrosequencing, that one of these MVPs, labelled ATMmvp2b, was 
significantly hypermethylated in blood samples of bilateral breast cancer cases (n=190),  
taken at diagnosis, compared with healthy controls (n=190). Furthermore, Inter-quartile 
analysis revealed that individuals with ATMmvp2b methylation within the highest methylation 
quartile were at three-fold increased breast cancer risk compared with women in the lowest 
quartile.  ATMmvp2b is located within an intragenic repetitive element 4kb downstream of 
the ATM transcriptional start site (TSS), consistent with a significant enrichment of 
methylation variability at intragenic repetitive elements among 55 genes analysed by 
differential methylation hybridization in the same report. As bilaterality is proposed to be an 
indicator of constitutional, or systemic, breast cancer susceptibility (Weitzel et al., 2005), it 
was hypothesized that ATMmvp2b methylation may have represented a constitutional 
susceptibility factor for breast cancer, detectable prior to disease onset. However, 
prospective investigation of the association was required to exclude the possibility of reverse 
causality, or the possibility that hypermethylation represented an early tumorigenic event. 
(Marsit et al., 2011; Teschendorff et al., 2009).  
The possibility that ATM DNA methylation is related to breast cancer risk is particularly 
interesting as ATM is a well known breast cancer susceptibility gene. Ataxia telangiectasia, 
the rare recessive disorder of pleiotropic phenotype caused by ATM insufficiency, is 
associated with strong susceptibility to several cancer types, and non-affected female 
mutation carriers are at increased breast cancer risk (Goldgar et al., 2011; Lavin, 2008; Lu et 
al., 2011). Furthermore, SNPs within ATM confer increased breast cancer risk, though their 
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penetrance is not well established (Lee et al., 2005a). ATM is a highly conserved 
serine/threonine kinase with several critical cellular functions, including sensing of double 
strand breaks and oxidative stress (Goldgar et al., 2011; Okuno et al., 2012; Shiloh, 2001) 
and regulation of cell cycle, DNA damage response (DDR) and cell survival (Shiloh, 2001; 
Shiloh, 2003). Furthermore, ATM is a regulator of important kinases including breast cancer 
tumour-suppressor genes BRCA1 and P53 (Shiloh, 2003).    
Interestingly, Differential ATMmvp2b methylation was thought to be independent of overall 
changes in genome-wide DNA methylation, as DNA methylation of LINE1, a commonly used 
surrogate marker of genome-wide methylation, was not different between cases and 
controls. This was inconsistent with previous reports of LINE1 hypomethylation in blood of 
cancer patients compared with controls (Cash et al., 2011; Cho et al., 2010; Hsiung et al., 
2007; Moore et al., 2008; Wilhelm et al., 2010). 
In order to assess the relationship between ATM DNA methylation and breast cancer risk, 
we measured methylation of ATMmvp2b, and a neighbouring MVP termed ATMmvp2a, lying 
381bp upstream of ATMmvp2b, in pre-diagnostic blood samples from three breast cancer 
case-control studies. LINE1 DNA methylation was also assessed in the same studies.  
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2.2 Materials and Methods 
2.2.1 Study Populations 
Study participants were drawn from three large studies with blood samples collected prior to 
breast cancer diagnosis (Table 2.1). All contributing studies have appropriate ethical 
approval for sample and data collection.  
2.2.1.1 Kathleen Cunningham Foundation Consortium for Research into Familial Breast 
Cancer (KConFab)  
The study population has been described previously (Mann et al., 2006). Between 1997 and 
May 2011, KConFab collected peripheral blood samples from 12,240 members of 1,395 
families (~8.8 samples per family) in Australia and New Zealand. Included families had on 
average three verified (5.4 unverified) breast cancers per family. Case status was confirmed 
by clinical pathology report, doctor’s notes, cancer council registry verification or death 
certificate. Incident cases of invasive breast cancer were selected for this study from all 
individuals with a breast cancer diagnosis >1 month after blood sample collection (n=171). 
Five cases of non-white ethnicity were excluded from the analyses resulting in 166 invasive 
cases that were compared to 225 healthy unrelated controls without a family history of 
breast cancer drawn from “best friends” of subjects enrolled in KConFab. The average time 
to diagnosis (TTD, the duration between blood sample collection and subsequent breast 
cancer diagnosis) for incident cases was 45 months (range 1 to 140 months). Information on 
breast cancer risk factors including hormonal and reproductive factors, cigarette smoking 
and alcohol drinking was collected from questionnaires at enrolment. Pathology data 
(histology, grade, nodal status, ER, PR, HER2 status) and BRCA1/2 mutation status was 
available for breast cancer cases. Genetic polymorphism data for 15 common breast cancer 
susceptibility SNPs (rs1011970, rs10995190, rs2380205, rs2981582, rs614367, rs704010, 
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rs11249433, rs13387042, rs2046210, rs4973768, rs6504950, rs999737, rs3817198, 
rs889312, rs13281615) were available for 12 cases and 190 controls. 
2.2.1.2 Breakthrough generations study (BGS) 
This study cohort has been described elsewhere (Swerdlow et al., 2011). BGS represents a 
large general population cohort consisting of ~110,000 women enrolled in the UK between 
2003 and 2011. Participants were sampled from a nested case-control study of all incident 
cases of breast cancer diagnosed within the cohort before June 2010 and controls 
individually matched on recruitment source, year of enrolment, ethnicity (white only), date of 
birth within 12 months, availability of blood sample and the duration during which the blood 
sample was in the mail. Breast cancer cases were self-reported in a follow-up questionnaire 
completed approximately 2.5 years after enrolment, or notified by study participants by 
phone or letter. Self-reported diagnoses were confirmed through an electronic linkage with 
England/Wales/Scotland/Northern Ireland cancer registrations (or by the general practitioner 
for a small number of cases that could not be successfully linked).  Checks against UK 
cancer registrations were made for participants known to have died by the time of the 2.5 
year follow-up, and those who failed to provide follow-up (but had given permission for 
follow-up).  
A random sample of 257 case-control pairs was selected for analysis. Excluded from this 
were 4 controls that were subsequently found to have invasive breast cancer, 3 cases 
whose blood was collected after diagnosis, and 1 case of ductal carcinoma in situ (DCIS) 
resulting in a final sample set of 253 cases and 253 controls. Average TTD for incident 
cases was 18 months (range 0.03-59) (Table 2.1).Information on breast cancer risk factors 
was collected from a baseline questionnaire at enrolment. Pathology information from was 
available for ~25% of cases.  
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A longitudinal study to evaluate DNA methylation stability was conducted using paired buffy 
coat  samples collected at two time-points (enrolment (T0) and follow-up ~6 years later (T1)) 
from 92 healthy women from the BGS study. A sample and questionnaire were collected at 
T0 (2004), and again at T1. Inclusion criteria were: Age 35-84 years at enrolment, no history 
of breast cancer up to second blood collection, not known to have any relatives within the 
study, blood samples received at processing lab <1 day after collection, expected amount of 
blood received at the lab (three 10ml vials at baseline and two 10ml vials at follow up), no 
reported problems at collection or processing (e.g. lipeamic, heamolysed, clotted samples), 
and duration between T0 and T1between 5.5 and 6.5 years.  
2.2.1.3 European Prospective Investigation into Cancer and Nutrition (EPIC)  
The study population has been described elsewhere (Riboli and Kaaks). EPIC collected 
~520,000 individuals with standardized lifestyle and personal history questionnaires, 
anthropometric data and blood samples collected for DNA extraction. The sample set used 
for this study included two subgroups, including a group of premenopausal women (127 
cases and 145 controls) and post-menopausal women (121 cases and 149 controls), with 
menopausal status defined at the time of blood collection. Controls were individually 
matched on age at baseline, recruitment centre, date and time of blood collection. Precise 
ethnicity data was not available for these individuals, however ~80% of individuals were 
provided from study centres in Italy, Spain and the Netherlands and the remainder (20%) 
were provided from France, Germany, UK and Greece. DCIS cases were excluded from 
analyses (n=36).  Blood samples from cases were taken on average 55 months before 
diagnosis (range 24-108) (Table 2.1). Extensive information on cancer risk factors, including 
extensive alcohol, smoking and dietary data, family history and hormonal factors were 
collected from a baseline questionnaire at enrolment. Pathology information includes 
morphology, grade, stage, ER, PR and HER2 status. 
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Table2.1Characteristicsofstudypopulationsusedinchapter2
Study KConFab BGS** EPIC*** 
Case-control Controls Cases Controls Cases Controls Cases 
N 225 166 253 253 291 248 
Age (mean (range)) 60 (33-83) 50 (21-91) 54 (23-82) 54 (23-82) 52 (33-76) 
52 (33-
76) 
Family History, N (%)             
Yes 0 (0%) 166 (100%) 51 (20%) 69 (27%) 24 (14%) 
23 
(18%) 
No 225 (100%) 0 (0%) 201 (80%) 183 (73%) 144 (86%) 
108 
(82%) 
Menopausal status, N (%) 
Pre-menopausal 37 (17%) 101 (65%) 135 (61%) 134 (62%) 145 (50%) 
127 
(50%) 
Post-menopausal 183 (83%) 54 (35%) 87 (39%) 83 (38%) 146 (50%) 
121 
(50%) 
Time to diagnosis, mean 
(range) 
- 45 (1-140) - 
18  (<1-
59) 
- 
55 (24-
108) 
Age at diagnosis, mean  
(range) 
- 52 (29-88) - 55 (23-84) - 
57 (37-
80) 
Tumor Characteristics* 
Morphology - Ductal - n/a - 78% - 73% 
Morphology - Lobular  - n/a - 12% - 14% 
Morphology - Other - n/a - 10% - 13% 
Mutation - BRCA1 - 23% - n/a - n/a 
Mutation - BRCA2 - 14% - n/a - n/a 
Grade – I   12%   14%   15% 
Grade – II - 33% - 50% - 65% 
Grade – III - 40% - 36% - 20% 
Nodes Positive - 37% - 33% - 36% 
ER+ - 63% - 84% - 79% 
HER2+ - 27% - 19% - 20% 
ER- - 24% - 16% - 21% 
*Proportions in each category are reported due to missing/incomplete data for these variables in each of the 
studies. n/a = data not available. 
** Cases were individually matched to controls for recruitment source, year of completion of the baseline 
questionnaire at enrolment, ethnicity, availability of blood sample and date of birth within 12 months and 
duration that the blood sample was in the mail. 
*** Cases and controls were selected within strata of menopausal status (pre- and post-) and individually 
matched on age, recruitment centre, date and time of blood collection. 
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2.2.2 Laboratory methods 
2.2.2.1 DNA extraction 
DNA samples were extracted from whole blood using Qiagen DNA blood Mini Kits in 
KConFab. DNA samples from BGS and EPIC were extracted from buffy coats using DNA 
Blood Mini Kits (Qiagen, UK), except for 29 cases and 15 controls in BGS extracted using 
Nucleon Genomic DNA Extraction Kit (Tepnel, Life Sciences, UK).  
2.2.2.2 Bisulphite conversion 
500 ng of DNA (KConFab) or 250ng (BGS and EPIC studies) from each subject was 
bisulphite converted using EZ-96 DNA Methylation-Gold kit according to the manufacturer’s 
protocol (Zymo Research, Orange, CA).  
2.2.2.3 PCR and pyrosequencing 
PCR and pyrosequencing assays for ATM were previously described (Flanagan et al., 
2009a). ATM primers are shown in table 2.2. Nested PCR was used to amplify repetitive 
element regions of ATM, with the first-round primer set located outside of repetitive regions. 
A common  tag was incorporated at the 5’ end of reverse primers of each assay and a 
universal biotinylated primer was included in the second PCR reaction round for each ATM 
assay as previously described (Royo et al., 2007). The first round of PCR was carried out in 
a 10ȝl volume consisting of 0.2ul Faststart taq DNA polymerase (Roche), 0.6ul MgCL2 
(25mM), 1ȝl 10x PCR buffer (Roche), 0.5ȝl of 10mM DNTP mix (Geneamp), 0.2ȝl of outer 
forward (F) and outer reverse (R) PCR primers (10mM), 6.6ul H20 and 1ȝl of bisulphite 
treated DNA template. PCR thermocycling conditions for the 1st round of PCR included 
denaturation at 95°C for 4 min, followed by 10 cycles of 94°C for 15 s, touchdown from 60–
50°C (í1 degree/cycle) for 15 s and 72°C for 20 s, followed by a further 30 cycles of 
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denaturation at 94°C for 20 s, annealing at 50°C for 20 s, and extension at 72°C for 20 s.  
Round 1 product were diluted 1:10 by adding 90ȝl H20. Diluted product (1ȝl) was added to a 
45ul master mix including 0.45ul taq polymerase, 2.7ȝl Mgcl2, 6.3ȝl 10 x buffer, 1.8ȝl DNTP 
mix, 0.9ȝl of each of inner forward and inner reverse primers at 10mM, and 31.95ȝl H20. 
PCR thermocycling conditions for the 2nd round of PCR included denaturation at 95°C for 10 
min, followed by 40 cycles of 95°C for 20 s, 50°C, 72°C for 20 s, followed by a final 
annealing step of 72°C for 5 min. Thermocycling conditions were the same as for the first 
round PCR step. For long interspersed nuclear element-1 (LINE-1) methylation analysis, 
commercially available primers (Qiagen UK) were used as per user manual. Each PCR 
product was confirmed as a single product by ethidium bromide-stained agarose gel 
electrophoresis, along with no-template control samples. Pyrosequencing was carried out 
using the PyroMark Q96 MD system from Qiagen, following standard protocol as per user 
manual, and 10ȝl PCR product for each reaction. Methylation values were calculated as an 
average of all high quality CpG sites (determined as “passed” by the quality-control 
thresholds within the Pyro Q-CpG Software (Qiagen, UK)). The Pyro Q-CpG Software has 
inbuilt overall quality assessment for each sample which flags any sequence that deviates 
from the expected pattern. Any sample failing quality control was removed from analysis. 
The number of samples failing in each assay were ATMmvp2a (55/1436 subjects), 
ATMmvp2b (56/1436 subjects) and LINE1 (87/1436 subjects). Additionally, a commercially 
available fully methylated genomic DNA sample was used as a positive control (Zymo 
Research, Orange, CA) and in-house whole genome amplified genomic DNA (Genomiphi, 
GE Healthcare) used as an unmethylated negative control. The percentage of cells with 
methylated DNA at each MVP was calculated as the average of 3 (ATMmvp2a) or 4 (LINE1 
and ATMmvp2b) CpG sites and was used as the measure of methylation for each subject. 
Based on previous experimental results the range for a typical assay is 90-98% for the 
positive control and 1-6% for the negative control. Further quality assurance was performed 
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with blinded duplicate samples (12 pairs) in the BGS and reference controls on each plate 
with median differences of 2.1%, 3.4%, 1.8% for ATMmvp2a, ATMmvp2b and LINE1, 
respectively. 
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Table 2.2. ATM methylation primers 
Universal biotinylated 
primer biotin-GGGACACCGCTGATCGTTTA 
ATMmvp2a F (outer) AGTTGAGATGGAAGTGGTAGA 
ATMmvp2a R (outer) CTTTTTATTACTCTAAAACCAAAA 
ATMmvp2a F (inner) AAGTTTTTGGTTTAGTAAAATGA 
ATMmvp2a R (inner) gacgggacaccgctgatcgtttaCATTAACAATAAACTATT 
ATMmvp2a sequencing GTTATTAGGTTGGAGTGTAG 
ATMmvp2b F (outer) GAGTGTTTTAAATAGTTTATTGTTAATG 
ATMmvp2b R (outer) AACACAATAATTTTTCTTAACATTTCC 
ATMmvp2b F (inner) TTGGTTTTAGAGTAATAAAAAGTA 
ATMmvp2b R (inner) gacgggacaccgctgatcgtttaCCAACATAATAAAACCCTATC 
ATMmvp2b sequencing TTTTGAGTAGTTGGGATTAT  
*F=forward, R=reverse, S=sequencing 
*Lower case letters represent universal sequence tag (to which universal biotinylated primer 
binds).  
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2.2.2.4 Statistical Analysis  
The non-parametric Wilcoxon test for matched pairs was used for BGS and EPIC and the 
Wilcoxon rank sum test was used for KConFab, to test for differences in mean methylation 
levels between cases and controls. Non-parametric tests were used as ATM DNA 
methylation was not normally distributed, as indicated by a Shapiro Wilks test (p<0.05). DNA 
methylation Z-scores were calculated for each sample in order to make DNA methylation 
data comparable between studies. Z-scores were calculated for DNA methylation data 
categorised in quintiles based on their distribution in the combined control population. 
Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) 
for individuals in the 2nd, 3rd, 4th and 5th methylation quintiles, compared with individuals in 
the 1st (lowest (reference)) quintile. This enabled comparison of breast cancer risk between 
groups within DNA methylation categories at either end of the DNA methylation range (e.g 
highest versus lowest methylation category).  Analyses of combined data from all studies 
were adjusted by age in 5-year categories and study. Age at blood draw, age at menarche, 
parity, age at menopause, alcohol consumption, body mass index (BMI), oral contraceptive 
and hormone replacement use and family history of breast cancer were tested as potential 
significant effect modifiers (i.e. variables that change the effect estimate by >10%) using 
multivariable linear regression. Analyses were stratified by age at blood drawn using tertiles 
(33%) of the combined control population (21-49, >49-59, >59-91), and by family history and 
time from blood collection to diagnosis to evaluate effect modification by these variables. 
Estimates from conditional logistic regression models for individually matched pairs in the 
BGS and EPIC cohorts were similar to estimates from unconditional logistic models adjusted 
or unadjusted by matching factors. Only findings from the unconditional logistic analyses are 
presented to avoid loss of data from exclusion of pairs with one member excluded because 
of missing methylation data or other reasons (see study population section). Heterogeneity 
of estimates by study was tested by including an interaction term for the biomarker and an 
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indicator variable for study in the logistic model. Fixed-effect meta-analyses of estimated 
ORs from all studies in this report and a previously published study were performed in R 
using the “metafor” package. Multinomial (ordinal) logistic regression models with categories 
of methylation levels as the outcome variable were used to test for associations between 
methylation levels and the breast cancer risk factors specified above, adjusted for age. B-
spline quadratic logistic regression models fitted in the “bs” R package were used to explore 
the relationship between continuous measures of methylation levels and breast cancer risk. 
All statistical tests were performed using R (v 2.12.0). Statistical analyses were performed by 
Dr. James M. Flanagan, Prof. Montserrat Garcia-Closas and Dr. Charlotte Wilhelm-Benartzi. 
2.3 Results 
For the ATMmvp2a locus there was significantly higher median methylation in cases than 
controls in the familial samples from KConFab (81.8% vs. 76.9%, p=4.87x10-6; Table 2) and 
marginally higher median methylation in the population-based cases from BGS compared 
with controls (76.8% vs 76.4%, p=0.02). There was no significant differences in mean 
methylation levels in cases compared with controls in the EPIC cohort (75.7% vs 76.1%, 
p=0.40). There was an upward shift in the distribution of methylation in cases compared with 
controls in BGS and KConFab, which was not observed in EPIC (Fig 2.1). No significant 
differences were found for methylation levels at the ATMmvp2b locus (131bp downstream 
from ATMmvp2a) or LINE1 in any of the studies (Table 2.3). 
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Table 2.3 Distribution of methylation levels in ATMmvp2a, ATMmvp2b and LINE1 in breast cancer cases and 
controls  
Assay Study 
Control Case Control Case ** 
N* N* Median IQR Median IQR P-value 
ATMmvp2a 
BGS 248 249 76.4 70.2-80.2 76.8 70.9-82.7 0.02 
EPIC 283 235 76.1 70.5-80.6 75.7 70.0-80.8 0.4 
KConFab 210 156 76.9 71.6-81.5 81.8 75.8-86.5 4.87x10
-6
 
ATMmvp2b  
BGS 234 248 91 87.0-94.8 91.4 85.6-95.0 0.61 
EPIC 287 240 92.2 87.3-95.2 92.3 88.3-95.7 0.36 
KConFab 208 162 92.6 87.2- 96.3 92.3 82.4-96.5 0.24 
LINE1 
BGS 242 241 79 77.9-80.1 79 78.1-79.9 0.96 
EPIC 263 232 75.1 73.9-76.3 75.2 73.9-76.3 0.89 
KConFab 218 153 76 74.3-78.0 76.6 75.2-77.6 0.2 
* Differences in numbers of cases and controls within each study with total numbers are due to missing data 
(failed QC) on methylation markers.  
** Wilcoxon matched pairs test for BGS and EPIC and Wilcox-rank-sum test for 
KConFab 
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Figure 2.1. ATMmvp2a methylation distribution in breast cancer cases and controls. BGS (A), EPIC (B) and 
KConFab (C). DNA methylation of peripheral blood DNA displayed as a density distribution with controls in black 
and cases in red.
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Quintile analyses for the ATMmvp2a locus, adjusted by age at blood collection in 5 year 
categories, showed a significantly increased risk of breast cancer for women in the highest 
quintile compared with the lowest quintile in the BGS and KConFab studies, but not in EPIC 
(Table 2.4). Further adjustment by age as continuous variable and conditional logistic 
analyses for paired samples individually matched in BGS and EPIC showed similar results 
(data not shown). Analyses of combined data from all studies adjusting by study and age at 
blood collection indicated that women in the highest quintile (>6.3% methylation above study 
mean methylation) were at 1.9-fold increased risk of breast cancer compared with women in 
the lowest quintile (OR=1.89 (1.36-2.64), p=1.64x10-4) (Table 2.4). While the overall 
difference in median levels between cases and controls was small (1.1%), the difference in 
median methylation between the highest quintile (86%) and lowest (65%), where the 
association with cancer status is observed was large (21%). A quadratic B-spline regression 
model of continuous levels of methylation at ATMmvp2a and breast cancer risk confirmed a 
threshold association, rather than a linear association, between methylation levels and 
breast cancer risk (Fig 2.2). 
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Figure 2.2: Effect estimate of the logistic model of splined ATMmvp2a methylation as it relates to case-
control status. Combined analysis of three prospective case-control studies using Z-scores, shows the cutoff 
level for quintile five at +6.3% above the median methylation level in controls on the X-axis with log odds ratio of 
the quadratic splined ATM methylation on the Y-axis. Yellow dotted line represents 95% CI. Black vertical bars 
each represent a sample, indicating the frequency distribution of samples within the methylation range. 
61
62 
 
Study-adjusted analyses stratified by age at blood collection suggested a weaker 
ATMmvp2a risk association when methylation was measured in samples collected from 
women >59 years of age (Table 2.5). Similar results were obtained when stratified by age at 
diagnosis (data not shown). However, age-specific estimates within study revealed that the 
weaker association was driven by the EPIC cohort that showed no increased risk in this age 
subgroup (Fig 2.3). Overall analyses showed some evidence for heterogeneity of estimates 
between studies (Table 2.4; p-value for test for heterogeneity=0.07). This evidence was 
limited to women in the older age group and there was no evidence for study heterogeneity 
within the younger age subgroups (p-value for study heterogeneity by age subgroups 21-49 
(p=0.51), 50-59 (p=0.72), 60-91 years (p=0.09)) (Table 2.5).  
There was a significant association between ATMmvp2a methylation levels and increasing 
age at blood collection in controls (Spearman’s rho=0.15, p=0.0015), but not in cases 
(Spearman’s rho=-0.02, p=0.43), that was most significant in the EPIC cohort (rho=0.11, 
p=0.007) compared to KConFab (rho=0.06, p=0.26) and BGS (rho=0.02, p=0.40). This 
underlying age association may account for the apparent cross-over risk association with 
ATM methylation by age at blood collection seen in EPIC (Fig 2.4).  Analyses by 
menopausal status at blood collection, adjusted by study and age, showed similar risk 
estimates for pre- and post-menopausal women (Table 2.6).  
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Table 2.5. Association between methylation levels in ATMmvp2a and breast cancer risk in combined analysis 
stratified by age at blood draw 
  
Controls Cases 
Case 
Proportions 
   
By Study 
Age range 
Quintile
s 
N Freq. N 
Freq
. 
 (K, B, E)* OR** 95%CI P-value 
21-49 
years 
Qi1 45 0.21 44 0.17 0.20, 0.27, 0.52 1     
Qi2 51 0.23 39 0.15 0.28, 0.26, 0.46 0.68 0.37-1.25 0.21 
Qi3 44 0.2 41 0.16 0.27, 0.32, 0.41 0.94 0.51-1.72 0.83 
Qi4 38 0.18 44 0.17 0.43, 0.18, 0.39 1 0.54-2.17 0.99 
Qi5 39 0.18 90 0.35 0.40, 0.33, 0.27 2.07*** 1.16-3.68 0.01 
Total 217   258   0.33, 0.28, 0.38       
>49-59 
years 
Qi1 54 0.2 27 0.13 0.19, 0.41, 0.41 1     
Qi2 55 0.2 43 0.21 0.05, 0.49, 0.47 1.57 0.84-2.91 0.15 
Qi3 62 0.23 48 0.24 0.19, 0.38, 0.44 1.56 0.85-2.86 0.15 
Qi4 50 0.19 33 0.16 0.09, 0.48, 0.42 1.26 0.66-2.41 0.48 
Qi5 49 0.18 53 0.26 0.19, 0.49, 0.32 2.25*** 1.21-4.17 0.01 
Total 270   204   0.14, 0.45, 0.41       
>59-91 
years 
Qi1 49 0.19 33 0.19 0.18, 0.36, 0.45 1     
Qi2 42 0.17 31 0.17 0.10, 0.48, 0.42 1 0.51-1.97 0.99 
Qi3 42 0.17 26 0.15 0.08, 0.62, 0.31 0.84 0.45-1.58 0.61 
Qi4 60 0.24 34 0.19 0.26, 0.53, 0.21 0.8 0.45-1.45 0.5 
Qi5 61 0.24 54 0.31 0.39, 0.43, 0.19 1.39** 0.87-2.26 0.27 
Total 254   178   0.23, 0.47, 0.30       
* Study proportions for KConFab, BGS and EPIC contributing to each quintile in each age group. 
**ORs within each age-group are adjusted by study. Test for Heterogeneity of effects by age group in combined 
analysis p= 0.3109 for Qi5 vs Qi1 
***P-values for study heterogeneity for ORs comparing Qi5 vs Qi1 within age subgroups: 21-49 years (p=0.51), 
50-59 years (p=0.73), 60-91 years (p=0.09)  
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Fig2.3
Figure 2.3. Association between ATMmvp2a methylation levels and breast cancer risk in combined
analysis stratified by age. Study specific estimates (unadjusted) are shown. Study heterogeneity by age
subgroups was 21-49 (p=0.51), 50-59 (p=0.72), 60-91 years (p=0.09).
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Figure 2.4. ATMmvp2a DNA methylation  in blood, measured by pyrosequencing plotted against age  at 
blood draw. (A) combined control samples from the EPIC, BGS and KConFab studies. Linear regression lines for 
association between ATMmvp2a methylation and age are shown for EPIC (black), BGS (red) and KConFab (blue), 
with corresponding p-values, and Spearman correlation rho-values shown . (B) Combined cases and controls from 
all three studies. Linear regression lines for association between ATMmvp2a methylation and age are shown for 
controls (black), and cases (red) with corresponding p-values, and Spearman correlation rho-values. 
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Table 2.6. Association between methylation levels in ATMmvp2a and breast cancer risk in combined analysis stratified 
by menopausal status at blood drawn 
Controls Cases 
Menopausal 
status Quintiles* N Freq. N Freq. OR** 95%CI P-value 
Pre-menopausal 
Qi1 51 0.17 50 0.15 1 _   
Qi2 69 0.23 60 0.18 0.82 0.48-1.39 0.47 
Qi3 69 0.23 61 0.18 0.89 0.53-1.51 0.67 
Qi4 62 0.2 65 0.19 1.01 0.59-1.71 0.98 
Qi5 53 0.17 103 0.3 1.76 1.04-2.96 0.03 
Totals 304   339         
                  
Post-
menopausal 
Qi1 90 0.22 49 0.18 1 _   
Qi2 76 0.19 48 0.18 1.16 0.7-1.92 0.58 
Qi3 73 0.18 46 0.17 1.19 0.71-1.98 0.52 
Qi4 77 0.19 44 0.17 1.13 0.67-1.89 0.65 
Qi5 87 0.22 79 0.3 1.8 1.12-2.88 0.02 
Totals 403   266         
Test for Heterogeneity of effects by menopausal status for combined analysis p= 0.62 for Qi5 vs Qi1 
* Cut-off values determined by quintiles of Z-scores based on the distribution in the combined control population. Z-
score cut off values are -0.83, -0.24, 0.19 and 0.64. 
**ORs adjusted by study and age in 5-year categories. 
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Adjustment by breast cancer risk factors (age at menarche, menopausal status at blood 
drawn, parity, age at menopause, alcohol consumption, body mass index, oral contraceptive 
and hormone replacement use and family history of breast cancer) did not result in 
appreciable changes in relative risk estimates for any of the markers across the three 
studies in this report. Consistently, these risk factors were not significantly associated with 
ATMmvp2a methylation levels in any of the three control populations (data not shown). In 
the familial cases from KConFab, ATMmvp2a methylation was not associated with BRCA1/2 
mutation status, tumour pathology (morphology, grade, node status, ER, PR and HER2 
status) (data not shown). Similarly in EPIC and BGS samples, ATMmvp2a methylation was 
not associated with tumour pathological features (data not shown).  
Analyses stratified by length of time between blood collection and diagnosis, known as time 
to diagnosis (TTD) (<=1 year vs. >1 year) showed no significant differences in effect 
estimates using the combined data (Table 2.7). Consistently, there was no association 
between ATMmvp2a methylation and TTD (0-11 years) using linear regression (KConFab 
p=0.97; BGS p=0.10, EPIC p=0.28).  
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Table 2.7. Association between ATMmvp2a methylation levels and breast cancer risk by time from blood 
collection to diagnosis in combined analysis  
    Controls Cases       
Study Quintile* N Freq. N Freq. OR** 95%CI P-value 
<1yr from 
diagnosis 
Qi1 148 0.2 18 0.16 1     
Qi2 148 0.2 20 0.18 1.19 
0.59-
2.43 0.63 
Qi3 148 0.2 20 0.18 1.07 
0.53-
2.19 0.84 
Qi4 148 0.2 19 0.17 0.97 
0.47-
1.99 0.93 
Qi5 149 0.2 35 0.31 2.02 
1.05-
3.86 0.03 
Totals 741   112         
>1yr from 
diagnosis 
Qi1 148 0.2 86 0.16 1     
Qi2 148 0.2 93 0.18 1.08 
0.74-
1.57 0.68 
Qi3 148 0.2 95 0.18 1.1 
0.76-
1.60 0.6 
Qi4 148 0.2 92 0.17 1.09 
0.75-
1.59 0.65 
Qi5 149 0.2 162 0.31 1.94 
1.36-
2.75 2.2x10
-4
 
Totals 741   528         
Test for Heterogeneity of effects by time from blood to Dx p= 0.93 for Qi5 vs Qi1 
* Cut-off values determined by quintiles of Z-scores based on the distribution in the combined control 
population. Z-score cut off values are -0.83, -0.24, 0.19 and 0.64. 
**ORs adjusted by 5-year age categories and study. 
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A risk biomarker that is measured at one time point only (as is the case with most case-
control studies) would ideally be stable over time. Temporal stability of ATMmvp2a and 
LINE1 DNA methylation was assessed by  methylation analysis of ATMmvp2a within a 
control population where blood samples were taken 6 years apart from the same individuals 
in the BGS cohort (n=92 pairs). There was no significant change in either ATMmvp2a 
(median change = 0.19%, p= 0.51) or LINE1 (median change = 0.27%, p= 0.69) over 6 
years, using conditional logistic regression. Conditional logistic regression showed that ATM 
variation between individuals was much larger than within individuals at two time points 
(ICC=0.57; between time points correlation R2= 0.79) and there was no significant difference 
in median methylation between time points overall (p=0.24 (paired T-test)) (fig 2.5).  These 
data suggest that the ATM methylation is stable for at least ~6 years. 
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Figure 2.5. Difference in ATMmvp2a and LINE1 DNA methylation between time-points in serially collected 
blood samples. Methylation of (A) ATMmvp2a and (B) LINE1 in 92 pairs of serially collected blood samples from  
healthy women from the Breakthrough Generations study (BGS).  Samples were collected at T0 and T1 (~6 years 
later) for each individual. The difference in methylation between T0 and T1 for each individual (Y-axis), is plotted 
against age (X-axis). Central horizontal line represents 0% difference in methylation. Broken lines represent 
confidence intervals. 
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Inter-quartile analysis of the association between ATMmvp2b DNA methylation and bilateral 
breast cancer prevalence in a retrospective case-control study was previously reported 
(Flanagan et al., 2009a). Re-analysis of this data for both the ATMmvp2a and ATMmvp2b 
regions was performed, using quintiles (based on control methylation distribution) rather than 
quartiles as methylation categories. Consistent with prospective studies, individuals within 
the highest ATMmvp2a methylation quintile were significantly more likely to be cases 
compared with individuals within the lowest quintile (age-adjusted OR=1.90 (95% CI=1.00-
3.62), p=0.05). For the ATMmvp2b region, case-status was also significantly more likely for 
women within the highest DNA methylation quintile compared with women in the lowest 
(age-adjusted OR=3.07 (95% CI=1.58-5.93), p=8.8x10-4) (Table 2.8). Meta-analysis of odds 
ratio estimates for all three prospective studies and the retrospective BBC study indicated 
that ATMmvp2a methylation within the highest quintile was associated with an OR for breast 
cancer risk of 1.89 ratio (95% CI 1.36-2.64, p=1.64x10-4) compared with women in the 
lowest quintile (fig 2.6), with no significant heterogeneity between studies (p=0.15). 
TestforHeterogeneity:Q(df=3)=5.3232,pͲval=0.1496
OddsRatio
Combined
0.44 0.90 1.88 3.90 8.08
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BBCS‡
3.06[1.53,6.10]
1.13[0.66,1.94]
2.31[1.31,4.06]
1.90[1.00,3.62]
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Fig2.6
Figure 2.6. Meta-analysis of ATM methylation in four case – control studies. Methylation levels at 
ATMmvp2a were separated into control quintile ranges (using identical ranges from combined analysis), for the 
previously published report on the British Breast Cancer Study (BBCS ‡)(Flanagan et al., 2009) and the three 
new case-control studies. Odds ratio of highest vs. lowest methylation quartile is shown. Combined overall 
analysis was determined using a random effects model. 
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Table2.8.AssociationbetweenmethylationlevelsattheATMlocusandbreastcancerriskintheBritish
BilateralBreastCancerStudy(BBCS)(Flanaganetal.,2009b)
Quintiles Methylation
range
Controls
(n)
Frequency
of
controls
Cases
(n)
Frequency
ofcases OR 95%CI PͲvalue
ATMmvp2a
Qi1 61.6 - 74.3  38 0.2 28 0.15 1     
Qi2 74.3 - 78.0  38 0.2 34 0.18 1.22 0.62-2.38 0.57 
Qi3 78.0 - 80.4  38 0.2 33 0.17 1.18 0.60-2.31 0.64 
Qi4 80.4 - 83.6  38 0.2 41 0.22 1.46 0.75-2.82 0.26 
Qi5 83.6 - 96.1  38 0.2 53 0.28 1.9 1.00-3.62 0.05 
ATMmvp2b
Qi1 53.0- 86.8  38 0.2 22 0.12 1     
Qi2 86.8 - 89.8  38 0.2 30 0.16 1.36 0.67-2.77 0.39 
Qi3 89.8 - 91.7  37 0.2 35 0.18 1.64 0.82-3.31 0.17 
Qi4 91.7 - 93.5  38 0.2 36 0.19 1.63 0.81-3.27 0.17 
Qi5 93.5 - 98.2  38 0.2 67 0.35 3.07 1.58-5.93 8.8x10-4 
*ORsforeachmarkerareadjustedby5Ͳyearagecategories.
**CutͲoffvaluesdeterminedbyquintilesofZͲscoresdeterminedbasedonthedistributioninthecontrol
population.ZͲscorecutoffvaluesareͲ0.77,Ͳ0.13,0.29and0.83forATMmvp2a,andͲ0.63,0.03,0.38
and0.75forATMmvp2b.
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2.4 Discussion 
 
Our findings indicate that ATMmvp2a hypermethylation may represent a marker of breast 
cancer risk, potentially making this of the first known examples of epigenetic variability 
associated with breast cancer risk.  
Previously reported epigenetic cancer risk markers include rare hypermethylation events 
within gene promoters that are normally unmethylated (epimutations) (Hansmann et al., 
2012; Hesson et al., 2010), and significantly decreased levels of genome-wide DNA 
methylation (Woo and Kim, 2012). ATM hypermethylation is distinct in that it represents a 
slightly increased frequency of methylated cells in WBCs of cancer cases relative to controls, 
detectable several years before diagnosis. Furthermore, all previous studies investigating 
gene-specific DMRs used retrospectively collected samples, often with small sample size, 
and using non-quantitative methylation-analysis methods (Widschwendter et al., 2008), 
therefore this study utilised a more thorough approach to investigation of DNA methylation 
and cancer risk. Candidate cancer risk markers similar to the ATMmvp2a DMR have been 
reported by retrospective discovery studies using candidate gene (Widschwendter et al., 
2008) and array-based (Langevin et al., 2012) approaches. External validation of loci 
identified in these studies may provide additional cancer risk biomarkers, as our investigation 
of ATM methylation supports the notion that associations between DNA methylation and 
cancer risk in retrospective studies (Flanagan et al., 2009b) may be reproducible in 
prospective studies. A recent discovery study of DNA methylation associated with breast 
cancer risk using prospectively collected DNA samples identified several significantly loci 
which remain to be validated (Xu et al., 2013b). Discovery studies for breast cancer risk are 
discussed further in chapter 6.  
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Whereas findings for ATMmvp2a were consistent between the retrospective BBC study and 
prospective studies, the previously reported (Flanagan et al., 2009b) strong association 
between methylation at the neighbouring ATMmvp2b DMR in the BBC study was not 
replicated in prospective studies. Differences in findings could be due to differences in study 
populations including the use of pre-diagnostic versus post-diagnostic blood samples, or the 
investigation of (mostly) unilateral breast cancer rather than bilateral breast cancer. 
Alternatively, the association between ATMmvp2b methylation and bilateral breast cancer 
prevalence may have occurred by chance. Methylation analysis of ATMmvp2b in an 
independent set of blood samples collected from bilateral breast cancer patients at diagnosis 
would be required for external validation, and to assess the potential value of ATMmvp2b 
methylation for diagnostic biomarker development.  
Although we did not find significant heterogeneity in ATMmvp2a risk associations across 
studies, the evidence for association of ATM DNA methylation with breast cancer risk was 
strongest for KConFab and weaker for the BGS study, and, weaker still for the EPIC cohort. 
The stronger association in KConFab may be due to the inclusion of cases with very strong 
family histories, and/or to the choice of controls that were selected from best friends of 
KConFab participants, and had no family history of breast cancer. In contrast, BGS and 
EPIC studies were nested case-control studies within general population cohorts, thus 
ensuring that cases and controls come from the same source population. There was a 
correlation between increasing methylation and increasing age at blood draw in the control 
EPIC population, as has been previously reported for DNA methylation in blood (Gomes et 
al., 2012).The age correlation was particularly strong in the EPIC cohort, which might explain 
that the risk association in this cohort was not seen in women with bloods collected at older 
ages. The use of pre-diagnostic samples from incident breast cancer cases reduces the 
possibility that methylation variability in WBC DNA was influenced by the presence of clinical 
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cancer or treatment in these patients. Furthermore, ATM methylation was not associated 
with TTD, indicating that ATM hypermethylation may represent a disease susceptibility 
marker rather than a marker of  pre-clinical disease (range of TTD in included studies was 
<1month to 11 years). Furthermore, a longitudinal study did not show a significant difference 
in average ATMmvp2a methylation between blood samples collected at two time-points from 
the same individuals, suggesting that ATMmvp2a methylation may be temporally stable, and 
may thus confer long-term breast cancer susceptibility.   
The mechanism by which methylation at ATMmvp2a could increase risk is not known, 
however the association between breast cancer risk and methylation of an intragenic 
repetitive element in ATM is consistent with a functional role for intragenic DNA methylation 
(Aporntewan et al., 2011; Flanagan and Wild, 2007; Kulis et al., 2013; Shenker and 
Flanagan, 2012). ATMmvp2a resides within an intragenic Alu repetitive element ~4kb 
downstream of the ATM transcription start site (genomic location of the ATMmvp2a shown in 
Fig 2.7). Potential functional roles of intragenic DNA methylation include regulation of 
enhancers, non-coding RNAs, gene expression, alternative splicing and alternative gene 
promoters (Akhtar-Zaidi et al., 2012; Illingworth et al., 2008; Kulis et al., 2013; Maunakea et 
al., 2010). Several recent studies have confirmed  a highly-conserved role of intragenic DNA 
methylation in regulation of alternative RNA splicing (Flores et al., 2012; Maunakea et al., 
2013; Wan et al., 2013) and experimentally induced aberrant intragenic methylation can 
result in aberrant alternative splicing (Maunakea et al., 2013). Furthermore, tissue-specific 
DNA methylation is enriched at alternatively spliced genes (Wan et al., 2013), and intragenic 
DNA methylation and alternative splicing may be associated with gene length (Flores et al., 
2012). It is plausible that intragenic ATM methylation may play such a role, as ATM is a 
particularly long gene and undergoes alternative splicing (Pagani et al., 2002). Interestingly, 
recent studies have identified a cryptic enhancer within an intragenic Alu element in the ATM 
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gene, which regulates inclusion of an adjacent exon (Pastor and Pagani, 2011; Pastor et al., 
2009). Consistently, Alu elements preferentially flank alternatively spliced exons, and may 
play a number of roles in human gene regulation including regulation of alternative splicing 
(Lev-Maor et al., 2008; Lev-Maor et al., 2003). Given the location of the ATMmvp2a DMR 
within an intragenic Alu element, the possibility that DNA methylation at this region regulates 
alternative splicing may be worth investigating. 
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Figure 2.7. Single nucleotide resolution methylation of the entire ATM gene in PBMCs. Whole genome 
methylome was obtained by deep sequencing of bisulphite treated DNA from PBMCs of a single individual. 
Methylation (%) of individual CpG sites are shown (grey dots), with a smoothed average (black line), exonic 
structure at the top of the graph (shown as black dots) and ATM risk locus marked by the vertical red line at +4kb 
(data obtained from (Li et al., 2010)) 
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It has been previously reported (LaBreche et al., 2011) that ATM expression was decreased 
in WBCs of breast cancer patients taken at the time of mammographic screening (n=51), 
compared with healthy controls (n=31). Whereas regulation of ATM at the protein level is 
relatively well understood, very little is known about transcriptional regulation of ATM. 
Investigations to date have shown that ATM transcription is regulated by binding of E2F1 to 
the ATM promoter in vitro (Berkovich and Ginsberg, 2003), and binding of  BRCA1, E2F1 
and CTIP to the ATM proximal promoter is reported to activate ATM transcription in 
response to DNA damage (Moiola et al., 2012). Intragenic ATM methylation may play a role 
in altering gene expression, as hypermethylation of the ATMmvp2b DMR was associated 
with reduced ATM expression within a panel of cell lines in a previous study (Flanagan et al., 
2009a). Analysis of potential association of ATMmvp2a methylation with ATM expression 
remains to be carried out.  
Inconsistent with the hypothesis that cancer-risk associated DNA methylation variability may 
represent an intermediate marker of environmental disease risk factors (Christensen and 
Marsit, 2011), ATM methylation was not associated with any life-style/environmental factor 
analysed, including smoking or alcohol consumption, as well as hormonal risk factors such 
as age at menarche, oral contraceptive use, parity, menopausal status and HRT use. 
Further investigation of factors underlying the association between ATMmvp2a methylation 
and breast cancer risk is reported in chapter 4.  
The possibility that ATM methylation may confer susceptibility to specific breast cancer 
subtypes was not supported by our findings, as methylation was not associated with tumour 
features or subtypes such as triple negative cancer, however, this may be due to limited 
subject numbers in this study.   
Associations of WBC genome-wide DNA methylation (and surrogate measures of genome-
wide methylation, such as methylation of LINE1 repetitive elements) with cancer have been 
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widely reported (Di et al., 2011), including studies investigating breast cancer (Xu et al., 
2012b). We found no evidence, however, of association between LINE1 methylation and 
breast cancer risk in any study within this report, and found that there was very little 
variability in LINE1 methylation overall. This is consistent with a retrospective study reported 
by our own group (Flanagan et al., 2009b). The collective evidence for association of 
genome-wide DNA methylation and cancer risk will be further discussed in chapter 3.  
 
.  
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CHAPTER 3 
 
GENOME-WIDE METHYLATION AS A CANCER RISK 
FACTOR 
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3.1. Introduction  
Genome-wide DNA methylation is the epigenetic event most widely studied in blood in 
relation to cancer risk, and in relation to epigenetic consequences of cancer-related 
exposures (Nelson et al., 2011). Genome-wide or ‘global’ DNA hypomethylation was first 
described in tumours as the lower net percentage of 5meC in tumour tissue compared with 
equivalent normal tissue, and is now known to occur frequently in all cancer types (Feinberg 
and Vogelstein, 1983; Lapeyre et al., 1981). In recent years, genome-wide hypomethylation 
in histologically normal tissue and blood of cancer patients has been extensively reported, 
leading to widespread speculation that genome-wide hypomethylation may be a cancer risk 
factor, and that measurement of genomic 5meC (and surrogate measures thereof) may 
represent useful cancer risk biomarkers. However, our prospective investigation of LINE1 
methylation in relation to breast cancer risk (chapter 2), and  other reports (Cash et al., 2011; 
Gao et al., 2012; Xu et al., 2012b), fail to reproduce these findings.  
3.1.1 Genome-Wide DNA methylation 
Despite considerable research, the causes, consequences, and exact nature of genome-
wide DNA hypomethylation remain poorly defined. An explanation for the paradoxical 
coincidence of genome-wide hypomethylation with CpG island hypermethylation in cancer 
has been long sought, yet it remains unclear whether these two phenomena are 
independent or mechanistically linked (Estecio et al., 2007; Wild and Flanagan, 2010). In 
recent years, whole-methylome analysis has revealed that rather than representing a ‘global’ 
reduction of 5meC, tumour-associated hypomethylation is confined to large genomic 
‘hypomethylation blocks’ (Hansen et al., 2011; Pujadas and Feinberg, 2012), that tend to 
occur in regions that display intermediate methylation levels in normal tissue, termed 
partially methylated domains (PMDs) (Hansen et al., 2011; Lister et al., 2009), and regions 
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of low CpG density (Ruike et al., 2010). The prevailing idea that genome-wide 
hypomethylation reflects loss of methylation primarily at repetitive elements (Aporntewan et 
al., 2011; Estecio et al., 2007; Yang et al., 2004) has been called into question with only a 
modest enrichment of repeats in hypomethylation blocks (Hansen et al.; Hon et al., 2012). 
Whereas genome-wide hypomethylation has long been implicated in loss of transcriptional 
repression, recent evidence suggests that hypomethylation at PMDs or gene-bodies may be 
also associated with gene repression through formation of repressive chromatin (Hon et al., 
2012).  
3.1.2 Causes and Consequences  
The cause of genome-wide hypomethylation remains unknown, and several potential 
contributing factors have been identified (Wild and Flanagan, 2010; Wilson et al., 2007). 
Exogenous exposures such as carcinogenic compounds may influence DNA methylation by 
inducing DNA damage or by affecting the activity of DNMT enzymes (Feinberg, 2007; 
Tajuddin et al., 2013; Yang et al., 2012). Lack of methyl donors required for DNA 
methylation, due to dietary insufficiency of folate, choline, methionine or cobalamin may 
induce hypomethylation (Friso et al., 2013; Nelson et al., 2011; Vineis et al., 2011). 
Hypomethylation has also been linked with age-associated loss of efficiency of DNA 
methylation maintenance (Rakyan et al., 2010; Teschendorff et al., 2010). Genetic factors, 
such as polymorphisms in one-carbon metabolism genes, DNMTs, and other genes (Friso et 
al., 2013; Haggarty et al., 2013; Inoue-Choi et al., 2013; Vineis et al., 2011; Wilson et al., 
2007) are associated with hypomethylation. Mutation of the MILI, MIW12 (Di Giacomo et al., 
2013), Maelstrom (Soper et al., 2008), ATRX (Gibbons et al., 2000), LSH (Dennis et al., 
2001) and CXX1 (Carlone and Skalnik, 2001) genes have been shown to induce 
hypomethylation of repetitive elements in different tissues and developmental contexts 
(reviewed by Ooi et al (Ooi et al., 2009)). Lastly, ‘field-effect’ hypomethylation in cancer and 
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surrounding histologically normal tissues may occur due to sequestration of DNA 
methylation machinery and substrates by rapidly proliferating cancer cells; therefore, 
hypomethylation in normal tissues may reflect the presence of preclinical disease within an 
individual (Lim et al., 2008; Suter et al., 2004; Wilson et al., 2007).  
Several tumorigenic consequences result from genome-wide hypomethylation, including 
chromosomal instability, potentially leading to gene-dosage alterations, increased mutation 
rates, genetic recombination events, large deletions or translocations (Laird, 2005; 
Matsuzaki et al., 2005; Wilson et al., 2007). Hypomethylation may also lead to altered 
expression of oncogenes, tumour suppressor genes, and spurious transcription of non-
coding RNAs via transcriptional read-through subsequent to a loss of repression at repetitive 
DNA (Aporntewan et al., 2011; Faulkner et al., 2009; Slotkin and Martienssen, 2007). 
Transcription of repetitive elements is a feature of many cancers, and occurs frequently in 
brain tissue, with largely unknown consequences (Faulkner et al., 2009; Rangwala et al., 
2009). Whether genome-wide hypomethylation represents an early or causative event in 
cancer or a passive consequence remains unknown (Wild and Flanagan, 2010). The 
detection of hypomethylation in cancer precursor lesions and normal adjacent tissue and the 
induction of cancers in animal models  with experimentally induced hypomethylation suggest 
a causative role (Flatley et al., 2009; Gaudet et al., 2003; Suter et al., 2004; van Hoesel et 
al., 2012). However, the occurrence of many cancers in the absence of genome-wide 
hypomethylation, and the progression of hypomethylation with cancer stage suggest a 
passive role (Estecio et al., 2007; Wild and Flanagan, 2010). 
3.1.3 Repetitive element hypomethylation 
Due to the long held view that genome-wide hypomethylation was associated with repetitive 
elements (Yang et al., 2004); numerous surrogate assays for genome-wide methylation have 
been developed specifically targeting consensus sequences for repetitive elements. These 
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include the long interspersed nuclear element 1 (LINE1), Alu elements (a family of short 
interspersed nuclear elements (SINEs), and Sat2, a satellite repeat element (Laird, 2010; 
Yang et al., 2004). LINE1 (hereafter referred to as ‘L1’) is the only autonomous (capable of 
independent retrotransposition (transposition via an RNA intermediate)), and most highly 
expressed TE in the human genome, comprising ~17% of the human genome, with over 
500,000 copies (Beck et al., 2010; Cordaux and Batzer, 2009; Wilson et al., 2007). A full 
length L1 element is ~6kb long with a bi-directional, non-canonical promoter and two open 
reading frames (ORFs) coding for an endonuclease and retrotransposition machinery 
proteins (Beck et al., 2010; Cordaux and Batzer, 2009; Wilson et al., 2007). L1 transcription 
is largely regulated by DNA methylation of the 5’ promoter; however, the majority of L1 
elements are truncated and cannot be transcribed (Faulkner et al., 2009; Rangwala et al., 
2009; Slotkin and Martienssen, 2007). Less than 100 L1 elements are functionally capable of 
retrotransposition, only a few of which contribute to the vast majority of retrotransposition 
events (Beck et al., 2010). Alu elements, of which there are multiple families, are the most 
common TE in the human genome, with ~1.1 million copies, comprising roughly 11% of the 
genome (Cordaux and Batzer, 2009; Wilson et al., 2007). Alu elements are non-autonomous 
and their transposition requires the transposition machinery of L1(Wilson et al., 2007). 
Satellite repeats (including Sat2) are short tandemly repeated non-coding DNA, frequently in 
centromeric and heterochromatic regions of chromosome 1 (Wu et al., 2012a). Both L1 and 
Alu elements are heavily methylated in normal somatic tissue, however, hypomethylation of 
both, especially L1, is often detectable in tumours (Estecio et al., 2007; Figueiredo et al., 
2009; Suter et al., 2004). Whereas transcription of TEs are required for their transposition, 
transposition-independent consequences of transcription may have functional 
consequences, as an estimated 7% of the human transcriptome is derived from transcription 
start sites (TSS) within L1 elements (Faulkner et al., 2009) and hypomethylation induced 
transcription of L1 elements within host gene introns can effect host gene transcription 
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through RNA interference (Aporntewan et al., 2011) and through driving host gene ectopic 
expression from the L1 antisense promoter (Wolff et al., 2010).  
 
3.1.4 Methods for Investigating Genome-Wide Methylation 
Several methods have been designed to investigate genome-wide DNA methylation. Some 
methods capture overall genomic DNA 5-methyl-cytosine (5meC) content, using 5meC-
specific antibodies (Weber et al., 2005), methyl-acceptance (Pufulete et al., 2003) and High 
Performance Liquid Chromatography (HPLC), often combined with mass spectrometry (MS) 
(Choi et al., 2009). These methods provide accurate measurement of whole-genome 
methylation, but with no information about the spatial arrangement or genomic location of 
DNA methylation, and require large amounts of input DNA, making them unsuitable for many 
population studies using precious (such as prospectively collected) patient samples 
(Brennan and Flanagan, 2013). Widespread DNA methylation patterns may be measured 
using methylation sensitive restriction enzymes with relatively high resolution; however, 
methylation analysis is biased towards regions of high CpG density, as the enzyme 
restriction sites occur at sequences such as CCGG, and CGCG for the HpaII and Hha1 
restriction enzymes, respectively (Laird, 2010; Xu et al., 2012a). Many other genome-wide 
methylation assays are based on bisulphite sequencing (Beck and Rakyan, 2008; Rakyan et 
al., 2011), however, real-time PCR, restriction enzyme based (combined bisulphite 
restriction analysis (COBRA)(Hsiung et al., 2007)), and microarray-based methods (Beck 
and Rakyan, 2008) are also used. Most popular and convenient for population studies is the 
measurement of methylation at repetitive elements such as L1, Alu and Sat2, which are 
distributed at high frequency throughout the human genome (Wilson et al., 2007; Yang et al., 
2004). These are considered ‘surrogate’ measures of genome-wide DNA methylation as 
their methylation is thought to reflect genome-wide methylation levels (Yang et al., 2006). 
87 
 
However, the efficacy of these surrogate assays for genome-wide methylation has been 
questioned (Brennan et al., 2012a; Nelson et al., 2011), and a re-interpretation of the results 
reported using these assays is warranted.  
In order to assess the current evidence for association of genome-wide DNA methylation 
with cancer risk, and to identify the most promising research avenues and methods for 
development of cancer risk biomarkers,  we conducted a meta-analysis of all available 
studies investigating blood genome-wide DNA methylation in relation to cancer risk. 
 
  
88 
 
3.2 Methods 
3.2.1 Search strategy 
Eligible studies included prospective and retrospective case-control studies published 
between 01/01/2000 and 08/06/2012 that investigated genomic DNA methylation in blood, 
and its potential association with either cancer incidence or prevalence (Details provided in 
appendix table1). Studies using any quantitative measure of genome-wide DNA methylation, 
or any surrogate measurement thereof, were included. Required for meta-analysis was the 
reporting of categorical analysis of the relationship between DNA methylation and the cancer 
outcome, including odds ratio (OR) and confidence intervals. Cancer types included 
malignant disease and colorectal adenoma, a non-malignant colorectal cancer precursor. 
Controls included individuals without cancer, with variable control selection criteria. Literary 
searches were performed using Pubmed, by Brennan K. B.Sc and Flanagan J.M. PhD. 
Pubmed Search terms used were ‘LINE1 blood risk’, ‘DNA methylation blood risk’, 
‘methylation blood cancer’ and ‘hypomethylation blood cancer’. Reference lists from all 
included studies and relevant reviews were screened for additional studies, but yielded no 
additional reports. No unreported studies or reports in languages other than English were 
identified, therefore all relevant studies, both included and excluded, are represented 
appendix table1 
3.2.1.1 Excluded studies 
All relevant studies found are included in Appendix table1. Inclusion criteria were kept as 
broad as possible in order to avoid selection bias. Six studies (Appendix table1) were 
excluded due to non-reporting of categorical analysis only. 
3.2.1.2 Data abstraction 
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All data included in meta-analyses (except for our own unpublished data), including effect 
estimates and study details, was abstracted directly from the reports referenced in Appendix 
table1. Inverse odds ratios were calculated for studies reporting odds ratios for the highest 
methylation category compared with the lowest (reference) category, and standard errors 
(SE) for ORs were calculated from confidence intervals (CI) using the formula SE=(log(upper 
CI)-log(lower CI))/(2*1.96). ORs for L1 studies not reporting categorical analysis was 
performed by inference based on the sample size, mean methylation and standard deviation.  
While an ideal meta-analysis would extract raw data and perform the same analysis on all 
data, this was not possible due to raw data not being available for most published studies. 
3.2.1.3 Inclusion of unreported data 
The only included studies that were not publicly available were those conducted by 
ourselves, for which categorical analysis was conducted and included. Study populations 
and laboratory methods were previously reported(Brennan et al., 2012a). LINE1 methylation, 
measured by bisulphite pyrosequencing, was split into quartiles based on control methylation 
distribution. Unconditional logistic regression was used to determine the OR for disease, 
comparing the lowest quartile to the highest (reference) category. 
3.2.2 Meta-analysis 
Meta-analysis was carried out using the R statistical program. The ‘meta.summaries’ 
command within the ‘rmeta’ R package was used to generate average summary estimates, 
weighted by sample size, using random-effects models due to significant inter-study effect 
heterogeneity, as indicated by Woolf’s test for heterogeneity (p<0.05).  
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3.2.3 Funnel plot 
A funnel plot for publication bias was generated using the ‘funnel’ command within the ‘meta’ 
R package, with standard error on the Y axis.  
3.3 Results 
 3.3.1 Meta-analysis 01/01/2000-08/06/2012 
Twenty three publications reported population-based cancer case-control studies 
investigating blood genomic DNA methylation in relation to cancer risk (Appendix table 1). It 
is important to note that the comparability of these studies is limited by a wide range of 
differences between them; however, such differences may also help to determine the 
characteristics of genome-wide hypomethylation that are potentially associated with cancer 
risk. Major variables between these reports included cancer type, assay used, study design 
(prospective/retrospective), sample size, sex (male/female/mixed), ethnicity and 
analytical/statistical methods. Furthermore, populations at different cancer risk are included, 
for instance one report included elderly men at high risk (Zhu et al., 2011), whereas another 
included Asian women who are at lower risk of breast cancer (Cash et al., 2012). Some of 
these reports included more than one “study”, due to use of different assays, different 
populations or different study designs, so altogether there were 34 individual studies of 
genome-wide methylation and cancer risk (Appendix table1). The greatest limitation to 
comparison between these studies was reporting of data analyses. Some studies compared 
average DNA methylation between cases and controls only at the mean or median level, 
whereas most studies also included categorical analysis, generating an OR for disease for 
individuals in the lowest methylation category compared with the highest (reference) 
category. The OR for disease within the risk-associated methylation category was the most 
consistently reported, comparable, and representative (of overall results) factor reported 
between studies, and was, therefore used for comparison between studies. Therefore, eight 
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studies that did not report categorical analyses and indeed were not significantly different 
between cases and controls, could not be included resulting in an over-estimate of any 
positive effects (Cho et al., 2010; Choi et al., 2009; Patchsung et al., 2012; Pobsook et al., 
2011; Widschwendter et al., 2008; Zhu et al., 2011) (Appendix table1). We have also 
included categorical analyses of L1 methylation in two of our own population-based 
prospective case-control studies for breast cancer risk (chapter 2), for which categorical 
analysis was not previously reported. As four studies (three reports)(Liao et al., 2011; Lim et 
al., 2008; Xu et al., 2012b) used the lowest, rather than the highest methylation category as 
the reference category, inverse ORs were calculated for these studies. Importantly, the 
methylation ‘split’ (tertile, quartile, quintile or decile), used for categorical analysis varied 
between reports, and is a potential effect modifier, however, this cannot be easily corrected 
without obtaining the raw data for each of the studies.  A meta-analysis of many of the 
relevant studies was recently reported by Woo et al (Woo and Kim, 2012), which did not 
include five relevant, recent and predominantly null reports (Brennan et al., 2012b; Di et al., 
2011; Mirabello et al., 2010; Wu et al., 2012b; Xu et al., 2012b).Therefore, this analysis 
represents a revised meta-analysis including all reported studies.  
The overall summary estimate OR for all genomic DNA methylation studies using a random 
effects model was OR=1.4 (95% CI= 0.9-1.9), suggesting no overall association (Fig 3.1). 
Summary ORs for studies using L1 (OR=1.24, 95% CI=0.76-1.72), Alu (OR=1.31, 95% 
CI=0.93-1.68) and Sat2 repetitive elements (OR=1.55, 95% CI=0.99-2.10) were not 
significantly associated with cancer risk. Significant heterogeneity between studies was 
evident (p=<0.001), likely due to the use of different assays and investigation of different 
diseases, including both cancers and CRA (Lim et al., 2008; Pufulete et al., 2003).
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Figure 3.1. Meta Analysis of Studies investigating Genome-wide DNA methylation in peripheral blood DNA for 
cancer risk (studies published between 01/01/2000 and 08/06/2012). Test for heterogeneity showed highly 
significant heterogeneity across all studies (p<0.001), and specifically in the analysis of 5meC (p<0.001) and LINE1 
(p<0.001), but not significant for Alu (p=0.121) or Sat2 (p=0.827). Random Effects (RE) model was used for all 
summary analyses. CRC=colorectal cancer, CRA=colorectal adenoma, BGS=Breakthrough Generations Study, 
EPIC=European Prospective Investigation into Cancer and Nutrition. Study reference numbers correspond to 
appendix Table 1. 
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We investigated whether there was evidence of publication bias among studies investigating 
L1 methylation by generating a funnel plot (Stroup et al., 2000; Thornton and Lee, 2000) 
using all available studies (Fig 3.2). We did not observe funnel-plot asymmetry (evidence of 
publication bias); however, the ability of this plot to indicate publication bias may be limited 
by the small number of studies (n = 14), and variable direction of effect in studies showing 
significant associations. All of the included reports showing significant association between 
L1 methylation and cancer included investigations of L1 methylation only; however, all 
reports showing negative results for L1 also included studies showing significant 
associations between another methylation marker and cancer incidence/prevalence, 
consistent with a bias toward publication of significant associations. There appears to be a 
trend toward lower effect size with later publication date, as OR is significantly correlated 
with publication year among L1 methylation studies (spearman r = 0.49, P = 0.05). This 
appears to be independent of sample size, as the correlations between OR and sample size 
(r = í0.19), and sample size and year of publication (r = 0.2), are not significant. Inclusion of 
all relevant reports is critical to the accuracy of meta-analyses (Thornton and Lee, 2000), 
therefore, publication and reporting biases may affect our ability to identify the true effect 
size.  
  
Fig3.2
Figure 3.2 Funnel plot for potential publication bias in LINE1 reports. Log Odds Ratio is shown on the X-axis, 
with Standard Error on the Y-axis and summary effect size and 95% confidence intervals are shown as dotted vertical 
lines. Studies are shown with shape representing the categorical split reported in the study, size representing the size 
of the study and open shapes representing retrospective studies and filled shapes representing prospective studies. 
The light grey area represents 99% confidence limits and dark grey represents the 95% confidence limits. 
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A reporting bias exists whereby categorical analysis of methylation-risk associations tends 
only to be reported if it reveals statistically significant results, and if the authors deem 
categorical analysis appropriate. In order to address this bias, we conducted a meta-analysis 
of all published L1 studies (01/01/2000-08/06/2012), including estimated ORs for those 
studies that did not include categorical analysis, by inferring OR based on sample size, 
mean methylation and standard deviation of methylation. This was in addition to inclusion of 
our own L1 studies, for which we had not previously reported categorical analysis (Brennan 
et al., 2012a). Meta-analysis of all L1 studies shows that blood L1 methylation is not 
associated with cancer risk (summary OR= 1.10, 95% CI=0.92-1.32), and there was 
significant heterogeneity across studies (p<0.001) (Fig 3.3). 
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Figure 3.3. Meta Analysis of Studies investigating LINE1 DNA methylation in peripheral blood DNA for 
cancer risk. Test for heterogeneity showed highly significant heterogeneity across all studies (p<0.001), and 
therefore random effects (RE) model was used for summary analyses. Four additional studies that showed no 
significant difference between cases and controls and did not report categorical analysis have been included 
showing an estimated odds ratio of 1 and standard error estimated from sample sizes. 
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3.3.2 Update meta-analysis (08/06/2012-05/09/2013)  
Since compilation of the above meta-analysis, 8 publications have reported 11 studies of 
genome-wide DNA methylation of cancer risk (Appendix table1). An update meta-analysis 
was conducted for all studies reporting categorical analysis published within this time. Of 11 
studies overall, only seven reported ORs for categorical analysis of the association between 
DNA methylation and cancer risk, including studies using HPLC, methyl-acceptance assay, 
LUMA, MethyLight methylation analysis of ALU, Sat1, and L1, and pyrosequencing of L1. 
Consistent with the previous meta-analysis, there was no overall association between DNA 
methylation within the lowest methylation category and cancer risk (OR=0.82, 95% CI=0.56-
1.19) (Fig 3.4). Furthermore, there was significant heterogeneity variance between study 
estimates (Woolf’s test of heterogeneity) (p=0.003). 
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Figure 3.4. Update meta Analysis of Studies investigating Genome-wide DNA methylation in peripheral 
blood DNA for cancer risk (studies published between 08/06/2012 and 05/09/2013). Test for heterogeneity 
showed highly significant heterogeneity across all studies (p=0.003) Random Effects (RE) model was used for all 
summary analyses. Reference numbers for studies correspond to those shown in Appendix Table 1. 
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3.4 Discussion 
According to the STROBE-ME (Strengthening the reporting of observational studies in 
epidemiology-molecular epidemiology) guidelines, all basic statistics of a biomarker measure 
distribution (mean, median, range and variance) and details of all other analyses should be 
reported in studies investigating molecular biomarkers for disease risk (Gallo et al., 2011). 
However, many reports do not include these basic statistics making comparison between 
studies difficult, and making thorough meta-analysis of the collective evidence impossible.  
Overall, we did not find a significant association between genome-wide DNA methylation 
and cancer risk, either in a meta-analysis of 28 studies published between 01/01/2000 and 
08/06/2012, or in an update meta-analysis of 11 studies published since then. Therefore, 
that genome-wide hypomethylation is detectable in blood of cancer patients is not supported 
by the data overall. Consistently, two studies reporting hypomethylation detectable in tumour 
and normal adjacent tissue of bladder (Wolff et al., 2010) and colon (Suter et al., 2004)  
failed to detect hypomethylation in blood in the same sample sets (Suter et al., 2004; Wolff 
et al., 2010), suggesting that hypomethylation may be restricted to the disease affected 
tissue. Indeed, a number of studies have indicated that methylation of repetitive elements 
may be tissue specific, most pronounced in tumour, and not correlated between tumour and 
blood (Cho et al., 2010; Piyathilake et al., 2011; van Bemmel et al., 2012). Furthermore, 
~36% of L1 elements display tissue-specific expression (Faulkner et al., 2009).  
The current findings are inconsistent with a previous meta-analysis (Woo and Kim, 2012) 
which reported a significant inverse association between both genome-wide DNA 
methylation and cancer risk overall, as well as a significant inverse association between L1 
methylation an cancer risk. The current analysis, however, included five additional studies 
(Brennan et al., 2012b; Di et al., 2011; Mirabello et al., 2010; Wu et al., 2012b; Xu et al., 
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2012b) within the primary meta-analysis, and seven additional studies within the update 
meta-analysis, therefore representing an updated revision of the evidence.  
There is great inconsistency between findings reported by different studies, as is evident 
from the highly significant heterogeneity variance between effect estimates between studies 
found in the primary meta-analysis, L1 study analysis, and update meta-analysis. Many 
factors may account for this variability, as follows.  
 
3.4.1 Cancer heterogeneity 
One consideration is that heterogeneity between cancer types may affect the overall findings 
from this meta-analysis. For example, in tumour tissue, L1 hypomethylation frequently 
occurs in cancers displaying chromosome instability, but rarely in cancers with microsatellite 
instability (Estecio et al., 2007; Matsuzaki et al., 2005; Ogino et al., 2008). Consistently, L1 
hypomethylation shows considerable inter-individual variability in colon cancer, and is 
frequently undetectable in tumours (Estecio et al., 2007). Therefore, it might be expected 
that DNA methylation variability in blood may predict risk of some, but not all cancers. In 
breast cancer, however, two studies (Choi et al., 2009; Xu et al., 2012b) investigating blood 
L1 methylation failed to find any associations, consistent with our own studies.  
 
3.4.2 Methylation measurement/assay-type 
There appears to be some evidence for association of genome-wide DNA hypomethylation 
and cancer prevalence within studies using measures of 5meC content, as our primary 
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meta-analysis (studies published between 01/01/2000 and 08/06/2012) showed a significant 
association with cancer risk overall. Furthermore, all five studies included reported significant 
associations between hypomethylation and cancer prevalence in categorical analysis, four of 
which also found significant association at the mean level. However, of four studies 
published since 08/06/2012, only two showed evidence of association between 5meC 
content and cancer risk (Friso et al., 2013), whereas two studies (Huang et al., 2012; Tahara 
et al., 2013), including the first prospective investigation (Huang et al., 2012) found no 
association. A recent study (Friso et al., 2013), which could not be included in our analysis 
due to incomplete reporting of categorical analysis statistics, reported very strong 
association between HPLC-measured hypomethylation and gastric cancer risk using inter-
quartile analysis, yet the ORs  and 95% CIs were not reported. Instead, ORs for cancer risk 
within the retrospective study (OR=45.9, 95% CI= 14.3-147.6), and prospective study 
(OR=36, 95% CI=3.9-329.9) were calculated using categorical analysis with subjects 
dichotomised at methylation cut-offs calculated to best discriminate cases from controls 
using ROC curves. As the proportions of cases and controls within each methylation quartile 
were reported for the retrospective study (but not the prospective study) the OR for 
individuals within the lowest methylation quartile (n=64) compared with the highest quartile 
(n=21) was 19.6, however confidence intervals or standard error could not be calculated 
based on reported data. Overall, it appears likely that 5meC content is reduced in blood of 
cancer patients; however this may not be evident in all cancers and populations, and may 
not be reproducible in prospective studies, therefore, 5meC loss may be a marker of disease 
prevalence rather than risk.  
Two studies to date have investigated genome-wide DNA methylation in blood of breast 
cancer patients using the LUMA method, with one study (Xu et al., 2012b)  reporting a 
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strong protective effect of genomic DNA hypomethylation on breast cancer risk; however, a 
more recent study (Wu et al., 2012a) failed to replicate this. The identification of 
hypermethylation, rather than hypomethylation associated with cancer may be due to the 
measurements of methylation at CCGG restriction sites, which are enriched at CpG islands. 
These regions tend to be unmethylated in normal tissue, meaning that the only change 
detectable would be an increase in methylation (Xu et al., 2012b). 
Consistent with our own research findings (chapter 2), there was no overall association 
between blood L1 methylation and cancer. Whereas early studies suggested an association 
of blood L1 hypomethylation with cancer, later studies have failed to replicate this. 
Experimental improvements and advances in larger epigenetic epidemiological studies may 
account for this. Furthermore, the direction of effect on cancer prevalence of L1 
hypomethylation was inconsistent between studies (Liao et al., 2011), suggesting that these 
associations may have occurred by chance.  
Methylation of TEs, particularly L1, is often reported as genome-wide or ‘global’ DNA 
methylation. This is confusing and inappropriate as L1 pyrosequencing measures 
methylation at only three to four CpG sites within the promoters of a pool of L1 elements 
(Yang et al., 2004), which cannot be considered representative of genome-wide methylation 
(Nelson et al., 2011). The detection of genome-wide hypomethylation by these assays in 
tumour DNA is likely due the occurrence of a proportion of repetitive elements within 
hypomethylated domains, rather than to a specific enrichment of hypomethylation at 
repetitive elements (Hansen et al., 2011; Hon et al., 2012). Furthermore, whereas an early 
study reported that L1 and Alu methylation were correlated with 5meC levels in blood, a 
more recent report was unable to validate this (Choi et al., 2009). This lack of correlation is 
supported by the stronger association with cancer risk of blood methylation detected with 
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5meC measures than with surrogate assays such as L1. Two prospective cancer risk studies 
detected blood hypomethylation at Alu (Gao et al., 2012) and Sat2 (Wu et al., 2012b), but 
not at L1 in the same samples. This is inconsistent with these assays detecting “genome-
wide methylation”, but suggests that hypomethylation may be restricted to specific genomic 
sequences. Technical biases, such as the preferential amplification of different elements due 
to PCR annealing temperature may be a problem for primers with multiple binding sites (El-
Maarri et al., 2011), as L1 elements are differentially methylated at different genomic loci 
(Phokaew et al., 2008; Singer et al., 2012; Wolff et al., 2010). The precise selection of CpG 
sites within the L1 consensus sequence is also important, as we and others (Piyathilake et 
al., 2011) have noticed that L1 methylation varies significantly between CpG sites, a factor 
that may explain some of the disparities between studies. L1 sequence heterogeneity poses 
yet another bias, as this may cause cellular and allelic heterogeneity in L1 methylation 
(Burden et al., 2005), and may lead to underestimation of methylation levels (Yang et al., 
2006). Differential methylation of individual L1 elements may yet be important, as a recent 
study showed that potentially pathogenic hypomethylation of an individual L1 within gene 
introns was much more pronounced than hypomethylation of global L1 elements, and was 
detectable in normal tissue, where global L1 hypomethylation was not (Wolff et al., 2010). 
Furthermore, hypomethylation of a specific L1 element, LRE1 was detected in blood of head 
and neck cancer patients (Hsiung et al., 2007), suggesting that methylation analysis of 
individual TEs may yet be useful as biomarkers of cancer risk.  
 
3.4.3 Prospective versus retrospective studies  
Of four prospective studies investigating L1 methylation and cancer risk that were included in 
the primary meta-analysis, only one (Zhu et al., 2011) identified an association between low 
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L1 methylation and cancer incidence, however, small sample size (n=30 cases, 487 
controls), combining of multiple cancer types, and selection of a very high-risk population 
(elderly males) may all be confounding this finding. A recent study (Li et al., 2013), which 
showed statistically significant L1 hypomethylation (pyrosequencing) in cancer patients 
(mixed cancers), could not be included in the meta-analysis due to non-reporting of 
categorical analysis. This association, however, was not adjusted for age, smoking and 
occupational exposures, all of which were also associated with L1 methylation and cancer 
risk. The four most recent, relatively large studies, have failed to identify any such 
associations (Brennan et al., 2012b; Cash et al., 2011; Wu et al., 2012b). Therefore, the 
current evidence suggests that L1 methylation is not a risk factor for cancer. Of two 
prospective studies to date investigating 5meC (measured by HPLC) in relation to cancer 
risk, one small study identified a significant association with gastric cancer risk (Friso et al., 
2013), whereas a larger study (Huang et al., 2012) found no association with colorectal 
cancer.   
 
3.4.4 Other study design factors 
Differences between study designs tend to contribute to heterogeneity and bias in meta-
analyses (Stroup et al., 2000; Thornton and Lee, 2000). These analyses included studies of 
different study designs, included familial studies, hospital-based studies and nested case-
control studies. Sample size is another likely bias, and varies largely between the reports, 
including two studies with very small sample size of less than 40 cases (Pufulete et al., 
2003; Zhu et al., 2011). Small sample sizes are only appropriate where the difference in 
methylation between groups is large, as such studies do not have the power to detect subtle 
methylation variability, perhaps leading to an interpretation bias towards non-significance, or 
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to chance detection (Rakyan et al., 2011). Control for potential confounding factors, including 
any factor that may influence both exposure and outcome independently, is a basic 
requirement for all molecular epidemiological studies, and may be achieved by matching of 
cases with controls based on potential confounding factors, or by adjustment within 
statistical models. Several cancer risk factors, including age (Christensen et al., 2009; 
Rakyan et al., 2010), gender (Cash et al., 2012; Wilhelm et al., 2010) (El-Maarri et al., 2011) 
, ethnicity (Cash et al., 2012; Hou et al., 2010; Zhang et al., 2011a) (Fraser et al., 2012; 
Zhang et al., 2011a) and environmental carcinogen exposures (Bollati et al., 2007; Cash et 
al., 2011) are reported to influence genome-wide DNA methylation patterns. Therefore, 
overall findings of included studies may depend on the influence of study-specific 
confounding factors, and on the degree to which they were controlled for.  
 
3.4.5 Statistical factors 
Publication bias, whereby studies reporting significant results are more likely to be 
published, is one of the most significant potential biases in meta-analysis of scientific studies 
(Thornton and Lee, 2000). A funnel plot of studies investigating L1 methylation in relation to 
cancer risk did not show evidence of publication bias; however publication of negative L1 
studies only within papers reporting other significant findings suggest publication bias. 
Furthermore, as categorical analysis is generally only included in reports if it shows 
significant results, an over-estimation of the true summary effect size in meta-analysis is 
likely.  
A prominent bias between studies was the use of different numbers of categories for 
categorical analysis, which included tertiles, quartiles, quintiles and deciles. Categorical 
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analysis may not have been appropriate for these studies, especially with use of larger 
numbers of quantiles, as the narrow ranges of DNA methylation reported, especially at L1, 
would mean that the difference in percentage methylation between categories would be far 
below the detection sensitivity of the assay. for instance the technical variation for 
pyrosequencing is around 2-3%, and we observed an intra-class correlation coefficient (ICC) 
for LINE1 in blinded duplicate samples of 0 (95% CI 0-0.61) which suggests higher within 
individual variability than between individual variability (chapter 2).  
 
3.4.6 Conclusions 
We conclude from our meta-analysis that that genome-wide DNA methylation, as measured 
by surrogate repetitive element assays, is not associated with cancer risk, demonstrated 
most appropriately by several prospective cohort studies. In contrast, associations of total 
methylation levels observed with HPLC and LUMA based measurements appear to be 
associated with cancer risk, but remain to be validated. 
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CHAPTER 4 
 
Investigation of Factors Influencing ATM Methylation 
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4.1 Introduction 
Many studies have identified significant association between DNA methylation and diseases; 
however, few have sought to determine the mechanism, or potential factors underlying the 
association. Our research indicated that ATMmvp2a hypermethylation is associated with 
breast cancer risk, however whether ATM hypermethylation represented an innate 
epimutation-like risk factor, or an intermediate marker of other breast cancer risk factors, 
such age, BMI, or dietary factors, was not clear.  
DNA hypermethylation associated with epimutations and repeat instability disorders may be 
caused by underlying genetic variability, however it is epigenetic silencing of gene 
expression that confers disease risk (Dolinoy et al., 2006; Hesson et al., 2010; Hitchins and 
Ward, 2009). The stronger association between ATMmvp2a methylation and cancer risk in 
the familial KConFab study than the sporadic studies suggests underlying genetic factors, 
consistent with the genetically mediated heritability of aberrant epigenetic patterns 
associated with cancer risk (Hitchins et al., 2011; Ligtenberg et al., 2009). 
Conversely, epigenetic epidemiological research postulates that epigenetic mechanisms 
mediate aberrant gene expression through alteration by age and environmental risk factors 
(Bollati et al., 2007; Brennan and Flanagan, 2012a; Christensen and Marsit, 2011; Shenker 
et al., 2013). This is supported for breast cancer by the finding that environment-linked 
metabolic diseases associated with increased breast cancer risk, including diabetes and 
obesity, are associated with epigenetic changes (Bell et al., 2010; Cheraghi et al., 2012; 
Milagro et al., 2011; Xu et al., 2013a). The association of ATMmvp2a methylation with age in 
control supports the idea of non-genetic modifiers of ATMmvp2a methylation; however the 
temporal stability of ATMmvp2a methylation between time-points ~6 years apart suggests 
that methylation is not strongly altered by age or environmental factors.  
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Lastly, In the case of agouti mice, genetic factors (the presence of an intracisternal A particle 
retrotransposon within the agouti gene) and environmental factors (maternal dietary folate 
insufficiency) are required to bring about the agouti phenotype associated with metabolic 
disease and cancer risk (Dolinoy et al., 2006), therefore complex genetic-epigenetic-
environmental interactions may contribute to disease susceptibility.  
 In order to determine the factors driving the association, we investigated the effect on 
ATMmvp2a methylation of genetic and environmental factors.  
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4.2 Materials and Methods.  
4.2.1 Subjects 
The KConfab study population, described in chapter 2 (materials and methods, study 
populations) was used to investigate the potential influence of haplotype on DNA 
methylation. The study consisted of 166 blood samples collected prospectively from breast 
cancer cases within high-risk families, and 225 samples collected from healthy unrelated 
control at the same time. Cases were invasive breast cancers collected at a median 45 
months (range 1 – 140) prior to diagnosis.  
The EPIC study was designed to enable prospective investigation of dietary and metabolic 
factors in relation to cancer risk (Riboli and Kaaks, 1997), and was therefore used to assess 
the effect of serum metabolites, fasting status, BMI, age, and MTHFRc677t genotype on 
ATMmvp2a methylation. Five EPIC sub-groups (labelled EPIC1, EPIC2, EPIC3, EPIC4 and 
EPIC5 (table 4.1)) were included in the analyses of ATMmvp2a methylation.These included 
two healthy control populations for which serum metabolite data for 24 metabolites related to 
one carbon metabolism, inflammation, and tryptophan metabolism were measured. 
Metabolites were measured by Bevital A/S (www.bevital.no) using liquid chromatography 
and gas chromatography with tandem-mass spectrometry, and microbial assays to measure 
folate and cobalomine (Johansson et al., 2010). Three prospective breast cancer case-
control sub-groups were used, including one sub-group (EPIC3, n=277 cases, 282 controls) 
that was included in the investigation of ATMmvp2a methylation in relation to breast cancer 
risk (chapter 2), and two new sub-groups (EPIC4 (n=92 cases, 92 controls) (Shenker et al., 
2012)and EPIC5 (n=109 cases, 119 controls) (van Veldhoven et al., unpublished data)) 
(Table 4.1). 4 cases and 8 controls within the EPIC4 subgroup were removed from analysis 
due to sample overlap with the EPIC5 subgroup. These samples were removed from EPIC4 
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rather than EPIC5 prior to analysis, as EPIC4 samples had been bisulphite converted ~1 
year before EPIC5 samples, therefore EPIC5 samples are likely to be of higher quality 
according to the Zymo-research bisulphite conversion kit manual (EPIC4 data in table 4.1. 
shown for included samples only). Methylation values from EPIC4 were removed, rather 
than calculating average methylation values for methylation analysis within EPIC4 and 
EPIC5 subgroups in order to avoid introducing batch-effects. Microarray-based investigation 
of fasting on DNA methylation was carried out using all samples from EPIC5, and an 
addition 104 samples, including 49 controls and 55 cases (see table 4.1(B)).  .  
Fasting-status was self-reported as part of a standardised dietary questionnaire completed 
at the time of blood draw. Fasting time (time since last meal to blood draw) was available for 
98 subjects with median length of time for fasting individuals 12.8 (IQR 12-13.7) hours 
compared with 2.4 (IQR=1.5-3.2) hours in non-fasting individuals.  
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Table 4.1 Characteristics of EPIC study subgroups used in chapter 4 
4.1 (A) Characteristics of EPIC study participants included in analysis of ATMmvp2a DNA methylation 
Control studies 
Study EPIC1 EPIC2 
Fasting status Non-fasting Fasting Non-fasting Fasting 
N 24 48 8 135 
Age (median (IQR)) 56 (53.6-56.1) 56.2 (53.3-59.1) 56 (54-58.5) 55 (50-60) 
Prospective case control breast cancer studies 
Study EPIC3 
Case-control Case Control 
Fasting status Non-fasting Fasting Non-fasting Fasting 
N 151 126 157 125 
Age (median (IQR)) 56.1 (47.1-63.2) 47.2 (43.9-54.5) 56.6 (48.3-63.3) 47.2 (44.2-55.5) 
BMI (median (IQR)) 25.36 (22.66-29.00) 24.72 (22.46-28.18) 24.74 (22.57-27.71) 25.04 (22.69-27.47) 
    
Study EPIC4 
Case-control Case Control 
Fasting status Non-fasting Fasting Non-fasting Fasting 
N 51 37 41 43 
Age (median (IQR)) 51.04 (44.2-55.3) 51.8 (48.2-58.4) 49 (44.3-54.4) 53.8 (50.3-57) 
BMI (median (IQR)) 23.78 (21.95-26.85) 25.98 (23.51-28.89) 24.51(22.09-27.44) 24.94 (22.44-27.63) 
    
Study EPIC5 
Case-control Case Control 
Fasting status Non-fasting Fasting Non-fasting Fasting 
N 23 86 30 89 
Age (median (IQR)) 54.5 (50.2-57.6) 55.3 (51.0-58.1) 55.2 (51.9-60.0) 55.2 (48.0-58.0) 
BMI (median (IQR)) 24.42 (22.32-25.91) 25.25 (22.55-27.59) 24.72 (21.38-26.46) 24.5 (22.44-26.6) 
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Table 4.1 (B) Characteristics of EPIC study participants included in EWAS study of DNA methylation and fasting  
Discovery set analysis 1  
Study EPIC5 
Case-control Case Control 
Fasting status Non-fasting Fasting Non-fasting Fasting 
N 23 86 23 84 
Age (median (IQR)) 54.37 (45.85-57.9) 54.70 (48.65-57.57) 55.2 (51.53-59.24)  54.23 (47.25-57.63) 
BMI (median (IQR)) 24.27 (22.45-25.99) 25.32 (22.56-27.62) 24.72 (21.40-26.54) 24.38 (22.34-26.56) 
Discovery set analysis 2  
Study EPIC5/EPIC6  
Case-control Case Control 
Fasting status Non-fasting Fasting Non-fasting Fasting 
N 23 86 30 89 
Age (median (IQR)) 53.84 (46.37-58.17) 54.53 (48.49-57.75) 53.27 (47.06-58.28) 54.32 (47.68-57.75) 
BMI (median (IQR)) 24.51 (22.63-26.43) 25.25 (22.67-27.77) 24.64 (21-39-26.55) 24.28 (22.31-26.57) 
Control studies (validation set) 
Study EPIC7  
Fasting status Non-fasting Fasting 
N 104 76 
Age (median (IQR)) 48.5(42.75-54.00) 50 (44.75-55)  
BMI (median (IQR)) 23.71 (22.00-27.06) 26.31 (22.77-29.50) 
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4.2.2 Laboratory methods 
4.2.2.1 DNA extraction 
DNA samples were extracted from whole blood using Qiagen DNA blood Mini Kits in 
KConFab.  DNA was extracted from buffy coat using DNA Blood Mini Kits (Qiagen, UK) for 
all EPIC studies except EPIC2, for which DNA was extracted from whole blood using the 
same kit.  
PCR and pyrosequencing for ATM and LINE1 was performed as described in chapter 2, 
materials and methods. PCR and pyrosequencing for MTHFR was carried out using a single 
round PCR with a biotinylated reverse primer. Single round semi-nested PCR was used to 
amplifyTOX2, ASB10, ADARB2, PER3 and LGR6, with a common tag incorporated into 
either the forward or reverse primer, depending on the strand being sequenced, and a 
universal biotinylated primer, as described previously (Royo et al., 2007). Primers were 
designed using the Pyromark Assay Design software 2.0 (Qiagen). Primers are shown in 
table 4.2 (a). Pyrosequencing was carried out as described in chapter 2.  
4.2.2.2 Acquirement of DNA from specific blood cell fractions.     
DNA isolated form monocytes, B lymphocytes and T lymphocytes from two individuals were 
provided generated for a previous study (Flanagan et al., 2009b). Blood cell fractionation 
was carried out using antibody-coated microbeads and MACS MS separation columns 
(Miltenyi Biotech) following standard manufacturers protocol. 
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4.2.2.3 Genotyping 
Genotyping of ATM to determine the haplotype was carried out by pyrosequencing in 
bisulphite converted DNA with assays for three SNPs within the ATM gene (rs228589, 
rs664677 and rs664982), allowing distinction of a putative risk haplotype from the reference 
haplotypes, and from a further three rare possible haplotypes (Rebbeck et al., 2011). DNA 
methylation of four CpG sites surrounding rs228589, and methylation of a polymorphic CpG 
site harbouring a SNP at the guanine (rs664982) was simultaneously measured within the 
same pyrosequencing runs. The allele frequency for a given SNP was determined by 
calculating the ratio of peak heights for each allele to reference peak heights for nearby non-
polymorphic single nucleotides of the same base types, which represented the ‘expected’ 
peak heights for individuals homozygous for a given allele. Thresholds of less than 10% 
difference between observed and expected peak heights were set, so that a sample 
homozygous for an A allele within a SNP should have an A peak height of within 10% of the 
peak height of a reference A outside of a SNP, and an individual heterozygous for the A 
allele should display an A peak height of within 10% of half of the height of the reference A 
nucleotide. As the frequency of each allele within a SNP were calculated separately, 
agreement between the allele values was required to ‘pass’ a sample.  All samples that were 
not called automatically we re-called by manually assessing individual peaks. Genotyping of 
all three SNPs was successful for 307 out of 399 samples. Genotypes were within the Hardy 
Weinberg Equilibrium (HWE p= 0.789). MTHFRc677t (rs1801133) genotype was measured 
using the same method, and genotype was within HWE (p=0.62). Primers are shown in table 
4.2 (b). 
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Table 4.2 Primers designed for work within chapter 4  
A. Primers for validation of fasting-associated loci from 450k analysis 
Primer Name  Sequence (5’ – 3’)  
TOX2 F  TTATGGTTGTATAGTATTTTATGGTGTATG  
TOX2 R gacgggacaccgctgatcgtttaCCAAACCAACTAAATCCAATCTCTAAA  
TOX2 S ATGGATATTTGGGTTGATT 
HDAC4 F gacgggacaccgctgatcgtttaTTGGGAGGTTTTTGGGAAGTTTAGA  
HDAC4 R ACCTCTTTTTCAAACCAAATCAAC 
HDAC4 S AAATCCTAACCTACTCTC 
ASB10 F GTGGATTAAAAGGAAAAAAAGAGAGAA 
ASB10 R gacgggacaccgctgatcgtttaACTAAAACACCTCAAACCCATAAT 
ASB10 S AGAAGATGAGAAATTAGGTT 
PER3 F ATGGGAGGAAAAAATTATTTGAGAGG  
PER3 R gacgggacaccgctgatcgtttaATCCTTTCAAACTTTACTTTTTAAATTTAC  
PER3 S GGAGTATTTAGGAAGGT  
ADARB2 F gacgggacaccgctgatcgtttaGGGGYGTAGTAAGAAGTTGGT  
ADARB2 R CAACACCTATTCTCCCATCAA  
ADARB2 S CCCCCRCRCCCCCAAC  
LGR6 F GTGATTTGTTGTAGGAAGTGAGAAATATA  
LGR6 R gacgggacaccgctgatcgtttaACCTTAATCTTCCCATTCCTTAACC  
LGR6 S GGGGTATAGAGGAGG 
B. Primers for genotyping of ATM 
Primer Name  Sequence (5’ – 3’)  
ATM rs228589 F GTGGTTTTTGTTGTGGTTTTGATTAT 
ATM rs228589 R gacgggacaccgctgatcgtttaCCTTTAACCTCAAAAATCCTTCTATC 
ATM rs228589 S ATCCAATAACCCTCC 
ATM rs664677 F AAGTTTTAAGGTAATTTATTAGGGTTATTT 
ATM rs664677 R gacgggacaccgctgatcgtttaACCATTCTATAATAACCCCCAAAAAAA  
ATM rs664677 S AGTATTTAGAAAATTTATTGAAAGG 
ATM rs664982 F AATGGTTAATAGAGTTTTTTGAGAGT 
ATM rs664982 R gacgggacaccgctgatcgtttaTCAAACRTCTAATAAAAACCCACTCTACCA 
ATM rs664982 S ATTTTGTTATATATTAATGTTGT 
*F=forward, R=reverse, S=sequencing 
*Lower case letters represent universal tag sequence 
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4.2.2.3 Ex vivo culturing of PBMCs 
PBMCs from six healthy females were extracted from blood using ficoll gradient, and 
immediately cultured for 24 hours in Dulbecco’s modified eagle medium (Sigma) containing 
different concentrations of glucose (1.0g/L, 0.5g/L, 0.25g/L and 0g/L), and 10% dialysed 
(glucose depleted) foetal calf serum.  A ‘baseline’ PBMC sample from each individual was 
frozen overnight and processed at the same time as the cultured PBMC samples to control 
for the effect of in vitro culture on ATMmvp2a methylation. Glucose restriction was carried 
out in two batches of three participants, with three glucose concentrations (1g/L, 0.5g/L and 
0g/L) used for all individuals, and an extra concentration (0.25g/L) for the second batch 
(participants D, E and F). Glucose concentrations were based on a standard serial dilution, 
where 1g/L represented the 100% glucose concentration recommended by the manufacturer 
for the cell culture medium. Cell proliferation and viability was determined using the CellTiter 
96 Aqueous One solution (Promega). Cells were plated in triplicate at 1,000 cells per well of 
a 96-well plate. The CellTiter solution was added at 24 h using 30 uL/well and further 
incubated for 3 h at 37°C, and the absorbance was read at 490 nm to quantify the formazan 
product.  
 
4.2.2.4 Microarray  
Genome-wide investigation of the effect of fasting on DNA methylation was carried out using 
the Illumina Infinium HumanMethylayion450 BeadChip microarray (450k array). A detailed 
description of this array has been published previously (Dedeurwaerder et al., 2011). The 
450k array measured DNA methylation at 482,421 CpG sites and 3091 non-CpG sites 
genome wide, including sites within intragenic and intergenic regions as well as dense 
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coverage of CpG islands, island ‘shore’ and ‘shelf’ regions, imprinted regions, and known 
DMRs. DNA methylation is measured using two different assay types known as Infinium I 
and Infinium II assays. Both assays measure DNA methylation based on DNA sequencing of 
the methylation-dependent C>T polymorphism created at CpG sites on bisulphite 
conversion.  The type I Infinium assay utilises two different probe types, one which binds to 
unmethylated CpG sites and the other which binds to methylated CpG sites, each of which is 
attached to a different type I bead type. Base extension is identical for unmethylated and 
methylated probe types, and the signal from each is read within the same colour channel. 
The type II utilises a single probe type that binds to both unmethylated and methylated DNA 
due to mismatches at CpG sites within the probe sequence. This probe binds directly 
adjacent to the target cytosine, and differential incorporation of fluorescently labelled 
nucleotides occurs during base extension (green-labelled C or G nucleotides (depending on 
which strand is being measured) bind to unconverted sites, whereas red-labelled A or T 
nucleotides bind to converted sites). The methylated (green) and unmethylated (red) signals 
are generated in different colour channels. 500ng of each bisulphite-converted DNA was 
hybridized to the array following the Illumina Infinium HD methylation protocol. Microarray 
methylation values are represented as ȕ-values, which represent ratios of the fluorescence 
intensity of the methylated bead type to the fluorescence intensity of the unmethylated bead 
type for a given probe, so that 0 equates to a fully unmethylated CpG site and 1 represents a 
fully methylated CpG site. Methylation values were background-subtracted using Genome 
studio from Illumina. Samples in which 20% of probes failed (probe detection p-value >0.05) 
were removed and probes that failed in 20% of samples were removed from analysis. After 
quality control, 484,804 probes were included in analysis. Methylation data for each sample 
was normalised using quantile normalisation. Peak-based correction was used to adjust for 
differences in methylation distribution between type I and type II probes (Dedeurwaerder et 
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al., 2011), using type I probes as the reference type. This is because measurements of type 
I probes have been shown to be more accurate and reproducible, and to display less 
technical variability, compared with type II probes (Dedeurwaerder et al., 2011). The ComBat 
package (Johnson et al., 2007) was used to adjust for batch effect between experimental 
batches (array chips).  
 
4.2.3 Statistical analysis 
Pyrosequencing Data analysis 
The  Wilcoxon Rank Sum test was used as a non-parametric  test for difference in mean 
methylation between ATM haplotypes. Associations between DNA methylation and MTHFR 
genotype were conducted using linear regression models treating MTHFR genotype as a 
numerical variable when testing for a dose-effect association with the minor allele, and as a 
categorical variable when testing for differences in methylation between individual 
genotypes. A p-value for deviation from Hardy-Weinberg equilibrium was calculated using a 
non-parametric permutation Chi-squared test with 10000 permutations.  Linear regression 
models were used to test for associations between ATMmvp2a methylation and serum 
metabolites, using univariate models and models adjusted for age, fasting status and 
MTHFR genotype as there was evidence that these factors affect ATMmvp2a DNA 
methylation, and as these factors may affect metabolic profiles.  The association between 
ATM methylation and fasting was tested using non-parametric Wilcoxon Rank Sum test, and 
linear regression models adjusted for age, BMI, study centre, blood-donor status, and breast 
cancer case-control status were used. Logistic regression was used to generate odds ratios 
(ORs) for having below-median ATM methylation associated with fasting. A meta-analysis, 
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using effect estimates (ORs) and standard error for each study, was conducted, using a 
random-effects model weighted by study size. Two-tailed paired student’s T-tests were used 
to test differences in DNA methylation associated with glucose restriction, comparing mean 
methylation between conditions and paired for each participant. Unpaired two-tailed 
student’s T tests were used to test for differences in cell proliferation in different glucose 
conditions for the cell proliferation (MTT) assay. DNA methylation was log-transformed prior 
to using parametric tests, in order to transform methylation to a more normal distribution, as 
indicated by histogram-plotting. 
4.2.3.1 Microarray data analysis 
Individual univariate Linear regression models were used to test if fasting status was 
associated with potential effect modifiers including age, breast cancer case-control status or 
EPIC study centre.  As methylation was not associated with these factors, univariate linear 
regression models were used to investigate associations between DNA methylation and 
fasting status. Wilcoxon rank sum test was used as a non-parametric alternative model for 
testing associations between methylation and fasting status. FDR corrected p-values <0.05 
were considered statistically significant. 
Additional probe-filtration parameters used in this analysis included removal of probes 
harbouring SNPs within the CpG site at which DNA methylation is measured (polymorphic 
CpG sites), as DNA methylation at these sites is affected by genotype, which may be 
unevenly distributed between sample groups, and probes binding to >1 genomic locus in 
silico, as methylation at these sites may be affected by differential binding between samples 
(Price et al., 2013). Information for both of these factors is given for all probes n the 450k 
array in a recent ‘re-annotation’ of the 450k beadchip array (Price et al., 2013) (NCBI GEO 
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accession number [GSE:42409]).  All statistical analysis was conducted using the R 
statistical program (version 2.15.1). 
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4.3 Results  
4.3.1 ATM Haplotype  
We first investigated if ATMmvp2a methylation was associated with genetic haplotype as a 
previous study had reported that a common ATM haplotype is associated with increased risk 
of breast cancer in BRCA1 mutation carriers (Rebbeck et al., 2011). Furthermore, recent 
reports have indicated that haplotype-associated DNA methylation is relatively common 
across the genome (Kerkel et al., 2008; Schalkwyk et al., 2010; Shoemaker et al., 2010). 
ATM haplotype was measured for cases (n=166), and controls (n=225) within the kConFab 
familial breast cancer study, in which ATM methylation was most strongly associated with 
breast cancer risk (OR=3.06 (95% CI 1.53-6.10) (chapter 2) (Brennan et al., 2012b).  There 
were 89 individuals with the reference haplotype, defined as having the major allele for all 
three SNPs, 139 individuals heterozygous for all SNPs and 58 individuals homozygous for 
the minor alleles at all three SNPs (risk haplotype). ATMmvp2a methylation did not differ 
significantly between risk and reference haplotypes (p=0.29) (Fig4.1), or within BRCA1 
mutation carriers only (data not shown). Furthermore, methylation of CpG sites surrounding 
rs228589 did not differ between genotypes (data not shown). Therefore, methylation 
variability at ATMmvp2a is unlikely to be driven by genetic factors in cis. As expected, due to 
the small numbers, neither haplotype, nor any of the three SNPs individually were 
significantly associated with case control status. 
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Fig 4.1.
Figure 4.1. ATMmvp2a DNA methylation stratified by ATM haplotype. ATM Haplotype and ATMmvp2a 
methylation analysed in blood DNA samples from the the KConFab prospective breast cancer case-control study 
(n=166 cases, 225 controls) . Pyrosequencing was used for methylation analysis and genotyping of three ATM 
SNPs (rs228589, rs664677 and rs664982) that were informative of haplotype. TTTTA: individuals homozygous for 
the a common ‘reference’ haplotype (n=89), AACCGG: individual homozygous for the allele putatively associated 
with breast cancer risk (Rebbeck et al, Cancer Res 2011) (n=58), TATCAG: Individuals heterozygous for reference 
and risk alleles (n=139).  
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4.3.2 MTHFRc77t genotype 
DNA methylation can also be affected by genotype in trans, through alteration of OCM 
efficiency by genetic polymorphisms within genes encoding enzymes required for OCM, 
including a well-studied SNP  within the methylenetetrahydrofolate reductase (MTHFR) 
gene, known as MTHFRc677t (rs1801133) (Friso et al., 2013). To investigate the potential 
interaction of MTHFRc677t genotype with ATMmvp2a methylation and one carbon 
metabolism, rs1801133 was genotyped in all samples from EPIC1, EPIC2  EPIC 4 and 
EPIC5 sub-groups (n= 615 subjects combined). In controls, ATMmvp2a methylation was 
significantly increased in individuals with genotype CC (n=124) compared with combined 
genotypes CT and TT (n=296, p=0.003), after adjusting for age and fasting status. There 
was a significant positive linear relationship between ATMmvp2a methylation and presence 
of the C allele in controls (p=0.04) (fig4.2). In cases (EPIC4 and EPIC5 only), ATM 
methylation was not different between genotype CC (n=76) and genotypes CT and TT 
(n=123, p=0.92), and there was not a linear association between ATMmvp2a methylation 
and MTHFR genotype (p=0.863). The association in controls was mainly driven by a very 
strong association in the EPIC1 and EPIC2 subgroups (table 4.3).  
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Figure 4.2. ATMmvp2a DNA methylation stratified by MTHFRc677t genotype (both measured using 
pyrosequencing) in blood DNA samples of  (A) healthy female controls and (B) prospectively collected breast 
cancer cases, within four combined subgroups of the European Prospective Investigation into nutrition and 
Cancer (EPIC) study. DNA methylation values from all subgroups were combined as Z-scores (Y-axes). Numbers 
of individuals with each genotype were (control) TT n=78, CT n=218, CC n=124 , (cases) TT n=34, CT n=98, CC 
n=76. ** p-value <0.01 (logistic regression) for a difference in methylation between genotypes CC and combined 
genotypes CT and CT in controls. 
. 
Fig 4.2.
A. B.
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4.3.3 Serum Metabolites 
ATMmvp2a methylation was analysed in PBMC DNA from EPIC1 (n=72) and EPIC2 (n=146) 
for which 24 serum metabolite levels had been measured (Table 4.3). These included 15 
metabolites involved in one carbon metabolism (OCM), due to the known limiting role of 
OCM on DNA methylation genome wide (Chiacchiera et al., 2013), neopterin, and 9 
tryptophan metabolites, due to their roles in ageing and immune cell activation (Frick et al., 
2004). ATMmvp2a methylation was not consistently associated with serum levels of any 
OCM metabolite. Methylation was associated with serum folate levels in EPIC1 (p=0.005), 
but not in the EPIC2 (p=0.97), nor in combined analysis (p=0.09). Serum folate was 
significantly correlated with homocysteine levels in EPIC1 (p=8.022e-06, rho=-0.49) and 
EPIC2 (p=3.722e-06, rho=-0.37). The MTHFR C allele was negatively associated with serum 
homocysteine, with both heterozygotes and homozygotes showing significant associations in 
both EPIC1, EPIC2 and combined analysis, especially after adjustment for serum folate 
levels (CT p=0.00011, CC p=1.52e-05). However, adjustment for MTHFR genotype did not 
significantly alter associations between ATMmvp2a methylation and other serum metabolites 
(Table 4.3).
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Surprisingly, ATMmvp2a methylation was significantly associated with serum levels of 
tryptophan metabolites: kynurenic acid (KA), hydroxykynurenine, kynurenine-D and 3-
hydroxyanthranillic acid in EPIC2, and in the combined analysis, independent of MTHFR 
genotype or fasting status, however, only KA remained significant after adjusting for fasting 
status (p=0.02) or MTHFR genotype (p=0.03) (Table 4.3). Interquartile analysis of the 
association indicated that ATMmvp2a methylation was significantly lower within the highest 
KA quartile (median 73.89%, n=55) compared to the lowest quartile (median 77.90%, n=55) 
(p=0.009) (Fig 4.3). KA was positively correlated with hydroxykynurenine (p=1.143e-05, 
rho=0.29), 3-hydroxyanthranillic acid (p=1.424e-08, rho=0.37), and kynurenine (p=0.0014, 
rho=0.23), and negatively correlated with ATMmvp2a DNA methylation (p=0.007, rho=0.19), 
but was not correlated with tryptophan or OCM metabolites, folate or homocysteine (data not 
shown).  
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Fig4.3
Figure 4.3. ATMmvp2a DNA methylation measured by pyrosequencing, stratified by quartiles of 
kynurenic acid (KA) measured using liquid-chromatography-mass-spectrometry in healthy female 
control blood samples. Samples represent two subgroups (EPIC1 and EPIC2) within the European 
Prospective Investigation into Nutrition and Cancer (EPIC). DNA methylation is represented by z-
scores (Y-axis), enabling combined analysis of subgroups. 
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4.3.4 Tissue-specific DNA methylation 
Measurement of DNA methylation variability in whole blood cell populations is often 
confounded by the occurrence of tissues-specific DNA methylation between different cell 
types, leading to apparent differential methylation between individuals with different cell-type 
proportions (Koestler et al., 2012; Reinius et al., 2012). We measured ATM methylation in 
monocytes, B lymphocytes and T lymphocytes from a single individual, and monocytes and 
T cells from a second individual, separated by magnetic bead linked antibody cell separation 
(MACS) (Flanagan et al., 2009b). T lymphocytes displayed ATMmvp2a methylation of 28% 
and 43% in the two individuals, whereas monocytes and B cells were heavily methylated 
(93-98%) in monocytes and B cells (Fig 4.4).. The ATMmvp2b repetitive element MVP 
381bp downstream of ATMmvp2a also displays hypomethylation within T lymphocytes 
compared with other cell types, but to a lesser extent (21-28% lower methylation), consistent 
with higher methylation and lower methylation variability at this region, suggesting that inter-
individual variability in blood of ATMmvp2a methylation may be restricted to T lymphocytes. 
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Figure 4.4 DNA methylation analysis (pyrosequencing) of (A) ATMmvp2a and (B) ATMmvp2b in 
blood cell fractions for two individuals, including monocytes and T lymphocytes for participant A  (blue 
bars) , and B lymphocytes, monocytes and T lymphocytes from participant B (green bars). 100% 
methylated (MC) and unmethylated (UC) controls (red bars), and whole PBMCs from a third individual, 
participant C (purple bar) are shown for reference. Error bars represent standard deviation across three 
technical replicates (PCR and pyrosequencing). 
A.
B.
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4.3.5 Fasting Status 
ATMmvp2a methylation was substantially lower in blood samples from individuals who had 
fasted compared with non-fasting samples for both EPIC1, and EPIC2 sub-groups, and this 
difference was significant for the combined analysis (p=0.03) (Table 4.3 and Fig 4.5). The 
fasting-status variable was also available for three EPIC prospective breast cancer cases-
control sub-groups, including the previously reported EPIC3 sub-group (Shenker et al., 
2012), and two new sub-groups (EPIC4 and EPIC5). ATMmvp2a methylation was 
consistently lower in fasting blood samples compared with non-fasting samples in all studies, 
and this was statistically significant for EPIC3 (p=1.016e-05) and EPIC5 (p=0.005), but not 
for EPIC4 (p=0.37) (Fig 4.5). Using combined Z-scores for all sub-groups, ATMmvp2a 
methylation was significantly lower in individuals who had fasted prior to blood draw (n=689) 
compared to those who had not (n=485) (Wilcoxon signed rank sum test, p=4.572e-07), and 
this was independent of age, BMI and study centre. The average methylation difference 
between non-fasting and fasting individuals overall was 5.2% across all study subjects 
(range 4.0-12.2). In order to determine the effect of fasting on ATMmvp2a methylation, a 
meta-analysis was conducted, combining the odds ratios (OR) from all five sub-groups, 
representing the likelihood of a fasting individual displaying ATMmvp2a methylation below 
the median (Fig 4.5 (F)).  The individual ORs (95% confidence intervals (95% CIs) for the 
subgroups were: EPIC1: 1.57 (0.88-2.91), EPIC2: 1.32 (0.64-2.97), EPIC3: 1.66 (1.38-2.0), 
EPIC4: 1.25 (0.92-1.68), and EPIC5: 1.65 (1.16-2.38), and these were statistically significant 
for EPIC 3 (p=9.28E-08) and EPIC5 (p=0.006). The summary OR, using a random effects 
model, was 1.56 (1.36-1.77), and the estimated heterogeneity variance was not significant 
(p=0.207). Meta-analysis in controls and cases separately, using only case-control sub-
groups (EPIC3, EPIC4 and EPIC5), showed that ATMmvp2a methylation was significantly 
associated with fasting in both controls and cases, however, the summary effect was greater 
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in controls (1.68 (95% CI: 1.04, 2.32)) than in cases (1.46 (95% CI: 1.25, 1.66)), and there 
was significant heterogeneity variance in controls (0.2, p=0.002), but not in cases (0, p=1) 
(Fig 4.6).  
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Figure 4.5: Association of ATMmvp2a DNA methylation with Fasting Status. (A-E) ATMmvp2a 
methylation was lower in fasting individuals compared with non-fasting individuals in all studies. (F) Meta-
analysis of association between ATMmvp2a methylation and fasting status based on odds ratio (OR) of 
below median ATMmvp2a methylation in fasting individuals, using a random effects model weighted by 
study size. Het p=Estimated Heterogeneity Variance p-value.  
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Figure 4.6 Meta-analysis of association between ATMmvp2a methylation and fasting status stratified 
by case-control status based on odds ratio (OR) for having <median ATMmvp2a methylation in fasting 
individuals, using a random effects model weighted by study size . Cases in red and controls in black. 
het=estimated heterogeneity variance p-value.  
135
  
136 
 
4.3.6 Age 
As reported in chapter 2 ATMmvp2a methylation was significantly associated with age in 
controls (r2=0.27, p=0.008), but not cases (r2=0.035, p=0.583) in EPIC3. The association in 
controls remained significant after adjusting for fasting status (p=0.0003). Similarly, in 
combined new analysis, ATMmvp2a methylation was significantly increased with age in 
controls (n=418, r2=0.42, p=0.004), but not cases (n=197, r2=-0.05, p=0.99), after adjusting 
for fasting (Fig 4.7). A previous report indicated that DNA methylation at the LINE1 repetitive 
element may be associated with serum glucose (Ulrich et al., 2012). However, we observed 
no evidence of association with fasting status and DNA methylation at LINE1 (Fig 4.8 (A)). 
Furthermore, there was no association between DNA methylation at the ATMmvp2b region 
(Fig 4.8 (B)), suggesting that the fasting effect is locus specific.  
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4.3.7 Ex-vivo Glucose Restriction 
Since a response to fasting is rapid (~10 hours difference between fasting and non fasting 
individuals), and ATM has a role in glucose metabolism, we hypothesised that the effect of 
fasting on DNA methylation may be mediated by a depletion of a blood glucose or cellular 
energy. Therefore, we investigated whether the fasting effect could be recapitulated by in
vitro glucose restriction of peripheral blood mononuclear cells (PBMCs). Consistent with the 
epidemiological fasting data, average ATMmvp2a methylation across all subjects was 
significantly lower (5.15%) in PBMCs cultured in 0.5g/L (50%) glucose compared with 1.0g/L 
(100%, p=0.046) (Fig 4.9). There was inter-individual variability in the methylation response, 
whereby four out of six participants displayed methylation loss, whereas two subjects 
showed no change (Fig 4.9 (B)). Lower methylation with glucose restriction was consistent 
for the 0.25g/L glucose condition in two out of three individuals (Table 4.4). There was no 
change on average in ATMmvp2a methylation from baseline to 1.0g/L, indicating that 
ATMmvp2a methylation alteration was due to glucose restriction and not in vitro culturing 
alone. Using an MTT cell viability assay we show a significant loss of cell viability with 
complete glucose restriction (0%, p=1.74 e-05), however, there was no change between 
1.0g/L (100%) and 0.5g/L (50%), or 0.25g/L (25%) conditions, indicating that partial glucose-
restriction-induced ATMmvp2a hypomethylation was independent of cell death or 
proliferation (Fig 4.10). However, ATMmvp2a methylation was not altered by glucose 
restriction in cell lines derived from normal breast epithelium (MCF10a), and an ER+ 
invasive breast cancer (MCF7) (fig 4.11), supporting the idea that ATMmvp2a 
hypomethylation is cell-type-specific.  
  
20
25
30
35
40
45
50
55
60
Baseline 1.0g/L 0.5g/L
A
T
M
m
v
p
2
a
m
e
th
y
la
ti
o
n
(%
)
Mediumglucoseconcentration(g/L)
ATMmvp2amethylation
*
10
20
30
40
50
60
70
A B C D E F
A
T
M
m
v
p
2
a
m
e
th
y
la
ti
o
n
(%
)
participant
ATMmvp2amethylation
1.0g/L
0.5g/L
Fig 4.9.
A.
B.
Figure 4.9: Reduction of ATM methylation upon glucose restriction. (A) Mean ATMmvp2a methylation, 
measured by pyrosequencing in PBMCs from six individuals  at baseline, and after culture for 24h in media 
with glucose concentrations of 1g/L (full-glucose), and 0.5g/L (glucose-restricted). Error bars represent 
standard deviation across six individuals. *p<0.05. (B) Showing ATMmvp2a methylation at 1.0g/L and 0.5g/L 
glucose conditions for each individual separately, indicating inter-individual variability in epigenetic response 
to glucose restriction. Error bars represent standard error of the mean across three technical replicates. 
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Figure 4.10 Cell proliferation in PBMCs in response to glucose restriction. PBMCs collected from three 
healthy female participants,  were cultured for 24 hours  in different medium glucose concentrations (1g/L 
(100%) (X-axis). Y-axis represents Percentage Cell Viability measured by MTT assay.  Error bars represent 
standard deviation across three technical replicates. P-values represent t-test compared with 100% (1g/L) 
control.
Fig 4.10.
141
86
88
90
92
94
96
98
1g/L 0.5g/L 0.1g/L 0g/L
A
T
M
m
e
th
y
la
ti
o
n
(%
)
mediumglucoseconcentration
ATMmvp2amethylationanalysisinglucose
restrictedincelllines
MCF7
MCF10A
Fig 4.11.
Figure 4.11. ATMmvp2a methylation analysis in glucose restricted cell lines. Mean ATMmvp2a 
methylation, measured by pyrosequencing in an ER+ breast cancer (MCF7) and a normal breast 
epithelium (MCF10A) cell line, after culture for 24h in media with glucose concentrations of 1g/L ,  
0.5g/L, 0.1g/L and 0g/L . Error bars represent standard deviation across three technical replicates. 
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Table 4.4. Mean and standard deviation (SD) of ATMmvp2a methylation in PBMCs of 6 participants (A-F) after culture 
for 24 hours in media of different glucose concentrations (1.0g/L, 0.5g/L, 0.25g/L, 0g/L).  
Participant Baseline 
Mean 
1.0g/L 
SD 
1.0g/L 
Mean 
0.5g/L 
SD 
0.5g/L 
Mean 
0.25g/L 
SD 
0.25g/L 
Mean 
0g/L 
SD 
0g/L 
A 51 45.4 4.64 35.7 12.04 _*  _  49.51 4.61 
B 38.34 41.84 5.11 33.41 3.71 _  _  46.14 4.21 
C 49.71 50.68 5.61 50.54 5.96 _  _  49.56 3.52 
D 63.61 43.87 0.89 45.07 2.01 49.42 2.86 52.34 1.57 
E 38.17 40.97 1.32 36.41 4.11 36.65 4.94 34.8 3.83 
F 47.07 53.47 4.87 44.2 5.32 39.4 4.2 38.61 3.14 
* 0.25g/L glucose concentration not measured for participants A-C  
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4.3.8 Genome-wide Analysis of Effect of Fasting on DNA Methylation 
DNA methylation data at ~480,000 loci genome-wide, generated using the Illumina Infinium 
HumanMethylayion450 BeadChip array, was available for 311 EPIC PBMC DNA samples 
(controls=156, n cases=155) for which fasting status was available, enabling genome-wide 
screening for additional loci associated with fasting. This sample set included 210 samples 
from EPIC5, and an additional 101 samples (Table 4.1).  
4.3.8.1 Analysis Method 1 
Initial analysis was restricted to the EPIC5 subgroup for which ATMmvp2a methylation data 
was also available (n=210) as this represented a positive control for the effect of fasting on 
DNA methylation. Using univariate linear regression, 8112 loci were significantly associated 
with fasting with q value <0.05 (p value after FDR correction) (Fig 4.12). 149 significant loci 
had median absolute ǻȕ-values associated with fasting (difference in median methylation 
between non-fasting and fasting individuals) >0.05 (5%), with 146 loci showing a loss of 
methylation in fasting individuals and 3 loci an increase in methylation in fasting individuals. 
The largest decrease in methylation associated with fasting was 11%, and the largest 
increase was 5.7%. TOX2_ cg20889774 (ǻȕ =0.92), ASB10_ cg01954686 (ǻȕ =0.11) and 
HDAC4 cg04011897 (ǻȕ =0.037) were selected for validation in an independent sample set 
based on low q values, high absolute ǻȕ values in the case of TOX2 and ASB10, and 
multiple (11) loci associated with fasting within the same gene for HDAC4 (Table 4.5). The 
validation sample set consisted of 104 non-fasting and 76 fasting individuals (all healthy 
control subjects). TOX2 methylation was significantly lower in fasting (median=92.5) 
compared with non-fasting (median=93.7) individuals in the validation set (p=0.03) (Fig 4.13 
(A)), however, the difference in median methylation (1.2%) was much smaller than the ǻȕ-
value for the discovery set, and the methylation distribution was much higher and narrower 
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in the validation set than the discovery set (Fig 4.13 (B)). Fasting-associated methylation 
differences did not validate for either the ASB10 or HDAC4 loci, and both displayed very 
high methylation (90-95%) with narrow methylation ranges compared with array data (Fig 
4.13 (B,C)),  suggesting a skewing of methylation values caused either by differences 
between pyrosequencing and Infinium-based methylation analysis, or introduced through 
array data processing. 
ǻȕ (fasting-non-fasting)
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Fig 4.12.
Figure 4.12. Top 8378 loci significantly associated with fasting status (FDR <0.05). Each point represents
a single CpG site. –log10 q-values (Y-axis) are plotted against the ǻȕ-values (median ȕ-value for fasting
individuals - median ȕ-value for non-fasting individuals) (X-axis). Negative values on the X-axis indicate lower
methylation in fasting (n=170), compared with non-fasting (n=46) individuals. The solid line at 0.00 (X-axis)
represents a 0% difference in methylation. Broken lines represent cut-offs for ǻȕ-values of lesser than -0.05 or
greater than 0.05, indicating 5% decreases or increased in DNA methylation, respectively, in fasting versus
non-fasting individuals.
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4.3.8.2 Analysis Method 2 
In order to maximise the potential of identifying loci associated with fasting, the additional 
samples for which array data was available (n=49 controls, 55 cases, see table 4.1) were 
included in the analysis, and a new analytical approach was used. Firstly, all polymorphic 
CpG sites, i.e. CpG sites harbouring SNPs within the C or G, on the 450k array (listed within 
a recently reported re-annotation of the array (Price et al., 2013) were excluded from 
analysis in order to exclude false positives occurring due to chance differences in allele 
frequency between experimental groups, which bias methylation at those sites. Also 
excluded were probes with >1 in silico binding sites, listed in the same re-annotation, in 
order to restrict analysis to loci with high-confidence annotation. Using a non-parametric 
Wilcoxon-rank sum test to identify loci significantly associated with fasting, 106 loci were 
associated with fasting after FDR correction (q<0.05), with absolute ǻȕ-values > 0.05, 
included 58 loci displaying a decrease of methylation in fasting individuals and 48 loci 
displaying an increase in fasting individuals (Fig 4.14). Among these 106 were 4 adjacent 
loci within the promoter of LGR6, all displaying a methylation increase (11.9-21.4%) in 
fasting, compared with non-fasting individuals, and two adjacent loci within the FAM101A 
gene, both displaying decreased methylation (5.4-6%) in fasting, compared to non fasting 
individuals (Fig 4.14 and Table 4.5).  
Figure 4.14. Top 106 loci significantly associated with fasting status in analysis 2. Showing significant loci
(FDR p-value (q-value) <0.05) with absolute ǻȕ-values >0.05 (5%) . Each point represents a single CpG site. –
log10 q-values (Y-axis) are plotted against the ǻȕ-values (median ȕ-value for fasting individuals - median ȕ-value
for non-fasting individuals) (X-axis). Negative values on the X-axis indicate lower methylation in fasting, compared
with non-fasting individuals. The solid line at 0.00 (X-axis) represents a 0% difference in methylation. Coloured
points represent loci within LGR6 (red), ADARB2 (green), PER3 (dark blue), ASB10 (light blue) and FAM101A
(pink).
Fig 4.14.
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Spatial clustering of CpG sites displaying a consistent pattern of association with the 
outcome of interest have been validated in previous studies investigating the effect of 
smoking on DNA methylation (Joubert et al., 2012; Shenker et al., 2012). Spatial clustering 
of fasting-associated loci was therefore considered a potential indicator of genuine 
association, and was assessed for all genes to which ‘top hit’ fasting-associated loci were 
annotated, by plotting the ǻȕ-values for all loci within those genes against genomic location 
(representative examples shown in Fig 4.15). Clear spatial clustering of fasting associated 
loci was evident for loci within ADARB2, FAM101A, HTR3A, KLK15, LDHAL6A, LGR6, 
LIN7B, PER3, PLD6, TMEM151B and YTHDC1, but not other loci. 
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Figure 4.15. Selecting of loci significantly associated with fasting in Illumina Infinium HumanMethylayion450 
BeadChip array for pyrosequencing validation based on concordant patterns of fasting-associated methylation of 
neighbouring CpG sites. ǻȕ-values associated with fasting status (median DNA methylation in fasting individuals 
minus median methylation in non-fasting individuals (Y -axis)) for all loci annotated to genes in which  ‘top hit’ 
significantly fasting-associated loci reside , plotted against genomic location (X-axis). Each point represent a CpG 
site represented on the array (significantly associate loci  circled in red). (A) LDHAL6A, an example of a locus 
significantly associated with fasting and displaying clustering of fasting-associated methylation pattern with 
neighbouring CpG sites, whereby several local CpG sites, though not statistically significantly associated with 
fasting, display concordant hypomethylation. (B) GOLGA3, example of a locus not displaying clustering, as no 
neighbouring loci display concordant fasting-associated methylation. 
A.
B.
Fig 4.15.
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Plotting of fasting-associated regions displaying spatial clustering revealed that the 
association with fasting of loci within LGR6 and LIN7B were confounded by trimodal 
methylation patterns that are suggestive of a haplotype-associated DNA methylation pattern 
that is not due to polymorphic CpG sites (Discussed in chapter 6). Other loci displaying 
spatial clustering did not display clear trimodal methylation distributions (Fig 4.16); however, 
haplotype information would be required to determine whether allelic skewing of methylation 
occurs at these sites.  
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Figure 4.16. Strip-charts showing DNA methylation distributions at (A) PER3-cg10059324, 
(B) ADARB2-cg12799314, (C) LIN7B-cg10667338 and (D) FAM101A-cg06879608 in 
EPIC5/EPIC6 Illumina Infinium HumanMethylayion450 BeadChip array  data (n=332).
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Validation of many loci was limited by their occurrence within CpG islands, as high CpG 
density prevented pyrosequencing assay design for loci such as LDHAL6a and FAM101A. 
Validation was attempted for loci within intragenic regions of the ADARB2 (ADARB2-
cg12799314) and PER3 (PER3-cg10059324) genes; however neither of these loci validated 
in the EPIC6 independent sample set.  For PER3, as with TOX2, HDAC4 and ASB10, the 
methylation range was much narrower and higher in pyrosequencing data compared with 
array data, whereas for ADARB2, the methylation range was similar to the array data, but 
there was no association with fasting (Fig 4.13). 
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4.4 Discussion 
We aimed to identify the factors underpinning ATMmvp2a DNA methylation variability, 
including genetic, demographic, dietary and immunological factors. Whereas other studies 
have investigated factors affecting DNA methylation at multiple repetitive elements (Ulrich et 
al., 2012), and across the genome using microarrays (Lam et al., 2012), we have focused in 
detail on a single region of inter-individual variability, at which hypermethylation was 
associated with breast cancer risk in our previous investigation (Brennan et al., 2012b).  
We investigated the relationship between ATMmvp2a methylation variability and ATM 
genetic haplotype, as genetic polymorphisms within ATM are associated with breast cancer 
risk (Fanale et al., 2012; Lavin, 2008), and a common ATM haplotype may be associated 
with breast cancer risk in BRCA1 mutation carriers (Rebbeck et al., 2011).  It seemed likely 
that ATMmvp2a methylation had been associated with breast cancer risk due to haplotype-
associated DNA methylation, as allelic skewing of DNA methylation is a frequent event. 
(Schalkwyk et al., 2010; Shoemaker et al., 2010) However, we found no evidence for an 
association between DNA methylation and ATM haplotype. 
DNA methylation is also affected by genetic variability in trans, due to polymorphism is 
genes encoding enzymes required for methylation (Moarefi and Chedin, 2011; Vineis et al., 
2011). Folate-dependent one-carbon metabolism (OCM) provides methyl groups for all 
methylation reactions via the universal methyl donor S-adenosylmethionine (SAM), derived 
from dietary folate, choline, and B-vitamins (Chiacchiera et al., 2013); therefore genetic 
polymorphism in OCM enzymes such as MTHFR, as well as supply of OCM micronutrients, 
may be directly limiting of DNA methylation (Christensen and Marsit, 2011; Vineis et al., 
2011). ATMmvp2a methylation was associated with MTHFRc677t genotype in healthy 
control individuals, but not cases. Increased methylation associated with the C allele is 
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consistent with previous findings (Friso et al., 2002) therefore the association of ATMmvp2a 
methylation with MTHFR status is biologically plausible. Given the widespread affect of 
common MTHFR polymorphisms on DNA methylation and on disease risk (Friso et al., 2002; 
Liu et al., 2013), further work will be required to determine whether it is necessary to 
measure and adjust for MTHFR genotype in EWAS studies.  
We found a statistically significant association between ATMmvp2a methylation and the 
tryptophan derivative kynurenic acid (KA).  Whereas this requires further validation, the 
indication that DNA methylation might be altered by kynurenine pathway metabolites has not 
been previously reported and is potentially very interesting, as levels of blood kynurenic acid 
increase with age, and elevation of KA is associated with oxidative stress, and several 
conditions, including inflammatory bowel disease, Alzheimer’s disease and Schizophrenia 
(Colin-Gonzalez et al., 2013). Kynurenines also play roles in immunity and inflammation, 
including activation of T cells, as well as a role in activation of the Aryl hydrocarbon receptor, 
a key mediator of xenobiotic metabolism (Stone et al., 2013). Validation of the association of 
ATMmvp2a methylation and serum kynurenines, assessment of the degree to which 
kynurenines affects DNA methylation across the genome, and investigation of the 
mechanism would be worthwhile. Given the role of KA in immune activation (Stone et al., 
2013), it is possible that differential methylation associated with KA levels may reflect 
underlying variability in leukocyte populations. Otherwise, ATMmvp2a methylation variability 
may be specific to ATM, due to the role of ATM in mediating response of oxidative stress 
(Okuno et al., 2012). 
To our knowledge, this study is the first to link peripheral blood DNA methylation with fasting 
status, and coupled with the recapitulation of this effect through ex vivo glucose restriction, 
suggests that this rapid change in methylation is reproducible and potentially an important 
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confounding factor to consider for future EWAS studies. Alteration of ATMmvp2a methylation 
by transient exposures such as fasting is inconsistent with the prevailing dogma by which 
DNA methylation is established during early development  and displays long-term mitotic 
stability (Feinberg et al., 2010). The findings that blood methylation differences associated 
with smoking are detectable in former smokers many years after smoking cessation 
(Shenker et al., 2012), and that altered methylation at several loci associated with 
developmental exposure to famine are detectable in blood decades later (Heijmans et al., 
2008; Tobi et al., 2009), support the existence of stable epigenetic ‘memory’.  
However, rapid  genome-wide DNA demethylation occurs within the paternal genome during 
preimplantation (Chiacchiera et al., 2013) and occurs by ‘active’ demethylation, a poorly 
understood process which is thought to occur though sequential conversion of 5-
methylcytosine (5mC) to 5-hydroxymethylcyosine (5hmC), and then to 5-flourocytosine (5fC) 
and 5-carboxylcytosine (5CaC)  by the ten-eleven-translocase (TET) enzymes, possibly 
followed by a base-excision repair mechanism to restore 5mC (Chiacchiera et al., 2013). A 
few examples of active DNA methylation changes have been demonstrated in adult tissues. 
For example, Brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 1 (FGF1) 
undergo active demethylation in post-mitotic neurons via oxidation and deamination of 5mC 
followed by base excision repair (BER) (Guo et al., 2011; Martinowich et al., 2003). Rapid 
alteration of DNA methylation in skeletal muscle with exercise has been described (Barres et 
al., 2012), as has cyclical methylation of the Ps2/TTF1 gene promoter under estrogen 
activation in breast cells (Kangaspeska et al., 2008; Metivier et al., 2008). It is commonly 
speculated that epigenetic patterns associated with adult conditions may reflect aberrations 
in epigenetic programming due to innate influences or exogenous exposures during early 
development (Feinberg et al., 2006; Keating and El-Osta, 2013; Tobi et al., 2009), however, 
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greater consideration should be given to the possibility that associated epigenetic patterns 
represent consequences of disease-related metabolic or physiological states, as many loci, 
in addition to ATMmvp2a, may be responsive to metabolic conditions. 
Glucose and energy metabolism are linked with epigenetics mechanisms (Donohoe and 
Bultman, 2012). Studies investigating the profound effect of caloric restriction (CR) in 
extending cellular lifespan and preventing carcinogenesis in mammal (Hursting et al., 2010) 
have revealed that CR is largely mediated by histone deacetylation (Hursting et al., 2010; 
Willcox et al., 2007), and histone acetylation and DNA methylation are thought to work 
synergistically (Kalac et al., 2011). Long-term glucose restriction has been shown to alter 
gene expression, DNA methylation and histone acetylation of P16 and hTERT in vitro (Li et 
al., 2010b), however, our report of acute alteration of methylation on short-term glucose 
restriction supports the notion of rapid methylation changes independent of cell proliferation 
(Kangaspeska et al., 2008; Metivier et al., 2008). DNA methylation differences in blood 
(Milagro et al., 2011) and adipose tissue (Bouchard et al., 2010), associated with weight loss 
response to CR provide strong evidence that DNA methylation is implicated in the effects of 
energy metabolism on health outcomes. Whether variability in DNA methylation response to 
glucose restriction relates to metabolic disease or cancer risk remains to be investigated. 
Short-term fasting induces several acute molecular and physiological changes, including 
widespread gene expression changes (Bouchard et al., 2010; Bouwens et al., 2007; Caimari 
et al., 2010), weight-loss, increase in haemoglobin, red blood cell count and growth hormone 
levels, decrease in bicarbonate levels, and change in lipid profiles (Horne et al., 2012). 
Prolonged fasting is associated with a decrease in leukocyte count and proinflammatory 
cytokine levels (Faris et al., 2012). 
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We do not find an association between ATMmvp2a methylation and breast cancer risk in 
either of two new prospective case control studies from the EPIC cohort included in this 
report. The identification of metabolic factors affecting ATMmvp2a methylation indicate that 
analysis of the breast cancer risk association may have been confounded by additional 
factors for which information is not available, and highlight the necessity to understand and 
control for factors influencing DNA methylation in future disease-association studies. The 
first epigenome-wide association studies (EWAS) have highlighted the potential of 
investigation of DNA methylation to help understand the contribution of DNA methylation to 
disease (Rakyan et al., 2011; Shenker et al., 2012). In order to establish the efficacy of this 
approach, and to identify potential confounding factors, it will be important to determine the 
extent to which metabolic variables and transient exposures such as fasting may affect 
genome-wide DNA methylation.  
Epigenetic mechanisms are thought to interact with diet to influence breast cancer risk 
(Haggarty, 2013; Lampe et al., 2013; Li et al., 2003). Many breast cancer risk factors, such 
as obesity, diabetes, alcohol consumption, birth weight, menopause status, growth 
hormones, and circadian rhythm patterns, relate strongly to glucose metabolism and diet 
(Amadou et al., 2013; Choi et al., 2012; Feng and Lazar, 2012; Mauvais-Jarvis et al., 2013; 
McPherson et al., 2000; Thomson, 2012) and are associated with epigenetic signatures 
(Barres et al., 2009; Feinberg et al., 2010; Keating and El-Osta, 2013; Seki et al., 2012; Xu 
et al., 2013a). Biomarkers of response to fasting are frequently associated with metabolic 
phenotypes; Gene expression changes associated with fasting and re-feeding in PBMCs are 
blunted in obese rats (Oliver et al., 2013), and a recent study has identified DNA methylation 
signatures associated with weight-loss response to CR (Hursting et al., 2010);  therefore, 
inter-individual variability in ATMmvp2a methylation fasting response may relate to metabolic 
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factors such as age or BMI. ATMmp2a methylation response to fasting and glucose 
restriction displays inter-individual variability and fasting response may be stronger in control 
blood samples compared to incident breast cancer cases; however the factors underlying 
this remain unclear. It is possible that ATMmvp2a hypermethylation may be sustained in vivo 
due to hyperglycemia, an independent risk factor for breast cancer (Sieri et al., 2012). 
Whereas meta-analysis has indicated that the independent effect of hyperglycemia is likely 
to be mild (RR=1.11 (1.00-1.23)) (Boyle et al., 2012b), hyperglycemia  is associated with 
other metabolism-related risk factors, including diabetes (Boyle et al., 2012a),and obesity 
(Amadou et al., 2013; Cheraghi et al., 2012), age, or menopausal status.  A limitation of our 
study is that we did not have serial samples from the same individual before and after 
fasting, which would correct for baseline differences in methylation. A study using such 
samples, with phenotype data for metabolic factors would allow greater interrogation of the 
factors underlying response variability. The complex interactions between diet, epigenetics 
and disease risk are poorly understood, however, a greater understanding of the ways in 
which metabolic derivatives of dietary factors affect epigenetics will aid in our understanding 
(Donohoe and Bultman, 2012), as will investigation of variability in epigenetic response to 
dietary interventions that are known to reduce breast cancer risk (Lampe et al., 2013; 
Milagro et al., 2011).  
There are interesting links between ATM, breast cancer risk, and glucose metabolism, as 
ATM mutations and haploinsufficiency are associated with  diabetes mellitus (Bar et al., 
1978; Miles et al., 2007), as well as increased breast cancer risk (Lavin, 2008). Furthermore, 
a SNP in ATM is associated with improved glycemic response to the antidiabetic drug 
metformin (Tkac, 2012; van Leeuwen et al., 2012; Zhou et al., 2011), treatment with which is 
associated with reduced breast cancer risk in diabetic individuals (Decensi et al., 2010).  
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Immune shifts in cell count represent a potential explanation for the association between 
ATMmvp2a methylation and glucose metabolism, as inter-individual DNA methylation 
differences can reflect differences in proportions of cell types that display tissue-specific 
methylation, rather than differences in the number of cells that are methylated within a given 
cell type (i.e. a change in percentage methylation) (Koestler et al., 2012).  Both ATMmvp2a 
and ATMmvp2b were is hypomethylated in T cells compared with monocytes and B cells, 
with more significant hypomethylation in ATMmvp2a, consistent with lower methylation and 
higher variability at ATMmvp2a than ATMmvp2b in PBMCs overall. This suggests that 
ATMmvp2a WBC methylation variability may be unique to T lymphocytes, or a subset 
thereof, and case inter-individual variability may be far greater within this cell subset than in 
PBMCs overall. ATMmvp2a hypomethylation on fasting may reflect a proliferation or 
selective survival of hypomethylated T cells with fasting. However, hypomethylation induced 
by in vitro glucose restriction was independent of cell viability, suggesting active 
demethylation.  
Consistently, T cell activation is associated with active DNA methylation changes, as rapid 
demethylation of the interleukin-2 gene (IL2) occurs in non-dividing T lymphocytes on 
activation (Bruniquel and Schwartz, 2003), and active demethylation of Foxp3 is required for 
activation of regulatory T cells in the thymus (Toker et al., 2013). ATMmvp2a may play a 
functional role, as T cells display highly distinct methylation patterns relative to other cell 
types, and loci hypomethylated in CD4+ and CD8+ T cells are enriched for genes involved in 
lymphocyte activation and T-cell-specific immune function (Reinius et al., 2012). All of the 
factors associated with ATMmvp2a methylation (except MTHFRc677t genotype, for which 
the mechanism in affecting DNA methylation is well established (Friso et al., 2002)) relate to 
T cell activation, as both glucose availability (Jacobs et al., 2008) and kynurenines (Mandi 
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and Vecsei, 2012) regulate T cell activation, and activation is blunted with age 
(Czesnikiewicz-Guzik et al., 2008).Efficient T cell activation influences breast cancer risk as 
immunosurveillance mediated by tumour-specific T cells are required to detect and kill 
cancer cells (Haabeth et al., 2011). Furthermore ATM mutations are often associated with T 
cell proliferation and T cell lymphomas (Miles et al., 2007; Stankovic et al., 1998).  
Methylation analysis of blood samples sorted into discrete cell types, and functional assays 
will be required to confirm that ATMmvp2a methylation variability is restricted to T cells, and 
will determine if methylation is related to T cell activation state.  
ATMmvp2a methylation was not altered by glucose restriction in either MCF7 or MCF10, 
despite the fact that ATM is activated by serum starvation in vitro (Shi et al., 2012), and 
inhibition of ATM activity in MCF7 and MCF10a cells alters glucose metabolism (Zakikhani et 
al., 2012). This is possibly due to cell-type-specificity of ATMmvp2a methylation variability. 
Alternatively it could be due to the TET enzymes, required for active demethylation, not 
being expressed in cells lines that have been cultured long-term, or that cancer cells display 
abnormal glucose metabolism (Li et al., 2010b), MCF10A cells requires insulin 
supplementation, and DMSO required for cell cryopreservation, has been reported to induce 
active DNA demethylation (Thaler et al., 2012). Therefore, several factors may have 
impeded our ability to detect ATMmvp2a methylation alteration by glucose restriction in 
these cell lines.  
Of five fasting-associated loci selected for validation, only TOX2 validated, and four out of 
five loci, including TOX2, displayed methylation distributions that were far higher and 
narrower than was apparent in the array discovery set data, suggesting a skewing of the 
data in array data processing. This was not due to peak-based correction, as this only 
affects type II probes, whereas both probe types were represented among the fasting-
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associated loci. Normalisation steps such as quantile normalisation or ComBat may have 
introduced bias into the analysis.  
Further validation of TOX2 is required, as is further analysis to identify additional loci 
associated with fasting. Fasting-associated loci in addition to ATMmvp2a are likely to exist; 
however, the relative subtlety of the methylation change associated with fasting, in 
comparison to other factors that have been investigated using the 450k array, such as 
smoking or haplotype, may limit our ability to identify fasting-associated loci using this 
system.  Among loci apparently associated with fasting, loci within LGR6 and LIN7B 
displayed trimodal methylation patterns that may indicate allele-specific DNA methylation. 
Allelic skewing of DNA methylation is frequent in the human genome and occurs 
predominately at polymorphic CpG sites (Heyn et al., 2013; Kerkel et al., 2008; Schalkwyk et 
al., 2010; Shoemaker et al., 2010). Allelic skewing represents a potential source of bias for 
EWAS studies (Price et al., 2013) therefore polymorphic CpG sites may be excluded from 
analysis. However, haplotype-associated methylation of non-polymorphic CpG sites clearly 
represents an overlooked potential confounding factor that should be assessed in future 
EWAS studies, especially where patterns of differential methylation are consistent across 
multiple adjacent loci.    
High frequency of fasting-associated loci within CpG islands impeded validation of loci that 
displayed strong clustering of fasting-associated CpG sites, but that did not display apparent 
trimodal methylation distributions. It remains unclear, therefore, whether these regions are 
associated with fasting, or whether another unknown confounding factor accounts for these 
associations.   
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In conclusion, this study demonstrates the potential influence of disease-related metabolic 
pathways, other than OCM, in influencing DNA methylation, and raises the possibility that 
transient exposures such as fasting may have profound influence on DNA methylation. 
These findings may have important implications for epigenome-wide association studies 
investigating the role of peripheral blood DNA methylation in disease risk.  
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CHAPTER 5 
 
Microarray-based discovery studies to identify novel 
breast cancer risk markers 
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5.1 Introduction 
Novel breast cancer risk markers may help improve current disease risk models, improving 
early diagnosis, and aiding population stratification for screening (Amir et al., 2010). Our 
prospective investigation of ATM methylation (chapter2) provided proof of principle for the 
investigation of DNA methylation variability as a potential source of cancer risk biomarkers; 
however, additional markers, or ideally a panel of risk markers similar to the combination of 
multiple SNPs into a “polygenic risk score”, would be useful in helping to improve the 
sensitivity and specificity of breast cancer risk models.  In recent years, new technologies 
have enabled high-throughput, genome-scale investigation of epigenetic patterns associated 
with phenotypes, exposures and disease outcomes (Langevin and Kelsey, 2013; Rakyan et 
al., 2011).  Such technologies provide an opportunity to perform genome-scale discovery 
studies for identification of breast cancer risk markers.  
It is now possible to carry out genome-wide DNA methylation (whole-methylome) analysis at 
single-base-resolution (Li et al., 2010c), and future investigation of DNA methylation 
variability will likely be greatly assisted by this ‘gold-standard’ method (Rakyan et al., 2011). 
However, the use of whole -genome bisulphite sequencing is currently limited to studies of 
small sample sizes (Feber et al., 2011; Hansen et al., 2011), due to its high cost. For 
population studies, the value of genome-coverage must be balanced with the requirements 
for large sample sizes and highly quantitative measurement. To this end, candidate gene 
studies and array-based techniques measuring DNA methylation at a small proportion of 
CpG sites are used for population studies. Several studies have now investigated blood DNA 
methylation in cancer patients (Marsit et al., 2011; Teschendorff et al., 2009; Widschwendter 
et al., 2008), and each identified multiple loci significantly associated with disease, indicating 
that blood DNA methylation may be associated with cancer outcomes, and potentially 
providing useful biomarkers for cancer diagnosis.  
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Candidate-gene studies can be used to investigate risk-associated DNA methylation at 
genes implicated in breast cancer in the literature, but is limited by currently available 
knowledge. Using the methyLight technique, Widschwendter et al (Widschwendter et al., 
2008) identified five genes that were significantly differentially methylated in blood of breast 
cancer cases, and different gene sets predicting invasive-ductal and invasive-lobular 
carcinomas, potentially indicating cancer-pathway-specific differential methylation.  A recent 
study identified subtle SFRP1 hypermethylation in blood of gastric cancer patients compared 
with controls using pyrosequencing (Tahara et al., 2013).  
Illumina Infinium BeadChip arrays have become the most popular method for investigation of 
DNA methylation in population studies. Three retrospective studies have utilised the Illumina 
Infinium HumanMethylation27 BeadChip array, which measures methylation at ~27,578 CpG 
sites within gene promoters across the genome, to assess differential methylation in blood of 
cancer patients compared with controls. Teschendorff et al (Teschendorff et al., 2009) 
identified 2714 CpG sites that were differentially methylated in blood of ovarian cancer 
patients compared with unaffected controls in a relatively small sample set (n=113 cases, 
148 controls), and 355 of these loci validated in an independent sample set. Marsit et al 
(Marsit et al., 2011) found 9 CpG sites that were statistically significantly hypermethylated in 
bladder cancer cases compared with healthy controls. Langevin et al (Langevin et al., 2012) 
identified a panel of six CpG sites that could predict case-control status for head and neck 
squamous cell carcinoma. Each of these loci was significantly hypomethylated in cases 
compared with controls, though with absolute ǻȕ-values of only ~0.01 (1%), and with no 
evidence of validation presented in these studies.   
These studies provide evidence for the utility of DNA methylation variability for development 
of biomarkers for cancer diagnosis, and some of the loci identified may represent potential 
markers of cancer risk (Teschendorff et al., 2009; Widschwendter et al., 2008). However; 
  
170 
 
many factors associated with the presence of active disease may affect DNA methylation, 
most importantly the possibility that cancer-associated immune responses may alter 
leukocyte proportions resulting in apparent differential methylation due to cell-type specific 
DNA methylation (Koestler et al., 2012; Langevin et al., 2012). Another potential confounding 
factor is the use of case samples derived from individuals who have undergone cancer 
treatment (Langevin et al., 2012; Teschendorff et al., 2009; Widschwendter et al., 2008), as 
cancer treatment may affect epigenetic profiles (Rakyan et al., 2011; Xu et al., 2013b). It 
remains possible; however, that many loci associated with cancer prevalence in 
retrospective studies may represent risk markers, as ATM hypermethylation identified in a 
retrospective study was validated as a risk marker in our prospective investigation (Chapter 
2).  
Recently, the first array-based prospective investigation of blood DNA methylation 
associated with breast cancer risk was reported (Xu et al., 2013b), and identified 250 loci 
associated with increased risk using the Illumina 27k array, 75.2% of which were 
hypomethylated in cases. Furthermore, they reported a >2-fold enrichment of differentially 
methylated loci near known breast cancer susceptibility genes including ATM, though only 
one locus was statistically significant after FDR correction. Unfortunately, no external 
validation of any of the loci was performed; and as all of the differentially methylated loci 
displayed absolute ǻȕ-values of <0.05 (5% differential methylation), it is possible that many 
of the associated loci identified represent statistical or technical artefacts rather than genuine 
differential methylation (Garcia-Closas et al., 2013b). Some loci reported in this study 
displayed increasing strength of association with decreasing time to diagnosis (TTD), 
suggesting that they may represent markers of preclinical disease rather than susceptibility 
loci.  
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In order to identify potential risk markers, we aimed to conduct genome-scale discovery 
studies of DNA methylation loci associated with breast cancer, using blood DNA samples 
from prospective case-control studies and DNA methylation microarrays, and with an 
external validation stage using and independent sample set also from the EPIC study.  
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5.2 Materials and methods 
 
5.2.1 Discovery study 1 - Differential Methylation Hybridisation (DMH) 
5.2.1.1 Study samples 
A subset of the KConFab study sample set described in chapter 2 were used for the DMH 
microarray, including whole blood DNA samples prospectively collected from 21 invasive 
breast cancer cases and 30 healthy unrelated (best-friend) controls (Table 5.1). Reference 
DNA 100% methylated and 0% methylated controls were also included on the array. 
Biological validation by pyrosequencing was carried out in the remainder of the KConFab 
study sample set (Table 5.1). Further pyrosequencing in a sporadic breast cancer study was 
carried out using the Breakthrough Generations Study (BGS) study described in chapter 2 
(Table 5.1). 
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Table 5.1. KConFab study samples used for investigation of PARP1 methylation 
Sample set Discovery set Validation set 
Case/control status Controls Cases Controls Cases 
N 24 13 198 153 
Age at blood draw in years, mean 
(range/SD*) 
59 (49-
75/7.22) 
55 (36-
71/11.38) 
59.42 (31-
83/10.3) 
50.4 (22.16-
83.7/15.89) 
Menopausal status at blood draw, 
N (%) 
   
Pre-menopausal 4% 61% 19% 55% 
Post-menopausal 96% 39% 81% 45% 
TTD* in months mean (range/SD) _ 
21.46 (1-
74/23.92) 
_ 46.8 (1-140/32.77) 
Age at diagnosis, mean (range/SD) _ 
56(37-
72/10.67) 
_ 54.40(27-97/15.96) 
Alcohol drinker, N (%)**         
Drinker 69% 62% 67% 58% 
Non-drinker 27% 38% 31% 40% 
Smoker (ever), N, (%)         
Smoker  38% 38% 40% 45% 
Non-smoker 58% 62% 58% 54% 
*Time to diagnosis (from blood draw) 
**Alcohol drinker status for individuals for which data was available 
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5.2.1.2 DMH custom tiled microarray 
Differential methylation hybridisation (DMH) was carried out by Oxford Gene Technology 
(OGT). DMH is a semi-quantitative method of DNA methylation analysis which involves 
methylation-sensitive restriction digestion of DNA, fluorescent-labelling, followed by 
hybridisation of digestion fragments to an oligonucleotide microarray, allowing selective 
methylation analysis of candidate genes. Briefly, sample DNA is digested using the 
restriction enzyme MseI, which cuts at the restrictions site TTAA, and therefore, digests DNA 
into small ~200bp fragments, whilst leaving CpG islands (which are depleted for the TTAA 
sequence) intact.  Cleaved ends of DNA fragments are ligated to universal linkers, followed 
by methylation sensitive restriction digestion of ligated fragments with enzyme McrBI, which 
cleaves methylated DNA. Restriction with MseI and ‘mock-digestion’ is performed on a 
separate aliquot of the sample for comparison. Linker PCR is then used to amplify fragments 
from mock-digested and McrBI digested samples, followed by purification of amplicons, and 
fluorescent labelling with Cy5 and Cy3, respectively. This is followed by competitive 
hybridisation of mock digested and McrBI digested DNA to a custom tiled microarray, and 
scanning of fluorescence signal. A DMH ratio ( Ratio of the fluorescence signal intensities of 
Cy5 (mock-digested fragments) to Cy3 (digested fragments)) is used to estimate the 
methylation of a fragment, where unmethylated fragments have a DMH ratio ~1, whereas a 
DMH ratio >1 indicates that the fragment is methylated (Dai et al., 2008; Yan et al., 2002). 
The custom array was designed to cover gene promoters and intragenic regions, tiled every 
50bp from -2kb to +8kb around the transcription start sites of 1381 candidate genes resulting 
in 8758 MseI genomic fragments for analysis. Use of a custom array was required for 
methylation analysis of intragenic regions that were not covered by other available arrays.  
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Candidate genes were selected from seven pathways commonly deregulated in breast 
cancer, including the AKT, BRCA1/2, DNA repair (HR,MMR, NHEJ), Fanconi, p53, WNT,  
and Redox pathways.  
 
5.2.1.3 Statistical analysis 
Raw signal intensities from the samples were extracted using Agilent feature extraction 
software. Two criteria were used to ‘pass’ each probe: 1) Signal intensities must not be 
higher than 65,000 (signal saturation) or lower than mean+2 standard deviation from 
negative control , and 2) probes must not be flagged by Agilent extraction software. The data 
points failing either of these criteria were treated as poor-quality data points, and were 
removed from analysis. Probes with poor-quality data points in > 50% of samples were 
removed from analysis. The median difference between log2 of the DMH ratios for the 100% 
methylated and 0% methylated controls were used to determine efficiency of enzymatic 
digestion using McrBC. Samples with median difference between 100% and 0% methylated 
controls less than 1.87 were removed from further analysis resulting in a final dataset of 18 
cases and 24 controls. Methylation linear discriminant analysis (MLDA) was used to 
normalize the DMH ratios by equalising the signals from 100% and 0% methylated controls, 
as previously described (Dai et al., 2008). DMH ratios were expressed as a magnitude of 
difference. Data processing and normalisation was performed by the Epigenetics Unit 
Bioinformatician, Dr. Wei Dai. Wilcoxon rank sum test was used to test for differential 
methylation between cases and controls. False Discovery Rate (FDR) was used to correct 
for multiple testing, with FDR p<0.05 considered significant. Inter-quartile analysis and 
logistic regression was used to calculate an OR for breast cancer incidence for individuals 
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within the highest DNA methylation quartiles compared with the lowest (reference) quartile, 
with quartiles specified using controls only.  
For PARP1 pyrosequencing data, Wilcoxon rank sum test was used to test for differential 
methylation between cases and controls. Analysis of variance (ANOVA) was used to test for 
statistical significance of between cases and control groups for within-group DNA 
methylation variance. Spearman correlation tests were used to test for significance of 
correlations between DNA methylation and TTD.  
 
5.2.1.4 PCR and pyrosequencing 
We selected one of the top 8 hits mapping to the PARP1 gene for further validation. 
Pyrosequencing of the PARP1 739bp DMR fragment (NCBI136/hg18 genomic location chr1: 
224662084-224662823) in the validation sample set was performed with multiple assays, 
tiling a 530bp fragment (NCBI136/hg18 genomic location chr1: 224661898-224662428) 
spanning from base 186bp upstream of the fragment to 395bp into the fragment using six 
pyrosequencing assays (labelled PARP1s1-PARP1s6) within two PCR amplicons, with each 
pyrosequencing assay measuring 3-8 CpG sites (primer sequences shown in table 5.2 (A), 
schematic diagram of PARP1 primer-binding sites Fig 5.1). Performance of assays was 
variable; however, all six regions were pyrosequenced in order to achieve greater coverage 
of the DMH fragment. Methylation values were calculated as an average of all CpG sites 
within a given assay, that were labelled either ‘pass’ or ‘check’, based on the Pyromark 
pyrosequencing quality controls. ‘Check’ data, for which quality control thresholds were not 
reached (though the samples were not failed), were used in order to optimise sample 
numbers, as all assays displayed appropriate methylation values for 100% methylated and 
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0% methylated controls (i.e. >95% and <5%, respectively). The numbers of samples 
included in validation analysis was n=153 cases and n=198 controls, after exclusion of NAs, 
as shown in table 5.2.  Three samples with methylation data that representing extreme 
statistical outlier (>40% methylation, >99.99% confidence intervals) were removed from 
analyses, due to potential measurement error or contamination with the positive control 
DNA.  
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Table 5.2 Primers for chapter 5 
A. PARP1 primers 
Primer Name  Sequence (5’ – 3’) 
PARP1 Forward 1 biotin-GGTTAGGTATTAGTAATTTATTAGGGAA  
PARP1 Reverse 1 CACCTACACCATAATAACCATC  
PARP1 S1 CTCTCRCTACATTTCTTACAAAAAA  
PARP1 S2 CATCCTCCCCTAACT  
PARP1 S3 CCACRACCTAAAAACAC  
PARP1 Forward 2 biotin-GGATGGTTATTATGGTGTAGGT  
PARP1 Reverse 2 ACAACACCAACTACAAACTTTATTT  
PARP1 S4 CAACATCAACAAAACCT  
PARP1 S5 CCCATAAACCCCAAAT  
PARP1 S6 CCCTCCCCCAACCTT  
  
B. Primers for validation of loci associated with breast cancer risk in discovery study 2 
    
Primer Name  Sequence (5’ – 3’)  
HEATR2 F GTGGGAAAAATTAGGAATGGAATAAA 
HEATR2 R biotin-ACCCACAAAAAACACAAAACTAC 
HEATR2 S GGTTTTTGTGGGAGT 
SLFN12L F biotin-GTTTTGGGGAAGAGGTTGG 
SLFN12L R CCTCRACCAACTTCTATTTCTTTCTTTAT 
SLFN12L S AAAAACCCCRAATACTCCAA 
 
 
 
 
 
 
 
 
 
S1S2S3
R2 F2R1 F1
S4S5S6
Fig 5.1
Fig 5.1. Genomic loci of PCR amplicons and pyrosequencing assays for validation of PARP1 differential 
methylation by pyrosequencing. Gene-structure image taken from UCSC genome browser (NCBI136/hg18). 
Green bar represents CpG island . Coloured arrows represent binding-sites of PCR primers, and white arrows 
represent binding-sites of pyrosequencing primers, with arrow direction indicating sequencing direction. 
179
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5.2.2 Discovery study 2 (Illumina 450k beadchip array) 
5.2.2.1 Study samples 
Samples used for discovery study 2 were the EPIC4 subgroup described in chapter 4 prior to 
removal of samples overlapping with EPIC 5 (see chapter 4), and will be referred to in this 
chapter as EPIC4. These consisted of prospectively collected white blood cell DNA samples 
from 92 invasive breast cancers cases and 92 healthy unrelated controls (without breast 
cancer at follow-up) (Table 5.3). Case-control pairs were matched on age (within 5 years), 
ethnicity and study centre. Sample preparation for the EPIC4 subgroup was as for other 
EPIC study subgroups described in chapter 2. The validation cohort for discovery study 2 
(EPIC3) is as for chapter 2.  
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5.2.2.2 Illumina Infinium HumanMethylation 450k beadchip array 
The Illumina Infinium HumanMethylation 450k beadchip array (Illumina 450k array) is 
described in chapter 4, materials and methods.  
5.2.2.3 Statistical analysis (450k array)  
Background-subtracted ȕ-values were extracted from genome studio, and normalised using 
quantile normalisation. Conditional logistic regression was used to identify loci significantly 
associated with case control status, adjusting for age and experimental batch (array chip), 
with samples matched for age, study centre and ethnicity.  Loci associated with case/control-
status, with p<10-5 were considered statistically significant, with loci p<10-7 reaching genome-
wide significance. Wilcoxon rank sum test was used to test associations between DNA 
methylation and cancer risk in the validation set, and Interquartile analysis was conducted 
using multinomial logistic regression models to calculate an OR for breast cancer risk for 
individuals within each methylation quartile compared with individuals within the lowest 
(reference) methylation quartile, with quartiles specified using controls only.  
5.2.2.4 PCR and Pyrosequencing.  
Two genes from the top hits were selected for further validation, HEATR2 (cg11027456) and 
SLFN12L (cg21705506). PCR and pyrosequencing was carried out as described in chapter 
2, however, rather than using a universal biotinylated primers, one of the sequence-specific 
(forward or reverse) primers was biotinylated, depending on the DNA strand being 
sequenced (primer sequences shown in table 5.2 (B)). For HEATR2, 12 cases and 5 
controls failed pyrosequencing quality control, leaving 231 cases and 281 controls for further 
analysis. For SLFN12L, 9 cases and 7 controls failed leaving 234 cases and 279 controls.  
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5.3 Results 
 
5.3.1 Differential Methylation Hybridization 
Thirty eight genes were found to be significantly differentially methylated between cases and 
controls with FDR corrected p-values<0.01. Of these, 14 loci showed an increase in 
methylation whereas the remaining 24 displayed a loss of methylation in cases relative to 
controls. Of the loci with significant DMH ratios, those with the greatest absolute magnitude 
of difference (highest DMH ratio and FDR p-value<0.01) were FOXO3 (1.56,  p=1.322E-05 ), 
PARP1 (1.25, p=2.054E-05), TLE4 (1.10, p=1.32E-05), TGFBR2 (1.08, p=2.054E-05), LBH 
(1.04, p=1.122E-06), PRR5 (1.01, p=3.14E-05), FZD3 (0.93, p=2.05E-05), SMAD1 (0.90, 
p=7.76E-07), CXCL2 (0.89, p=2.27E-06) and HIF1Į (0.79, p=6.121e-06) (Fig 5.2, Table 5.4). 
All of these loci were located at gene promoters, and were hypermethylated in cases. 
Consistently, by aligning all significantly differentially methylated genes at transcription start -
sites and mapping methylation variability (standard deviation of methylation in cases and 
controls separately) relative to genomic location, a focus of increased methylation variability 
close to TSS, relative to the rest of the gene, may be clearly seen in cases compared to 
controls (Fig 5.3). DMH revealed a differentially methylated 740bp locus (DMH ratio 1.25) 
surrounding the Poly (ADP) ribose polymerase 1 (PARP1) gene transcription start site 
(TSS). This PARP1 locus was prioritised for pyrosequencing-based validation as it had the 
most significant p-value, second highest absolute magnitude of methylation difference 
between cases and controls, the well established biological role of PARP1 in breast cancer 
(De Soto et al., 2006), and the feasibility of validation based on fragment length.  
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Table 5.4. Top ten DMH fragments most significantly associated with breast cancer case-control status  
Gene Chromosome 
Fragment 
start site*    
Fragment 
end site**  
Fragment 
length 
Magnitude 
of 
difference***  
P-value (FDR 
corrected)*****  
FOXO3 6 108985118 108985861 744 1.562920707 1.32E-05 
PARP1 1 224662084 224662823 740 1.248197134 5.40E-07 
TLE4 9 81377472 81378298 827 1.098937779 1.32E-05 
TGFBR2 3 30622624 30624223 1600 1.084128379 2.05E-05 
LBH 2 30307336 30308069 734 1.0431579 1.12E-06 
PRR5 22 43476820 43477591 772 1.012598372 3.14E-05 
FZD3 8 28407046 28408099 1054 0.933635867 2.05E-05 
SMAD1 4 146622062 146623572 1511 0.900790693 7.76E-07 
CXCL2 4 75183210 75184256 1047 0.890253405 2.27E-06 
HIF1A 14 61231250 61232396 1147 0.791756546 6.12E-06 
* fragment start site: genomic location of fragment start (UCSC genome browser build (NCBI136/hg18))  
** fragment end site: genomic location of fragment end (UCSC genome browser build (NCBI136/hg18))  
*** Magnitude of difference in methylation between case and control sample groups.  
****Wilcoxon-rank sum test p-value for significance of differential methylation (case/control). 
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Figure 5.3. Methylation variability at all genes analysed by DMH, mapped in relation to genomic locus. 
Methylation variability (smoothed average of standard deviation of methylation) at all genes relative to distance 
from transcription start site (0), separated by case (blue) control (red) status of DNA samples.
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Validation of the PARP1 DMH fragment was carried out by pyrosequencing of six regions 
within the DMH region labelled PARP1s1-PARP1s6, each spanning 3-9 CpG sites (fig 5.1) 
and covering 54 CpG sites across the whole CpG island. Technical validation of PARP1 
hypermethylation in cases was carried out by pyrosequencing of the majority of the samples 
used for the DMH array (n cases=13, controls=24) (Fig 5.4).  Four loci were significantly 
hypermethylated in cases relative to controls, including PARP1s1 (median control 2.67% vs. 
median case 3.8%, p=0.02) PARP1s2 (median control 2.06% vs. median case 3.96%, 
p=0.002), PARP1s4 (median control 3.76% vs. median case 5.69%, p=0.01), and PARP1s5 
(median control 3% vs. median case 7.64%, p=0.003), whereas one locus was significantly 
hypomethylated in cases (PARP1s3 (median control 1.64% vs. median case 1.21%, 
p=0.04). Biological validation within the remainder of the KConFab study sample set (n=199 
controls, 158 cases) was confirmed for PARP1s2 (median control 2.5% vs. Median case 
2.98%, p=0.0000132), PARP1s4 (median control 3.55% vs. median case 4.34%, p= 9.37E-
11), PARP1s5 (median control 1.89% vs. median case 4.29%, p=9.52E-12) and PARP1s6 
(median control 1.99% vs. median case 2.55%), whereas PARP1s1 and PARP1s3 were not 
associated with case-control status (Fig 5.4). Linear regression indicated that association of 
PARP1 methylation with case-control status remained significant after adjusting for 
experimental batch (plate). Consistent with the finding of methylation hypervariability at gene 
promoters on the DMH array, ANOVA indicated that PARP1 methylation was hypervariable 
(within-group methylation variance was significantly higher) in cases compared with controls 
for PARP1s1 (p=0.04), PARP1s2 (p=0.00013), PARP1s4 (p=0.006) and PARP1s5 
(p=0.0007) in the technical validation set, and for PARP1s2 (p=1.32-5), PARP1s4 (p=5.12-9), 
PARP1s5 (p=5.21-12) and PARP1s6 (p=1.11-9) in the biological validation set. Whereas 
magnitudes of methylation difference between cases and controls were small (1-3%), the 
  
188 
 
consistency of the association of four regions, and between technical and biological 
validation sample sets using different assays suggests a genuine association.  
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Further validation of hypermethylation of the PARP1s4, PARP1s5 and PARP1s6 regions in 
an independent sample set was attempted using the BGS sample cohort described in 
chapter 2  (cases n=258, controls n=259). However, there was no evidence of differential 
methylation between cases and controls at any of the three loci, S4 (2.7% v 3.0% P=0 .07), 
S5 (2.4% v 2.6%, P= 0.43), S6 (1.5% v 1.6%, P=0.2) (Fig 5.5).  
We hypothesised that the difference in results between the KConFab and BGS studies may 
be due to association of PARP1 DNA methylation with subtype or molecular-pathway-
specific features that may be more common in familial breast cancer (KConFab) than in 
sporadic cancer (BGS), especially as the KConFab study was enriched for BRCA mutation 
carriers. However, there was no evidence of methylation associated with case status at any 
of these loci within individuals in the BGS study that reported family history of breast cancer 
(n=66 cases, 51 controls), S4 (2.7% v 2.6%, P=0.6358), S5 (2.3% v 2.4%, P=0.5), S6 (1.5% 
v 1.5%, P=0.24) (Fig 5.5). However, the criteria for family history of breast cancer for the 
BGS study (>1 affected relative) was less stringent than for KConFab (all participants belong 
to families with breast cancer susceptibility mutations or several affected relatives). 
Consistently, PARP1 was not differentially methylated in association with family history of 
breast cancer, irrespective of case-control status, in BGS data (data not shown). 
Furthermore, within the KConFab study, PARP1 methylation was not clearly associated with 
BRCA1/BRCA2 germline mutation status, or tumour features including expression of ER, PR 
and HER2, or triple negativity, for samples in which follow-up tumour pathological feature 
data was available (Table 5.5).   
  
Fig 5.5
Figure 5.5. Bisulphite pyrosequencing of three regions of PARP1; (i) PARP1s4, (ii) PARP1s5, (iii) 
PARP1s6 in  prospectively collected WBC DNA samples of (A) 258 invasive breast cancer cases and 259 
matched healthy unrelated healthy controls from the Breakthrough Generations  Study (BGS), and (B) a subset 
of BGS cases  (n=66) and controls (n=51) for which family history of breast cancer was reported. 
A.
B.
i
i
ii
ii
iii
iii
192
  
193 
 
 
Table 5.5. Assessment of association of blood PARP1 DNA methylation with tumour pathological features in 
the KConFab study.  
Locus  
Pathological 
feature 
N 
(+)*  
N 
(-)  
Mean 
methylation 
(+)  
Mean 
methylation 
(-) 
Median 
methylation 
(+)  
Median 
methylation 
(-) 
Wilcox 
p-
value*  
PARP1s4 BRCA1/2  47 81 4.179 4.528 3.94 4.05 0.02334 
PARP1s5 BRCA1/2  10 22 3.107 3.696 2.96 3.28 0.4157 
PARP1s6 BRCA1/2  46 83 2.965 3.025 2.32 2.58 0.5455 
PARP1s4 ER  59 34 4.236 4.241 3.86 3.935 0.7466 
PARP1s5 ER  15 9 3.969 3.01 4.15 2.97 0.07319 
PARP1s6 ER  61 30 3.19 2.989 2.67 2.375 0.4009 
PARP1s4 PR  47 46 4.223 4.253 3.84 3.93 0.5933 
PARP1s5 PR  13 11 3.964 3.19 4.15 2.97 0.1674 
PARP1s6 PR  51 39 3.209 3.021 2.67 2.42 0.4039 
PARP1s4 HER2  23 61 4.045 4.32 3.54 3.93 0.2026 
PARP1s5 HER2  12 6 4.327 3.408 4.015 3.355 0.3355 
PARP1s6 HER2  21 57 3.05 3.333 2.67 2.62 0.7825 
PARP1s4 TNBC 23 65 4.197 4.303 3.93 3.91 0.9848 
PARP1s5 TNBC  4 18 3.132 3.831 3.065 3.39 0.342 
PARP1s6 TNBC  15 71 3.169 3.179 2.42 2.67 0.8555 
*positive for ER or PR expression, HER2 amplification or triple-negative breast cancer (TBNC)  
*Wilcoxon rank sum test p-value 
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Lastly, we investigated whether DNA methylation at PARP1 regions significantly associated 
with cancer risk were associated with time to diagnosis (TTD) in KConFab. Interestingly, 
there was a significant inverse correlation between TTD and DNA methylation of the 
PARP1s2 (r2=0.22, p=0.03) and PARP1s6 (r2=0.2, p=0.03) regions, though not the 
PARP1s4 (r2=0.06, p=0.69) and PARP1s5 (r2=-0.19, p=0.13) regions (Fig 5.6), suggesting 
that blood PARP1 methylation may represent a marker of early preclinical disease. 
  
Fig 5.6
Figure 5.6.  Association of PARP1 DNA methylation with time to diagnosis. Scatter plots showing 
correlation of  DNA methylation (Y-axes) at (A) PARP1s2, (B) PARP1s4, (C) PARP1s5 and (D) PARP1s6 
with time in months between blood draw and breast cancer diagnosis (TTD)(X-axis). Red line represent 
regression line for association between DNA methylation and TTD. Rsq (r2) and p-values shown for 
Spearman correlation between methylation and TTD.   
A. B.
C. D.
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 5.3.2 Illumina 450k beadchip array discovery study 
A second discovery study was conducted using the Illumina Infinium HumanMethylation 
450k beadchip array, and including 92 matched case-control pairs from the EPIC study 
(Table, 5.3 (EPIC4)). Conditional logistic regression was used to identify mean methylation 
differences between cases and controls, with samples matched on age, ethnicity and study 
centre. Seventy five loci were nominally associated with case-control status at a threshold of 
p<10-5, however, no locus reached genome-wide significance level (p<10-7) (Fig 5.7). Of 
these, 65 displayed an increase in methylation in cases relative to controls, of which 46 loci 
displayed a ǻȕ>0.05 (5% higher mean methylation in cases), with the largest ǻȕ of 0.091 at 
the GABRQ gene. The largest decrease in methylation in cases relative to controls was 
within the ASB13 gene (ǻȕ = 0.04). Only at one gene (TFDP3), was there more than one 
locus (cg16829640 and cg13566059 (adjacent loci, 5bp apart) with ǻȕ-values of 0.07 and 
0.086, respectively) identified. TFDP3 is on the X chromosome, and these loci display 
unusually broad methylation ranges consistent with hypermethylation of the inactivated 
chromosome (as all participants are female), and methylation ranging between 0-100% on 
the active allele (Fig 5.8). Methylation at the TFDP3 cg16829640 was strongly correlated 
with methylation of TFDP3 cg13566059 (r2=0.85, p= 2.2e-16). 
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Fig 5.7
Figure 5.7. Manhattan plot showing statistical significance of associations between DNA methylation 
and breast cancer risk for all loci represented on the Infinium HumanMethylation 450k beadchip array, 
arranged by chromosome (coloured bands, X-axis). Statistical significance (conditional logistic regression) 
represented as –log10p-values (Y-axis). Grey lines represent cut-offs for statistical significance at p<10-5 and 
p<10-7 levels. 
197
Figure 5.8. Significant blood hypermethylation of neighbouring CpG sites in TFDP3. (A) 
TFDP3_cg16829640 and (B)TFDP3_cg13566059 in  breast cancer cases  (1, n=92) relative to controls  (0, 
n=92) in Illumina 450k beadchip array data (EPIC4 subgroup). Red lines represent median methylation . 
Fig 5.8
A. B.
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 Two loci, within the HEATR2 (cg11027456) and SLFN12L (cg21705506) genes were 
selected for validation, and selection was based on lowest p-values, highest ǻȕ-values 
(0.063 and 0.09 respectively), and ability to design working pyrosequencing assays (Fig 5.9, 
Table 5.6 (A)).   
Pyrosequencing of HEATR2 and SLFN12L was carried out in an independent data set of 
EPIC samples (EPIC3, n=243 cases, 286 controls). SLFN12L methylation was not 
significantly different in cases and controls, and quartile analysis did not reveal a significant 
difference in breast cancer risk in higher methylation categories compared with the lowest 
(reference category) (Fig 5.9, Table 5.6 (B)). Inconsistent with the discovery set, HEATR2 
was significantly hypomethylated in cases compared with controls (p=0.005), i.e. the 
direction of effect was opposite to the discovery set, however, the difference in median 
methylation between cases (median=86.6%) and controls (median=87.5%), was very small 
(0.9%). Quartile analysis indicated significantly decreased cancer risk in the highest 
(OR=0.48 (95% CI 0.29-0.80), p=0.005) and second highest (OR=0.62 (0.38-1.00), p=0.05) 
methylation quartiles compared with the lowest methylation quartile (Table 5.6 (B)). As with 
analysis of fasting-associated loci using the 450k array (chapter 4), methylation ranges of 
HEATR2 and SLFN12L were much higher and narrower in the pyrosequencing validation set 
data compared with the array-based discovery set data, indicating a consistent unidentified 
bias in our analysis pipeline. 
  
Fig 5.9
A.
B.
Figure 5.9. Association of loci within SLFN12L and HEATR2 with breast cancer case-control status. (A) 
450k array DNA methylation data for top hit loci within SLFN12L and HEATR2 in controls (n=92) and cases 
(n=92) in the EPIC study (EPIC4 subgroup). (B) pyrosequencing in an independent sample set (n=286 
controls, 243 cases) from the EPIC study (EPIC3 subgroup).  
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Table 5.6 (A). Median, mean and inter-quartile range (IQR) of  DNA methylation of controls and cases for 
HEATR2 and SLFN12L  (pyrosequencing data from validation sample set (EPIC3))  
Locus 
Mean 
control 
Mean  
case 
Median  
control 
Median 
case   
IQR  
control 
IQR 
case  
Wilcox p-
value* 
HEATR2  87 86.28 87.51 86.62 4.33 4.64 0.005 
SLFN12L  75.43 75.33 75.83 75.56 8.84 9.27 0.8 
*Wilcoxon rank sum test p-value 
 
Table 5.6 (B). Inter-quartile analysis of association between methylation and cancer incidence at HEATR2 and 
SLFN12L (pyrosequencing data from validation sample set (EPIC3).  
Locus Quartile (meth range) case (n) control (n) OR (95% CI)*  p **  
HEATR2  
Q4 (89.4-95.0) 41 73 0.48 (0.29-0.80) 0.005 
Q3 (87.5-89.4) 50 70 0.62 (0.38-1.00) 0.05 
Q2 (85.1-87.5) 66 70 0.81 (0.51-1.29) 0.385 
Q1 (53.5-85.1) 83 72 reference  _ 
SLFN12L  
Q4 (80.1-95.8) 73 73 1 (0.63-1.58)  1 
Q3 (75.8-80.1) 61 74 0.82 (0.51-1.32)  0.42 
Q2 (71.3-75.8) 73 69 1.05 (0.66-1.68)  0.81 
Q1 (45.8-71.3) 73 73 reference  _ 
*Odds ratio (95% confidence interval) for breast cancer incidence in highest, compared with the reference 
(lowest) methylation category.   
**p-value for logistic regression  
 
  
  
202 
 
5.3.3 Analysis of DMH candidate loci in EPIC4 450k array data 
450k array DNA methylation data was available for several loci located within the fragments 
associated with cancer risk in the DMH discovery study; enabling potential validation of DMH 
associated regions in an independent sample set using a different methylation microarray 
analysis method. Median methylation levels (control and case) and p-values (conditional 
linear regression, before and after FDR correction) for association with cancer risk are 
shown for all of the 450k array loci residing within the ten most significant DMH fragments, 
are shown in Appendix table 2. Of 87 450k array loci within DMH fragments, only 5 were 
significantly associated with case-control status with the same direction of effect in EPIC4. 
All of these displayed very small median methylation differences between case and control 
groups (<1%), and three loci were significantly differentially methylated in the 450k array 
data with the opposite direction of effect to the DMH study, and with case-control methylation 
differences of 0.5-2%; therefore, the loci associated with breast cancer risk in both studies 
may have occurred due to chance and are unlikely to be of biological relevance. Seven 450k 
loci were within the PARP1 DMH fragment, however, only three were within regions 
analysed by pyrosequencing in KConFab, and two were within the PARP1s1 region that was 
not differentially methylated in KConFab. Only one CpG site within the PARP1s6 region 
cg07113065 was, therefore, comparable with the KConFab data. This individual CpG sites 
was significantly hypermethylated in KConFab data (p<2.2e-16), combined technical and 
biological validation sets (data not shown), but not in the 450k array EPIC data set (p=0.42, 
Table 5.7), consistent with lack of association with sporadic breast cancer risk.  
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5.4 Discussion 
 
5.4.1 Differential methylation hybridization 
Our DMH study identified 38 genes that were differentially methylated in prospectively 
collected blood samples of familial breast cancer cases compared with healthy unrelated 
controls, with an enrichment of DNA methylation variability at gene promoters relative to 
other genomic regions. The top ten most differentially methylated fragments were 
hypermethylated in cases relative to controls, which is inconsistent with evidence for greater 
DNA methylation variability at intergenic, than promoter, gene regions (Flanagan and Wild, 
2007; Shenker and Flanagan, 2012). Promoter methylation hypervariability within this study 
may reflect an increased promoter hypermethylation frequency associated with familial 
breast cancer risk; however, our approach is biased by the selection of gene promoters on 
the custom oligonucleotide array. Promoter methylation hypervariability is thought to occur 
due to loss of protection from DNA methylation at CpG islands a frequent event during early 
tumorigenesis (Baylin et al., 1998).  
Technical validation and biological validation within the same sample study were achieved 
for promoter regions of the PARP1 promoter, directly upstream (PARP1s2) and directly 
downstream (PARP1s4, PARP1s5 and PARP1s6) of the TSS. Significant hypermethylation 
and methylation hypervariability in cases was identified, though the increase in percentage 
methylation was subtle. Consistency of these associations between samples sets (discovery 
and biological validation sets) and assay types (DMH and bisulphite pyrosequencing 
(including four pyrosequencing assays within two independent PCR amplicons)), indicates 
that PARP1 promoter hypermethylation is genuinely associated with breast cancer risk 
within the KConFab study.  
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The finding that hypermethylation of PARPs2 and PARPs6 was inversely correlated with 
Time to diagnosis in KConFab suggests that PARP1 hypermethylation may represent an 
early tumorigenic event rather than an innate disease risk factor. This result is similar to the 
report by Xu et al (Xu et al., 2013b), in which methylation at many loci associated with breast 
cancer risk was significantly correlated with TTD.  
Poly (ADP) ribose polymerase 1 (PARP1) is a key sensor in the DNA damage repair 
pathway,  in which most known breast cancer susceptibility genes are involved (Burkle, 
2000; van der Groep et al., 2011). PARP1 is of clinical interest for familial breast cancer, as 
PARP inhibitors induce synthetic lethality in tumour cells with defective DNA damage repair 
due BRCA1 mutations (Berrada et al., 2010; O'Shaughnessy et al., 2011). Furthermore, 
PARP inhibitors could be used in first line treatment of BRCA1 mutated or triple-negative 
breast cancers (breast cancers lacking expression of ER and PR, and lacking amplification 
of HER2, and therefore associated with poor prognosis due to lack of molecular targets for 
treatment). PARP1 is also over-expressed in triple-negative breast cancers (Ossovskaya et 
al., 2010). Little is known about epigenetic regulation of PARP1, however, some evidence of 
promoter hypermethylation associated with environmental carcinogen exposure in vitro has 
been reported (Gao et al., 2010), and PARP1 plays a role in regulation of DNA methylation, 
probably through regulation of DNMT1 (Beneke, 2012; Guastafierro et al., 2008; Reale et al., 
2005; Zampieri et al., 2009) 
Given that the PARP1 promoter was almost completely unmethylated in controls in our data, 
the increase in cases likely represents an aberrant hypermethylation of a small subset of 
leukocytes. As hypermethylation occurs at the TSS, it is likely to affect transcription, which 
may lead to aberrant DNA damage repair (DDR) in PARP1 hypermethylated cells (Bouchard 
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et al., 2003; Guastafierro et al., 2008), which may contribute to cellular tumourigenicity 
potential. Although the increase in PARP1 methylation in cases is subtle (0.48-2.4%), this 
equates to a 1.2-2.26-fold increase in the frequency of PARP1 hypermethylated cells 
considering that methylation in individual cells is binary, either methylated or unmethylated. 
Furthermore, given the technical validation of PARP1, promoter hypermethylation of several 
other breast cancer-related transcription factors in the DMH data, including FOXO3 (Zou et 
al., 2008), TGFBR2 (Lucke et al., 2001) and HIF1A (Chiavarina et al., 2010)  may be 
reproducible, at least within the KConFab study. This may be indicative of an underlying 
defect in the factors protecting the unmethylated state of gene promoter CpG islands in 
familial breast cancer. A ‘CpG methylator phenotype’ is evident in many cancers, whereby 
hypermethylation of multiple gene-promoters that are unmethylated in normal tissue occurs 
(Issa, 2004), therefore, increased frequency of gene promoter hypermethylation in blood of 
familial breast cancer cases may represent a less-pronounced precursor state for this 
phenomenon. It is important to remember, however, that our candidate-gene approach 
selected for genes known to be hypermethylated in breast cancer.  
PARP1 was not differentially methylated with case-control status in the BGS study, using 
pyrosequencing, nor was there any evidence of differential methylation of PARP1 promoter 
loci within the 450k array data in EPIC. Importantly, the BGS and EPIC studies represent 
nested case control studies, with most cases representing sporadic breast cancer, whereas 
all cases within the KConFab have strong family history of breast cancer. Therefore, 
heritable risk factors are likely to account for many KConFab cancer incidences, whereas 
environmental or stochastic factors may account for sporadic cases in the BGS and EPIC 
studies. We did not find evidence of PARP1 hypermethylation within a subset of breast 
cancer cases or controls for which family history of breast cancer was self-reported in BGS; 
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however, the criteria for familial breast cancer were less stringent for these individual 
compared with the KConFab study.  
There is increasing evidence that breast cancer risk factors can be disease subtype-specific 
(Tamimi et al., 2012), and genetic loci specifically associated with ER- disease have recently 
been identified (Garcia-Closas et al., 2013a). Epigenetic risk factors may also be subtype 
specific, as blood BRCA1 hypermethylation was associated with development of BRCA1-
hypermethylated breast cancer in two retrospective studies(Iwamoto et al., 2010; Wong et 
al., 2010). We investigated whether the association of PARP1 hypermethylation with familial, 
but not sporadic breast cancer could be due to association of PARP1 methylation with BRCA 
mutations or tumour markers that may be indicative of subtype-specific tumorigenic 
pathways, however, we did not find convincing evidence of this.    
A considerable proportion (60%) of familial breast cancer cases occur in the absence of any 
known susceptibility mutation (van der Groep et al., 2011).  It is possible, therefore, that 
epimutations or epigenetic abnormalities, such as a higher propensity for promoter 
hypermethylation, may account for some familial cancers (Hitchins et al., 2011; Hitchins et 
al., 2007b). While it is generally accepted that DNA methylation and epimutations are erased 
and re-established between generations, underlying genetic factors may mediate 
transgenerational inheritance of pathogenic epigenetic states (Hitchins and Ward, 2007a; 
Imai and Yamamoto, 2008; Ligtenberg et al., 2012). Genetic polymorphism in DNMT3b may 
be associated with risk of breast (Cebrian et al., 2006; Montgomery et al., 2004), prostate 
(Singal et al., 2005) and lung cancer (Lee et al., 2005b), and DNMT polymorphisms may 
influence blood DNA methylation patterns (Inoue-Choi et al., 2013), therefore, genetic breast 
cancer risk factors influencing  DNA methylation may account for the association PARP1 
hypermethylation in familial, but not sporadic breast cancer. Alternatively, an unknown bias 
within the KConFab study (discovery and validation sets) may account for the association 
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with case control status. Investigation in an independent familial breast cancer study is 
warranted, and is required for ‘external’ validation (Garcia-Closas et al., 2013b). 
 
5.4.2 Illumina Infinium HumanMethylation 450k beadchip array 
Our discovery study using the Illumina Infinium HumanMethylayion450 BeadChip microarray 
represents one of the first prospective EWAS studies for breast cancer risk. Unfortunately, 
no loci reached ‘genome-wide’ statistical significance (p<10-7) for association, indicating that 
it is unlikely that there are any loci represented on the 450k array that display large 
methylation differences associated with sporadic breast cancer risk, as have been identified 
for smoking (Shenker et al., 2012). Our EWAS study was not powered to identify subtle 
methylation variation between cases and controls (only 2% power to detect d=0.5 (~5% 
methylation case-control difference); 80% power to detect d=0.93 (~10% difference) at 
alpha=1e-7). Whereas the greater DNA methylation variability in tumours allows 
investigators to limit analysis to loci displaying ǻȕ-values of >0.2 (20%), which allows 
identification of differential methylation with 99% confidence (Bibikova et al., 2011; Wilhelm-
Benartzi et al., 2013), investigation of blood DNA methylation in population studies requires 
methods that allow discrimination of subtle methylation variability.  
Consistently, a recent prospective study conducted by Xu eta l (Xu et al., 2013b) reported 
associations of 250 loci with breast cancer risk, however, all loci displayed small absolute 
ǻȕ-values (<5% methylation difference) associated with breast cancer risk. Similarly, no 
cancer-associated loci identified in retrospective studies (Marsit et al., 2011; Teschendorff et 
al., 2009) displayed differential methylation of >6% in cases relative to controls. 
The associations of HEATR2 and SLFN12L hypermethylation with case-control status likely 
represent false-positives, as the methylation distributions of both loci in pyrosequencing data 
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appeared very different from the Illumina 450 array data. Technical validation was not 
possible in this case, as the samples used for the array were not available for 
pyrosequencing. It is possible that the detected hypermethylation represented technical 
artefacts or were introduced during array data processing. Attempts to validate loci 
associated with both case-control and fasting status have shown a consistent pattern of 
narrower and higher methylation ranges in pyrosequencing data compared with array data, 
at some, but not all loci. It is not known whether this bias lies with the array step or the 
pyrosequencing step, however as bisulphite sequencing represents the gold standard for 
DNA methylation analysis (Reed et al., 2010), it is likely that artefactual associations are 
caused either by technical or data-processing steps of the 450k array analysis pipeline.  
The EPIC4 Illumina 450k array data used for this case control analysis (following quality 
control and normalisation steps) has been previously used to identify loci associated with 
smoking, using similar analytical methods to the ones used to identify case-control 
associations (Shenker et al., 2012), and these loci were successfully validated by 
pyrosequencing in other EPIC data-sets. Therefore, technical validation of loci associated 
with DNA methylation differences of 2-20% in array data was achieved, providing proof-of-
principal for investigation of EWAS studies using our analytical approach. Whereas the ǻȕ-
values for some of the smoking-associated loci were lower than those for HEATR2 and 
SLFN12L associated with case-control status, the smoking associations were much more 
consistent than the case-control differences identified. However, technical factors may 
account (to some extent) for the greater reproducibility of smoking-associated loci than 
breast cancer-associated loci, as the quality and reproducibility of methylation analysis on 
the 450k array is locus-specific due to probe-specific biases such as DNA-bindings 
specificity and probe type (Price et al., 2013; Wilhelm-Benartzi et al., 2013). 
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Lastly, a caveat of using large sample sizes is that very strong statistical associations may 
occur in the absence of biologically meaningful differences (Burton et al., 2009); therefore, it 
is important to assess the reproducibility of associations in validation sample sets as well as 
their statistical significance (Garcia-Closas et al., 2013b).  
 
5.4.3 Comparison of arrays methods 
There was no apparent overlap between discovery studies in terms of loci associated with 
breast cancer risk, as only 5 of the 450k array loci within the DMH fragment regions were 
significantly associated with cancer risk in the same direction in the EPIC4 data set, and all 
of these loci displayed methylation differences between cases and controls of <1%. Both 
technical differences between array methods and biological differences between study 
populations may account for this.  
Coverage of the DMH fragments on the 450k array is limited to 3-18 CpG sites within each 
fragment; therefore, the differentially methylated regions discovered by DMH may not be 
covered on the 450k array. For example, of seven loci within the PARP1 DMH fragment 
represented on the 450k array, only one was within a region that was differentially 
methylated in the KConFab samples. Different assay types identify differential methylation 
based on different criteria, as DMH measures methylation of genomic fragments ~100-
200bp in length, enabling detection of small, but spatially consistent shifts in methylation 
frequency between sample groups. The Illumina 450k array measures methylation at single 
CpG sites; therefore, discovery of statistically significant differential methylation is dependent 
on highly consistent mean methylation differences at single CpG sites between cases and 
controls. Large sample sizes will be required to identify breast cancer-risk associated loci 
with modest ǻȕ-values and heterogeneity of effects. Meta-analyses of EWAS studies may 
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also be useful for identifying subtle differential methylation at individual loci across multiple 
studies. 
Regional methylation shifts may be identified using the 450k array as consistent methylation 
differences across neighbouring probes where neighbouring probes are sufficiently near to 
each other to detect methylation correlation between neighbouring probes (Jaffe et al., 
2012), as identified for two TFDP3 loci 5bp apart, and for haplotype-associated methylation 
(see chapter 4). Development of arrays with higher probe densities and bisulphite-
sequencing-based methods will enable assessment of regional differential methylation 
patterns in EWAS studies.  
The Illumina 450k beadchip array, however, has many practical advantages over DMH, as 
methylation analysis is more quantitative and is measured at single base resolution. 
Validation of single CpG sites is far more time and cost-effective than validation of genomic 
fragments, and is achieved with 100% coverage of the locus of interest; whereas full 
coverage of DMH fragments with pyrosequencing assays may often be impossible, 
especially at CpG dense gene promoters.  
As previously mentioned, the inconsistency between our DMH and Illumina arrays may be 
partially due to biological differences between the KConFab and EPIC study sample-sets, as 
promoter hypermethylation may be more frequent in familial breast cancer compared with 
sporadic breast cancer. Consistently, Xu et al found a statistically significant enrichment of 
breast cancer risk-associated differential methylation at CpG islands, in a prospective 
investigation of breast cancer (Xu et al., 2013b). However, a prospective study investigating 
blood DNA methylation in association with sporadic breast cancer also reported enrichment 
of CpG island loci (Widschwendter et al., 2008).  
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In conclusion, the identification of PARP1 hypermethylation associated with breast cancer 
risk supports the idea that prospective discovery studies may be used to identify additional 
DNA methylation biomarkers for breast cancer risk prediction. However, our inability to 
identify additional markers within the 450k array discovery study suggests that large sample 
sizes and greater understanding of potential confounding factors will be required to identify 
significant loci in EWAS studies. 
  
  
212 
 
 
CHAPTER 6 
 
Overall discussion, limitations and future perspectives 
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While a small proportion of breast cancers are caused by high penetrance mutations, the 
majority are likely attributable to combinations of common heritable and environmental risk 
factors, as well as stochastic somatic mutations. Our research contributes to the wealth of 
emerging evidence indicating that many of these risk factors, such as age, estrogen 
exposure, obesity, carcinogen exposure, and common genetic polymorphisms have 
profound influences on epigenetic patterns, providing insight into the mechanisms by which 
these factors affect breast cancer risk on a molecular level. While this evidence provides 
promise for identification of epigenetic patterns associated with and accounting for breast 
cancer risk, it also indicates that unlike easily quantifiable exposures such as smoking or 
age, breast cancer risk represents a highly heterogeneous combination of factors that 
cannot be easily collectively quantified.  
Combined with the low variability (relative to tumour tissue), tissue-specificity, population 
specificity, and susceptibility to alteration by exposures of DNA methylation, cancer risk 
heterogeneity greatly limits our ability to identify simple associations between DNA 
methylation and breast cancer risk. Furthermore, it is impossible to identify individuals who 
are truly at low risk of breast cancer in the absence of lifetime follow-up; therefore, the most 
appropriate control participants are unavailable. Complicating matters further are the known 
interactions between many risk factors such as the interaction between MTHFR genotype 
and serum folate in contributing to cancer risk (Liu et al., 2013), and the interaction between 
diet and genotype for obesity related genes (Kaklamani et al., 2011), therefore, many breast 
cancer risk factors will be context-dependent. Identifying key associations within such a 
complex systems is a major challenge facing breast cancer molecular epidemiology. The 
research presented in this thesis has identified some interesting associations with potential 
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implications for breast cancer risk and biomarker development, but also highlights some 
wider implications for EWAS studies and cancer risk epigenetics 
 
6.2 ATM DNA methylation 
From our analysis of ATMmvp2a methylation and breast cancer risk, the OR for increased 
breast cancer risk within the highest methylation quintile was 1.89 (95%CI 1.4-2.6). While 
this first candidate gene represents a higher risk-association than any breast cancer GWAS 
SNP identified to date (Michailidou et al., 2013), a biomarker of this relatively modest risk 
association would be unlikely to provide the sensitivity or specificity to predict risk 
independently. However, whether inclusion of this marker into a cancer risk model will 
improve the model performance is unknown.  
Despite consistent association between ATMmvp2a methylation and breast cancer risk 
within the KConFab and BGS prospective studies, and in the bilateral breast cancer 
retrospective study(Flanagan et al., 2009b), we did not find a clear association within the 
EPIC study. This inconsistency may be explained by biological or demographic differences 
between study populations, such as age or ethnicity, or by technical factors such as sample 
preparation.  
Given that several environmental factors appear to influence ATMmvp2a methylation, 
ATMmvp2a methylation is more likely to represent an intermediate marker of breast cancer 
risk-related exposures rather than an innate susceptibility factor. However, the mechanism 
underpinning the association with case control status remains unknown. A putative 
explanation is that ATMmvp2a hypermethylation may reflect increased blood glucose levels 
in individuals at higher breast cancer risk due to metabolic cancer risk factors.  
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Our analysis was limited by lack of availability of information on factors such as fasting 
status, kynurenic acid levels and MTHFR genotype within the studies in which ATMmvp2a 
methylation was associated with cancer risk. Further assessment of ATMmvp2a methylation 
in breast cancer case control studies, ideally familial cancer studies, may help to establish 
the consistency of the risk association, and the factors accounting for this association.  
A biological mechanism for the apparent specific demethylation of the ATMmvp2a region in 
response to glucose depletion remains lacking.  ATMmvp2a may undergo active 
demethylation upon T cell activation or deactivation, as has been reported for other genes 
(Bruniquel and Schwartz, 2003; Toker et al., 2013; Zhang et al., 2013), as we found 
preliminary evidence that ATM methylation variability is restricted to T lymphocytes, and T 
cell activation is influenced by glucose metabolism (Finlay, 2013; Jacobs et al., 2008). 
However, methylation analysis of ATMmvp2a within specific blood cellular subsets, in 
association with fasting and glucose restriction, is required to investigate this, and to rule out 
the alternative hypothesis that the apparent ATM demethylation occurs due to proliferation or 
selective survival of T cells. Further research will also be required to determine the 
mechanism by which ATM becomes demethylated upon glucose depletion, and to 
investigate the possibility that active demethylation occurs. Such research is highly 
warranted, as our research suggests that T cell-specific ATM demethylation may represent 
one the first reported examples of environmentally mediated active demethylation in vivo. 
Furthermore, this research provides novel evidence of interactions between DNA 
methylation and metabolism of glucose and kynurenines, both of which relate to cancer risk 
(Cairns et al., 2011; Mandi and Vecsei, 2012; Seyfried et al., 2011; Stone et al., 2013). This 
is consistent with emerging evidence of widespread interactions between the epigenome 
and the metabolome (Donohoe and Bultman, 2012; Petersen et al., 2013). As breast cancer 
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is associated with distinct metabolic profiles detectable in serum (Oakman et al., 2011), 
research into interactions in blood may uncover the epigenetic mechanisms by which 
cancer-associated metabolic profiles influence gene expression.  
6.3 Tissue-specific DNA methylation 
Tissue-specificity of DNA methylation presents two key caveats for investigation of blood 
DNA methylation biomarkers for cancer risk. Firstly, it is likely that whole blood DNA 
methylation does not directly reflect methylation within the cancer affected tissue. This, 
however, does not exclude the possibility that blood DNA contributes to cancer risk, as many 
blood DNA methylation patterns may contribute to breast cancer through roles in immune 
surveillance, inflammation, energy homeostasis, or other blood-related processes. 
Assessment of the relevance of blood DNA methylation for breast cancer risk may be aided 
by the increasing availability of DNA methylation data for normal breast epithelial tissue.   
Secondly, cell-type-specific methylation within whole blood, coupled with inter-individual 
variability in cell-type proportions within blood represent a common confounding factor for 
association of DNA methylation with different exposures (Koestler et al., 2012; Reinius et al., 
2012), especially as immune profiles are altered by innate inter-individual differences, 
exogenous exposures, and disease states (Koestler et al., 2012; Langevin and Kelsey, 
2013). This issue is currently being addressed by cataloguing of tissue-specificity of DNA 
methylation for all probes on the Illumina 450k array (Koestler et al., 2013a; Reinius et al., 
2012), and by development of statistical methods to adjust for cell count, which may be 
measured prior to analysis (Koestler et al., 2013b).  
Alternatively, methylation analysis may be carried out within specific blood cell populations 
separately (Zhang et al., 2013). As it becomes increasingly apparent that blood methylation 
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variability relates strongly to immune functions (Koestler et al., 2012; Zhang et al., 2013), 
investigation of methylation in specific immune cell-types may identify epigenetic patterns 
associated with immune-related breast cancer risk factors such as inflammation  and obesity 
(Grivennikov et al., 2010).  
6.4 Mechanisms of DNA methylation 
A common assumption of epigenetics association studies is that DNA methylation variability 
has mechanistic implication for gene transcription and genome function, yet the role of DNA 
methylation across the genome has not been fully elucidated. DNA methylation appears to 
have functions apart from transcriptional regulation, as several genome-scale studies have 
indicated that DNA methylation in blood is not associated with gene expression at the 
majority of loci (Eckhardt et al., 2006; Fraser et al., 2012; Illingworth et al., 2008; Lam et al., 
2012). Whereas the role of intragenic methylation remains unclear, the identification of 
intragenic, and even intergenic loci, with smoking (Shenker et al., 2012), and of breast 
cancer GWAS SNPs in distal enhancers (Ahmadiyeh et al., 2010), implicates intragenic 
regions in cancer risk. ATMmvp2a may represent an interesting model for further 
investigation of the role of intragenic DNA methylation, especially with regard to potential 
roles in alternative splicing.  Currently, mechanistic studies and investigating causality of 
differential methylation are limited by lack of methods to specifically alter epigenetic marks, 
as can be done for genetics studies using targeted mutagenesis. Understanding of the role 
of DNA methylation in cancer risk may benefit from investigation of interactions with other 
epigenetic mechanisms such as histone acetylation or nucleosome positioning.  
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6.5 Epigenetic biomarkers based on response to cancer related interventions 
ATMmvp2a methylation may represent an interesting marker of epigenetic response to 
environmental exposures, as there was evidence of inter-individual variability in response to 
fasting of methylation at the locus (albeit in only 6 individuals), and as markers of inter-
individual variability in response to fasting have been postulated as potential biomarkers for 
metabolic health (Oliver et al., 2013). 
Investigation of inter-individual variability in epigenetic response to cancer risk-related 
exposures and risk-modifying interventions, such as alcohol consumption, hormone-
replacement therapy, and treatment with anticarcinogenic chemotherapies such as 
tamoxifen or metformin, may represent a more relevant approach to investigate epigenetic 
breast cancer risk markers, compared with single time-point ‘snapshot’ measures of 
methylation. Furthermore, such studies would be more easily controlled due to the 
measurement of quantifiable risk exposures, and due to the elimination of bias associated 
with inter-individual variability in ‘baseline’ methylation levels and factors such as age, 
genetics and exposures. Measurement of response to transient exposures, such as fasting 
or chemo-preventative therapy may be easily controlled for batch effect due to the short 
duration between collection of ‘before and after’ samples. Inclusion of intermediate markers, 
such as circulating estrogen levels, as well as standardised questionnaires with regard to 
cancer risk exposures, and follow-up for cancer incidence would also improve such studies. 
A causal role for cancer risk exposure on the outcome (DNA methylation), often lacking in 
epidemiological studies, could be easily established by measurement at further time-points, 
such as before and after consecutive rounds of preventative therapy. Ideally, such studies 
would be incorporated into intervention studies for which the reduced risk associated with 
intervention has been quantified (Cuzick et al., 2002; Visvanathan et al., 2013).   
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6.6 genome-wide hypomethylation 
Overall evidence suggests that genomic 5meC levels are lower in cancer patients compared 
with healthy individuals; however, the inconsistent findings between studies, and failure to 
validate this association in prospective studies (Huang et al., 2012) may suggest that the 
finding is not generally applicable, or is a consequence of, rather than a risk factor for, 
cancer. This is consistent with perhaps the most plausible putative cause of genome-wide 
hypomethylation; that supply of dietary methyl donors is affected by the presence of rapidly 
proliferating tumour cells within an individual (Liu et al., 2013).  Whole-methylome analysis 
will likely improve our understanding of genomic methylation landscapes and the widespread 
and focal changes associated with cancer. Meanwhile, cost-effective mass-spectrometry-
based methods for 5meC analysis requiring smaller amounts of DNA will allow high-
throughput investigation of the utility of genomic 5meC levels for biomarker development.  
Despite the well-cited role of DNA methylation in repressing repetitive element transcription, 
potentially protecting against retrotransposition-mediated mutagenesis, genomic instability 
(Belshaw et al., 2010; Friso et al., 2013; Soares et al., 1999; Wilson et al., 2007), and 
spurious RNA transcription from within repetitive elements, DNA methylation of individual 
genomically distinct repetitive elements remains virtually unexplored. Novel methods using 
specific methods should enable the investigation into epigenetic regulation of specific 
‘functional’ L1 elements, such as those capable of retrotransposition (Cordaux and Batzer, 
2009; Wolff et al., 2010), or driving ectopic expression of neighbouring genes (Faulkner et 
al., 2009; Wolff et al., 2010).  
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6.7 PARP1 hypermethylation.  
Further investigation of the potential association of PARP1 hypermethylation with familial 
breast cancer risk, and the association of methylation with Time to diagnosis (TTD), is highly 
warranted, as there is a current requirement for biomarkers to improve sensitivity and 
specificity of breast cancer diagnosis at early stage (Garcia-Closas et al., 2013b). 
Association of PARP1 hypermethylation with familial, but not sporadic breast cancer is 
consistent with a stronger association of ATMmvp2a methylation with cancer risk in the 
KConFab study compared with other studies. Whereas this may point to unidentified 
confounding factors within the KConFab study underpinning both associations, it may also 
indicate heterogeneity between breast cancer types in terms of epigenetic etiology, and of 
general epigenetic dysregulation associated with familial breast cancer risk. This is 
somewhat paradoxical, as epigenetic marks are not thought to be heritable, therefore, 
should not contribute to heritable disease risk. Despite this, twin studies (Gordon et al., 
2012; Heijmans et al., 2007), and other population studies (Bjornsson et al., 2008; Dite et al., 
2012; Kile et al., 2010; Mirabello et al., 2010), have shown that heritable factors do 
contribute considerably to DNA methylation genome-wide. Mounting evidence that SNPs in 
epigenetic modifier enzymes affect DNA methylation in trans (Inoue-Choi et al., 2013; 
Shukla et al., 2010; Tajuddin et al., 2013), and are associated with increased cancer risk 
(Cebrian et al., 2006; Kullmann et al., 2013; Lee et al., 2005b; Montgomery et al., 2004; 
Shukla et al., 2010), indicate that common heritable factors may associate with DNA 
methylation variability contributing to cancer risk. Furthermore, the potential role of cancer 
susceptibility genes such as BRCA1 in regulating DNA methylation (Shukla et al., 2010), 
suggests that potential interaction between epigenetic mechanisms and genetic risk factors 
for breast cancer.  
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6.8 Additional candidate markers identified by DMH 
Requirement for coverage of ~100bp fragments using multiple pyrosequencing assays was 
a technical limitation that has impeded validation of other DMH fragments, however, given 
technical validation of PARP1 within the KConFab study; attempt to validate other ‘top hit’ 
fragments  displaying cancer-associated hypermethylation may be worthwhile. It may be that 
rather than representing a locus-specific event, PARP1 hypermethylation may be indicative 
of the beginnings of a general loss of protection from DNA at gene promoters referred to as 
the ‘CpG island methylator phenotype’ that occurs frequently in tumors (Issa, 2004). 
 
Despite the semi-quantitative nature of methylation analysis of DMH (Dai et al., 2008), this 
method had shown impressive sensitivity to detect subtle PARP1 hypermethylation within a 
relatively small set of blood samples, highlighting the potential utility of methylation-sensitive-
restriction enzyme-based assays as complementary methods of methylation analysis in 
addition to more quantitative bisulphite-sequencing-based approaches.  
 
6.9 Haplotype-associated DNA methylation.  
We observed a trimodal distribution of DNA methylation at an LGR6 promoter region, 
potentially indicative of haplotype-associated methylation (chapter 4). This  is interesting, as 
a recent GWAS study has reported that the LGR6 minor allele is associated with increased 
risk of ER- breast cancer (Garcia-Closas et al., 2013a), suggesting that the affect of the 
reported risk-associated SNP (rs6678914) may be mediated through haplotype-specific 
hypermethylation. The LGR6 DMR spans the transcription start site of the LGR6 
NM_021636 transcript, a POLR2A binding site, and conserved binding sites for GATA and 
EVL transcription factors, suggesting a potential effect of methylation on LGR6 transcription. 
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The trimodal distribution of a CpG site within the LGR6 DMR (Fig 6.1 labelled LGR6-DMR-
CpG3) was confirmed by pyrosequencing in EPIC3 (n=559, Fig 6.1). Surprisingly, the 
trimodal methylation pattern of LGR6_ cg05044291 was not evident in normal breast 
epithelium DNA samples (n=98, Fig 6.1), or breast tumour (n=382, data not shown) within 
publicly available Illumina Infinium HumanMethylation450 BeadChip array data from The 
Cancer Genome Atlas (TCGA) study. Similarly, haplotype-associated DNA methylation at 
the promoter of the FGFR2 gene has recently been reported (Heyn et al., 2013), and GWAS 
studies have reproducibly shown that the FGFR2 minor allele, displaying increased FGFR2 
expression, is associated with increased breast cancer risk (Easton et al., 2007; Garcia-
Closas et al., 2013a). Consistently, trimodal methylation of these FGFR2 CpG sites was 
apparent in our data (data not shown). The possibility that haplotype-associated promoter 
hypermethylation may represent a general silencing mechanism associated with GWAS 
SNPs has been raised before (Bell et al., 2012; Leung et al., 2012; Ogino et al., 2013), and 
DNA methylation pattern associated with a SNP in the obesity-associated FTO gene, 
potentially regulating activity of a long-range enhancer, has been identified (Bell et al., 2010). 
The importance of interactions between DNA methylation and genotype are currently being 
uncovered, as genetic motifs strongly influencing DNA methylation patterns in cis have been 
identified (Lienert et al., 2011). Tissue-specificity of the haplotype-associated methylation 
pattern of LGR6 is consistent with a recent study that reported tissue-specificity of ~40% of 
479 locus-specific haplotype-associated DNA methylation patterns (Heyn et al., 2013), and 
the observation that haplotype-associated FGFR2 expression is tissue-specific (Huijts et al., 
2011). This combined with the finding that haplotype-specific methylation patterns are 
enriched for H3k27ac and CTCF binding indicates that epigenetic factors must interact with 
haplotypic genetic differences to control promoter DNA methylation state. Therefore, 
investigation of tissue-specific haplotype-associated promoter hypermethylation may help 
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elucidate the mechanisms by which aberrant promoter hypermethylation occurs. Lastly, 
epigenetic mediation of the effects of disease-associated genetic variants may offer potential 
for therapeutic intervention, due to the reversible nature of epigenetic marks.  
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Figure 6.1. Trimodal DNA methylation of CpG sites within LGR6 (A) Methylation distributions (strip-charts) 
of all LGR6 loci represented on the Illumina Infinium HumanMethylayion450 BeadChip array arranged by 
genomic location in 228 blood DNA samples from the EPIC study (EPIC5/EPIC6). A trimodal distribution of 
DNA methylation at four  adjacent CpG sites within LGR6 promoter 2 (P2) is evident, compared with 
constitutively unmethylated loci within promoters 1 (P1) and 3 (P3), and constitutively methylated loci in P4.  
(B)The LGR6 locus selected for pyrosequencing validation is labelled CpG3. The only locus outside the DMR 
displaying trimodal methylation distribution is a polymorphic CpG site (PM CpG). rs6678914 marks the 
approximate location of a SNP associated with ER- breast cancer risk in a recant GWAS study (Garcia-Closas
et al, 2013). Map information indicating distance (bp) between CpG sites is shown on the  X-axis. (B) 
Individual strip-chart for LGR6 CpG3 within the same 450k array DNA methylation data as A (C) Validation of 
trimodal methylation distribution  by pyrosequencing in an independent sample set  of 559 blood DNA samples 
(EPIC3 subgroup) (D) Publicly available 450k array data for LGR6 CpG3 methylation in normal breast 
epithelial samples  (n=98), from The Cancer Genome Atlas (TCGA) study. 
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6.10 EWAS studies 
 
6.10.1 EWAS in general 
EWAS studies represent a potential way of identifying DNA methylation patterns associated 
with both breast cancer risk and breast cancer related exposures in a relatively unbiased, 
high-throughput way, and may therefore be useful for identification of epigenetic risk 
biomarkers. Methylation-dependent single-base sequence alteration by bisulphite conversion 
means that in practical terms, genome-wide methylation analysis is similar to measurement 
of SNPs genome-wide.  
It is becoming increasingly clear, however, that instability and tissue-specificity of DNA 
methylation at many loci make EWAS studies far more complicated than GWAS studies, and 
that great consideration for study design and exclusion of potential biases must be taken in 
order to ensure that EWAS studies can be appropriately controlled.  
 
6.10.2 DNA methylation stability 
Temporal stability of molecular markers is a prerequisite for their development as disease 
risk prediction biomarkers, as population screening would, in practicality, only allow testing 
every few years (Hanash et al., 2011). Furthermore, investigation of DNA methylation 
biomarkers within prospective studies using stored tissue samples requires methylation 
stability. Thirdly, contribution to long-term cancer risk, either as an innate factor or through 
marking epigenetic memory of early-life exposures, would also require long-term stability of 
DNA methylation (Jefferson et al., 2013; Talens et al., 2010). Methylation stability at many 
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loci has been shown in longitudinal studies (Talens et al., 2010; Woodfine et al., 2011), and 
association of methylation marks with past exposures to famine (Heijmans et al., 2008; 
Shenker et al., 2013) and smoking demonstrate epigenetic memory.   However, the finding 
of alteration of ATMmvp2a methylation with fasting and other environmental exposures, and 
PARP1 hypermethylation associated with TTD, as well as reported alteration of DNA 
methylation by immune activation (Lam et al., 2012; Zhang et al., 2013) metabolic profiles 
(Petersen et al., 2013), diet (Lampe et al., 2013), and age (Lam et al., 2012; Rakyan et al., 
2010), indicate that DNA methylation at many loci may undergo dynamic alteration, and that 
single time-point measures may reflect current environmental conditions rather than long 
term cancer risk. Despite this, DNA methylation likely displays strong stability at many loci, 
relative to other molecular measures  such as RNA expression, protein, and metabolic 
profiles, and other epigenetic marks such as histone modifications and miRNA expression 
(Hanash et al., 2011).  
 
6.10.3 450k array 
The 450k array represents the most suitable platform for current EWAS investigations, as it 
provides highly quantitative, single-base resolution methylation data, is a high-throughput 
system and relatively low cost, and is less biased than many other methods in terms of 
genome coverage (Langevin and Kelsey, 2013; Rakyan et al., 2011). 
However, technical biases caused by probe cross-hybridisation, different probe types and 
batch effects can be problematic, and methylation biases caused by polymorphic CpG sites 
or haplotype-specific methylation coupled with differential allele frequencies between 
experimental groups can confound analyses.   
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Despite widely reported technical validation of associations identified using the Illumina 450k 
array (Dedeurwaerder et al., 2011), we were unsuccessful in identifying differentially 
methylated loci that were reproducible in pyrosequencing-based assays, with the exception 
of haplotype-specific DNA methylation at LGR6. Though we did not carry out technical 
validation of the Illumina 450k array, it appears likely that technical artefacts within array 
data, rather than biological differences between test and validation sample sets account for 
failure to validate associations, as the distributions of methylation at many loci was 
inconsistent between array and pyrosequencing data.  
Perhaps the greatest challenge to identification of differential methylation in blood using this 
platform is the low variability in blood DNA methylation relative to tumour DNA methylation. 
For both EWAS analyses of fasting status and case-control status, almost all significantly 
differentially methylated loci displayed ǻȕ-values less than 10%, whereas a general 
consensus among researchers is that significant probes displaying ǻȕ-values less than 10-
20% should be excluded from analysis, due to high variability between technical replicates 
using the 450k array (Dedeurwaerder et al., 2013; Wilhelm-Benartzi et al., 2013). While 
pyrosequencing-based validation of smoking-associated loci with small ǻȕ values (~2%) 
using the same data-set and analytical methods as used for our case-control analysis has 
been published (Shenker et al., 2012), these associations were highly consistent. Such 
consistency of associations with breast cancer risk may be unlikely, due to the highly 
heterogeneous and multi-factorial nature of breast cancer risk compared with smoking. In 
the absence of large ǻȕ values or highly consistent associations, very large sample-sets will 
be required to identify significant associations in future studies. Power analysis to determine 
sample sizes required, as well as stratified and multivariate analyses to detect associations 
for specific disease subgroups may be useful in future studies, as will consortium-based 
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meta-analyses of multiple studies, which have been useful for identification of GWAS 
associations in breast cancer (Fanale et al., 2012).  
Lastly, it is possible that inter-individual DNA methylation variability may be greater within 
individual blood cell types than within whole blood, and that such variability may be masked 
in whole blood by methylation variability between cell types. Therefore, EWAS studies using 
DNA samples derived from specific blood cell types may have more power to detect 
reproducible associations compared with studies using whole blood.  
 
6.10.4 Potential rarity of epigenetic events associated with cancer risk 
The statistical approach we have used for EWAS studies selects for large, consistent 
differences in DNA methylation between experimental groups, as such loci are easier to 
detect and validate using available methods, and may offer better discriminatory value as 
biomarkers.  However, it is important to consider that this approach may filter out regions of 
low DNA methylation variability that may be of higher biological significance, and regions 
that are strongly associated with the exposure of interest, but only within a subset of cases.  
Prioritisation of loci with high ǻȕ-values tends to select for genomic regions of high DNA 
methylation variability, consistent with the finding that differential methylation associated with 
cancer and age is enriched at gene bodies (Teschendorff et al., 2009). However, it is 
possible that selection of high methylation variability enriches for regions at which DNA 
methylation is under low selective pressure, and is dispensable for normal cellular function. 
Furthermore, regions of high DNA methylation variability often display intermediate DNA 
methylation, suggesting that neither the unmethylated or methylated state is ‘abnormal’. In 
contrast, regions with low DNA methylation variability, such as CpG islands and 
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transposable elements are under tight epigenetic control in normal tissue, and display strong 
conservation between individuals and tissues, suggesting an important functional role of 
methylation at these regions (Jones, 2012). Therefore, the rarity of aberrant epigenetic event 
on a cellular level may be directly related to the functional importance of methylation at those 
regions, which would prevent us from detecting them in EWAS studies. The promoter 
regions of BRCA1(Hansmann et al., 2012) and PARP1 represent examples of loci identified 
through candidate gene approaches, at which aberrant DNA methylation appears to occur, 
yet hypermethylation is rare on a cellular level, and is therefore just within the detection 
sensitivity of pyrosequencing. While the functional consequences of hypermethylation of 
these regions for individual blood cells is not known, given that BRCA1 promoter 
hypermethylation is associated with transcriptional repression and impaired DDR in breast 
tumors (Catteau et al., 1999), it is highly plausible that BRCA1 hypermethylation in normal 
cells may increase propensity for tumourigenicity. Therefore, in order to identify epigenetic 
events contributing to cancer susceptibility,  it may be more worthwhile investigating subtle 
methylation changes at regions that are normally constitutively unmethylated or methylated 
rather than regions displaying intermediate or highly variable methylation. Assays with 
improved sensitivity to detect subtle aberrant DNA methylation, such as single-cell 
epigenetic technologies or methods that enrich for cells based on methylation state may 
enable investigation of the cellular consequences of rare epigenetic states in future studies. 
 
Another bias is that the current methodology selects for common DNA methylation changes 
potentially associated with disease, as rare events of high penetrance, would not 
significantly change median DNA methylation across populations. While we focused on 
median shifts in DNA methylation across populations, an alternative approach would be to 
assess the relative frequency of statistical outliers i.e. individuals with DNA methylation 
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outside the normal methylation range (Hansmann et al., 2012; Herman, 1998). The latter 
approach is limited in that vast numbers of samples are required to confirm association of 
rare events with disease risk, and that it ignores common epigenetic variability, therefore a 
combination of both approaches may be required.  
 
6.11 Conclusions 
Despite the challenges facing EWAS studies, the availability of large prospective study 
sample cohorts provides a unique opportunity to carry out appropriately powered molecular 
epidemiological studies for breast cancer. Furthermore, a range of different study cohort 
types, such as case-control studies, longitudinal studies and twin studies are available, 
allowing interrogation of different biological questions. The complexities of tissue-specific 
methylation, dynamic alteration of DNA methylation, and interactions of the epigenome with 
the genome, metabolome, environment and immune system highlight the requirement for a 
holistic, ‘systems biology’ approaches to investigating molecular mechanisms of cancer risk, 
with integration of different data-types, and sophisticated bioinformatic and statistical 
approaches that will allow modelling of complex interactions. 
 
6. 12 Summary 
Our research highlights the potential value of blood DNA methylation as a rich source of 
information for investigation of breast cancer risk factors and development of biomarker for 
both risk prediction and early detection using blood samples from population cohorts.  
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This research provides novel insights into interactions between the epigenome and factors 
affecting breast cancer risk, including both heritable and environmental factors.  
While there are many challenges facing EWAS studies for breast cancer risk, and direct 
associations with breast cancer incidence of DNA methylation patterns remain elusive, 
investigation of interactions between breast cancer risk factors and DNA methylation may 
provide insight into the mechanisms by which risk factors increase risk at the molecular 
level. Furthermore, investigation of inter-individual variability in epigenetic response to risk 
factors and risk altering interventions will likely provide insight into the factors affecting 
breast cancer risk. Additionally, we provide evidence that PARP1 hypermethylation in blood 
may represent an early marker of preclinical disease, supporting the idea that dysregulation 
of DNA methylation represents a very early event in disease initiation. Lastly, the potential 
role of DNA methylation in mediating effects of breast cancer associated genetic variability is 
supported by our findings. Further research into each of these findings will likely provide 
valuable and clinically relevant information regarding the contribution of DNA methylation to 
breast cancer susceptibility. 
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Appendix table 2. Assessment  of association with case-control status of 450k array loci (EPIC4) within the 
regions identified as significantly differentially methylated in the differential methylation hybridisation array 
discovery study.   
Chromosome 
Genomic 
location 
control 
median 
case 
median 
ǻȕ        
(case-
control)* 
cond_glm
-p** 
cond_glm_p(fdr)*
** 
gene 
region 
FOXO3 
6 1.09E+08 0.699 0.671 -0.028 0.000757 0.021879 N_Shore 
6 1.09E+08 0.057 0.052 -0.005 0.009338 0.060223 Island 
6 1.09E+08 0.024 0.028 0.004 0.269833 0.436705 Island 
PARP1 
1 2.27E+08 0.013 0.017 0.004 0.252119 0.41783 Island 
1 2.27E+08 0.052 0.047 -0.005 0.113018 0.248244 Island 
1 2.27E+08 0.005 0.005 0 0.770416 0.853954 Island 
1 2.27E+08 0.018 0.018 0 0.844013 0.90362 Island 
1 2.27E+08 0.053 0.05 -0.003 0.081674 0.202221 Island 
1 2.27E+08 0.065 0.06 -0.005 0.009269 0.060007 S_Shore 
1 2.27E+08 0.166 0.182 0.016 0.013828 0.073302 S_Shore 
TLE4 
9 82187670 0.015 0.015 0 0.408164 0.570606 Island 
9 82187855 0.008 0.01 0.002 0.093041 0.219343 Island 
9 82187938 0.082 0.074 -0.008 0.007547 0.054282 Island 
9 82187997 0.035 0.03 -0.005 0.014938 0.076342 Island 
9 82188393 0.011 0.008 -0.003 0.523045 0.667799 Island 
TGFBR2 
3 30647540 0.329 0.301 -0.028 0.001444 0.027167 N_Shore 
3 30647670 0.244 0.235 -0.009 0.213956 0.375037 N_Shore 
3 30647672 0.253 0.245 -0.008 0.214524 0.375705 N_Shore 
3 30647725 0.071 0.065 -0.006 0.895693 0.937007 N_Shore 
3 30647773 0.126 0.129 0.003 0.999556 0.999751 N_Shore 
3 30647802 0.048 0.045 -0.003 0.034671 0.121154 N_Shore 
3 30647808 0.035 0.04 0.005 0.005964 0.04852 N_Shore 
3 30647919 0.035 0.039 0.004 0.22666 0.389613 N_Shore 
3 30647968 0.05 0.055 0.005 0.545773 0.686039 N_Shore 
3 30647988 0.033 0.043 0.01 0.03862 0.128916 Island 
3 30648096 0.051 0.048 -0.003 0.312261 0.480468 Island 
3 30648098 0.052 0.049 -0.003 0.153762 0.30235 Island 
3 30648325 0.029 0.028 -0.001 0.322848 0.49074 Island 
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3 30648407 0.048 0.044 -0.004 0.01037 0.063464 Island 
3 30648598 0.033 0.031 -0.002 0.521665 0.666665 Island 
3 30648819 0.049 0.048 -0.001 0.125032 0.264708 Island 
3 30648949 0.021 0.031 0.01 0.095446 0.222978 S_Shore 
3 30649017 0.023 0.02 -0.003 0.881921 0.928128 S_Shore 
LBH 
2 30453758 0.055 0.053 -0.002 0.169786 0.322414 Island 
2 30454146 0.02 0.03 0.01 0.004687 0.043545 Island 
2 30454275 0.016 0.016 0 0.121003 0.25924 Island 
2 30454279 0.055 0.05 -0.005 0.007253 0.053263 Island 
2 30454334 0.069 0.076 0.007 0.134526 0.277395 Island 
2 30454344 0.027 0.031 0.004 0.003297 0.037427 Island 
2 30454363 0.037 0.036 -0.001 0.390592 0.554877 Island 
PRR5 
22 45098335 0.012 0.015 0.003 0.016752 0.081177 
NM_01536
6 
22 45098346 0.072 0.069 -0.003 0.090926 0.216224 
NM_01536
6 
22 45098367 0.057 0.054 -0.003 0.797592 0.872574 Island 
22 45098800 0.039 0.036 -0.003 0.009792 0.06166 Island 
22 45098907 0.007 0.009 0.002 0.068959 0.1821 S_Shore 
FZD3 
8 28351217 0.058 0.056 -0.002 0.443144 0.601361 N_Shore 
8 28351457 0.056 0.053 -0.003 0.042412 0.136066 Island 
8 28351501 0.046 0.046 0 0.029758 0.111002 Island 
8 28351567 0.033 0.039 0.006 0.006221 0.049528 Island 
8 28351601 0.064 0.063 -0.001 0.024936 0.100587 Island 
8 28352084 0.035 0.035 0 0.027404 0.105964 Island 
8 28352396 0.064 0.059 -0.005 0.796057 0.871462 Island 
SMAD1 
4 1.46E+08 0.02 0.021 0.001 0.017973 0.084275 N_Shore 
4 1.46E+08 0.018 0.019 0.001 0.462039 0.617553 Island 
4 1.46E+08 0.026 0.032 0.006 0.002112 0.031294 Island 
4 1.46E+08 0.046 0.042 -0.004 0.375589 0.540959 Island 
4 1.46E+08 0.071 0.064 -0.007 0.115489 0.251706 Island 
4 1.46E+08 0.045 0.049 0.004 0.926792 0.956258 Island 
4 1.46E+08 0.089 0.084 -0.005 0.023567 0.097479 Island 
4 1.46E+08 0.019 0.021 0.002 0.082892 0.20409 Island 
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4 1.46E+08 0.016 0.017 0.001 0.008662 0.058049 Island 
4 1.46E+08 0.026 0.03 0.004 0.067288 0.179395 Island 
4 1.46E+08 0.021 0.025 0.004 0.260197 0.426468 Island 
4 1.46E+08 0.011 0.013 0.002 0.949973 0.970512 S_Shore 
4 1.46E+08 0.043 0.039 -0.004 0.358502 0.524863 S_Shore 
CXCL2 
4 74964260 0.197 0.194 -0.003 0.535802 0.678067 N_Shore 
4 74964493 0.096 0.092 -0.004 0.907881 0.944651 N_Shore 
4 74964856 0.029 0.031 0.002 0.176206 0.330308 N_Shore 
4 74964920 0.094 0.09 -0.004 0.165471 0.317061 Island 
4 74965068 0.032 0.036 0.004 0.021065 0.091874 Island 
4 74965075 0.053 0.047 -0.006 0.048382 0.146922 Island 
4 74965079 0.06 0.055 -0.005 0.287643 0.455425 Island 
4 74965135 0.059 0.067 0.008 0.014618 0.075483 Island 
4 74965154 0.053 0.05 -0.003 0.193753 0.351502 Island 
4 74965162 0.032 0.022 -0.01 0.57804 0.711429 Island 
4 74965226 0.013 0.012 -0.001 0.922298 0.953536 Island 
4 74965262 0.153 0.146 -0.007 0.507926 0.655305 Island 
4 74965278 0.082 0.08 -0.002 0.124559 0.264099 Island 
HIF1A 
14 62161583 0.15 0.151 0.001 0.745886 0.836718 N_Shore 
14 62161848 0.068 0.062 -0.006 0.001149 0.025102 Island 
14 62161878 0.039 0.039 0 0.451068 0.608173 Island 
14 62161958 0.005 0.008 0.003 0.014684 0.075682 Island 
14 62161964 0.007 0.009 0.002 0.198307 0.35693 Island 
14 62162064 0.011 0.013 0.002 0.834167 0.89724 Island 
14 62162178 0.009 0.011 0.002 0.061346 0.169453 Island 
14 62162214 0.038 0.037 -0.001 0.173315 0.326743 Island 
14 62162460 0.043 0.04 -0.003 0.007494 0.054124 Island 
*ǻȕ  (case-control): Difference in median methylation between control and case groups 
**cond_glm-p: Conditional linear regression p-value for differential methylation between cases and 
controls 
***(fdr): FRD-corrected p-values 
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R script 
 Reading in and sub-setting data 
#The data frame is called dat# 
dat<-read.table("table.txt", header=TRUE, sep='\t') 
 
#to retrieve basic summary statistics, including mean, median, interquartile range, min and max, for a linear 
variable e.g age# 
summary(dat$age) 
 
#Standard deviation for age# 
sd(dat$age) 
 
#to retrieve numbers within each group for a categorical variable e.g. case_control status# 
summary(dat$case_control) 
 
#making index for categorical data i.e. subsetting data (e.g. case-control status)# 
case<-which(dat$case_control==1) 
control<-which(dat$case_control==0) 
 
#Subsetting data groups based on multiple criteria (e.g. case_control & fasting_status)# 
dat$groups[dat$case_control==0 & dat$fasting_status==0]=1 
dat$groups[dat$case_control==0 & dat$fasting_status==1]=2 
dat$groups[dat$case_control==1 & dat$fasting_status==0]=1 
dat$groups[dat$case_control==1 & dat$fasting_status==1]=2 
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#To make this a factor (column in dat)# 
dat$groups<-as.factor(dat$groups) 
 
#Splitting data for a continious variable into quantiles (in this case quintiles of age)# 
#package gregmisc# 
age_quintiles<-quantcut(dat$age, q=c(0, 1/5, 2/5, 3/5, 4/5,5/5), na.rm=TRUE) 
#To look at these quantiles# 
summary(age_quintiles) 
 
#To change which quantile is used as the reference quantile, e.g. the highest quintile (75,102)# 
age_quintiles<- relevel(age_quintiles, "(75,102]") 
 
#To make z-scores (for example, for methylation)# 
#Z score=(x-mean)/sd 
#first calculate mean and standard deviation of methylation for the population# 
mean(dat$methylation, na.rm=TRUE) 
sd(dat$methylation, na.rm=TRUE) 
#then make a column of z-scores (z) by applying (x-mean)/sd to the methylation data# 
dat$z<-(dat$methylation/(mean(dat$methylation))/(sd(dat$methylation)) 
 
Statistical tests 
#student's T-test (example association of age (exposure) with methylation (outcome). Default is unmatched, 2-
tailed T-test#  
t.test(dat$methylation~dat$age)  
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#Wilcoxon rank sum test for same variables# 
wilcox.test(dat$methylation~dat$age) 
 
#when I want to test an association within a sample subset e.g. controls# 
wilcox.test(dat$methylation[control]~dat$age[control]) 
 
#To test for significant differences in DNA methylation between different genotypes (in this case MTHFR 
genotype 'GG' vs. combined 'CG' and 'CC' genotypes# 
#first make factor# 
dat$MTHFR[dat$MTHFR_genotype!="GG"]=0 
dat$MTHFR[dat$MTHFR_genotype=="GG"]=1 
dat$MTHFR<-as.factor(dat$MTHFR) 
wilcox.test(dat$methylation~dat$MTHFR) 
 
#Chi-squared test (example association of age (exposure) with methylation (outcome))# 
chisq.test(table(dat$age,dat$methylation)) 
 
#ANOVA to test for difference in within group log(DNA methylation) variability between categories (e.g. 
case_control groups)# 
summary(aov(log(dat$methylation)~dat$case_control , data=dat)) 
 
#To find spearman correlation r-squared and p-value for two continious variables (paired samples), e.g. 
correlation between methylation and time to diagnosis for each sample [cases]#  
cor.test(dat$methylation[case],dat$TTD[case], method=c("spearman")) 
 
#linear regression model with two linear variables (e.g. age (exposure) and methylation (outcome)# 
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#First see if data is normally distributed for each variable by plotting histograms# 
hist(dat$methylation) 
#If not, log data, and again use historgram to see if data is more normally distributed# 
dat$log_methylation<-log(dat$methylation) 
Methage<-glm(dat$log_methylation~dat$age)) 
summary(methage) 
 
#To adjust for other variables such as case-control status and smoking status and for interactions between 
these# 
Methage_adjusted<-glm(dat$log_methylation~dat$age + dat$case_control + dat$smoking_status + 
dat$case_control*dat$smoking_status)) 
 
#Logistic regression with categorical variables, e.g. DNA methylation quartiles (outcome) and case_control status 
(exposure)# 
#first make methylation quartiles (package gregmisc)# 
meth_quartiles<-quantcut(dat$methylation, q=c(0, 1/4, 2/4, 3/4, 4/4), na.rm=TRUE) 
then run model 
summary(glm(meth_quartiles~dat$case_control)) 
#To get odds ratio for each quartile, exponentiate the estimates# 
exp(estimate) 
 
#conditional logistic regression using a matching variable (indicating which samples represent matched pairs) 
(survival package)# 
#This time treating methylation as the exposure and case_control status as the outcome# 
summary(clogit(dat$case_control~dat$methylation+strata(dat$matching_variable))) 
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plotting 
#boxplot e.g. methylation stratified by case_control status# 
boxplot(dat$methylation~dat$case_control) 
#or# 
boxplot(dat$meth[case],dat$meth[control])#Usually used if multiple boxes are required# 
 
#Strip-chart(e.g.methylation stratified by case_control status) with jitter distribution and vertical strips)# 
stripchart(dat$methylation~dat$case_control, vertical=T, method='jitter') 
 
#scatterplot for methylation vs. age, with line of best fit# 
#first make a line of best fit for methylation vs. age#  
line<-lm(dat$methylation~dat$age) 
#Make plot with labels# 
plot(dat$methlation~dat$age, ylab="methylation", xlab="age", main="methylation Vs. age", cex.axis=1.5, 
cex.lab=1.5, cex.main=1.5) 
abline(line, col="red") 
#Add text at position 110,5# 
text(110,5,labels="rsq=-0.2, p=0.026") 
 
Meta-analyses 
#make a data frame (meta) including study names, estimates (e.g. OR), standard error for the estimates and 
sample n# 
#To conduct a meta_analysis with random effects model, weighted by study size (n) (package rmeta)# 
meta_analysis=meta.summaries(meta$OR,meta$SE,method="random",names=meta$study, weights=meta$n) 
#To plot this model as a forset plot with title, adjusted axis label sizes and a vertical line at 0# 
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plot(meta_analysis, main="meta-analysis", cex.lab=1.5, cex.axis=1.5) 
abline(v=1) 
 
450k array analysis  
#Reading in 450k array data# 
mval<-read.table('M_values.txt', header=T, sep='\t') 
annot<-read.table('annotation_file.txt', header=T, sep='\t') 
pd2<-read.table('patient_information.txt', header=T, sep='\t') 
 
mval<-as.matrix(mval) 
annotmat<-as.matrix(annot) 
pd2<-as.data.frame(pd2) 
fasting=as.factor(pd2$fasting) 
 
#logistic regression model to identify loci associated with fasting or case-control status# 
#function code (provided by Dr. Charlotte Wilhelm-Benartzi) 
ggGLMByLocus <- function(ExData,model,LList=NULL,family=gaussian(),data=NULL,...){ 
if(is.null(data)) Xframe <- model.frame(model,na.action = na.pass) 
else Xframe <- model.frame(model,data=data,na.action = na.pass) 
#Xmiss <- apply(is.na(as.matrix(Xframe)),1,any) 
X <- model.matrix(model,data=Xframe) 
#ExData <- ExData[!Xmiss,] 
 
  if(is.null(LList)) { 
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  LList <- list(matrix(0,nrow=1,ncol=dim(X)[2])) 
  LList[[1]][2] <- 1 
 names(LList) <- colnames(X)[2] 
 } 
 nLoci <- dim(ExData)[2] 
 nLmat <- length(LList) 
 PVAL <- COEF <- matrix(NA,nLmat,nLoci) 
rownames(PVAL) <- rownames(COEF) <- names(LList) 
colnames(PVAL) <- colnames(COEF) <- colnames(ExData) 
for(j in 1:nLoci){ 
fit <- glm(ExData[,j]~X-1, family=family) 
for(l in 1:nLmat){ 
stat <- LList[[l]] %*% fit$coef 
if(length(stat)==1) COEF[l,j] <- stat 
else COEF[l,j] <- sum(stat*stat) 
V <- LList[[l]] %*% vcov(fit) %*% t(LList[[l]]) 
xstat <- t(stat) %*% solve(V, stat) 
PVAL[l,j] <- 1-pchisq(xstat,dim(LList[[l]])[1]) 
} 
}  
out <- list(coef=COEF, pv=PVAL) 
class(out) <- "ggGLMByLocus" 
out 
} 
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#Running model. Output is a matrix consisting of two columns including logistic regression estimates and p-
values for association of DNA methylation at all 450k probes with a categorical variable with two levels (in this 
case fasting –status)# 
glm_B2ck<- ggGLMByLocus(mval,~fasting) 
 
#converting list of coefficients and p-values for each probe to a data frame# 
coefficient=glm_B2ck$coef 
pval=glm_B2ck$pv 
coef<-as.vector(coefficient) 
pval<-as.vector(pval) 
results=cbind(coef,pval) 
rownames(results)=rownames(mval) 
 
#Making volcano plots where -log10 (p-value) is on Y axis, and estimate is on the X axis#plot(coef, -
log10(pvals),main="Volcano plot 450K data Breast II by significant p values",xlab="Linear model coefficient for 
Fasting status effect on methylation", ylab="-Log P value") 
#Adding FDR-corrected p-value (q) column to 'results' data frame (model estimates and p-values for each locus)# 
results$q=p.adjust(results$pval,method="fdr") 
#restricting hits to those with q-value <0.01# 
hits<-which(results$q<0.01) 
resultstop=results[hits,] 
 
#Sorting results on q-value (from smallest to largest)# 
hits_sort<-results[order(results$q),] 
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#Merging hits_sort  file with annotation file for array# 
annothits<-merge(annot,hits_sort, by="row.names") 
write.table(annothits3, file = "annothits.txt", sep="\t")     
 
#Making median non-fasting and fasting values, and delta beta values for all significant hits#  
non_fasting<-which(pd2$fasting==0) 
fasting<-which(pd2$fasting==1) 
med_non_fasting<-apply(bval[non_fasting],1,median,na.rm=T) 
med_fasting<-apply(bval[fasting],1,median,na.rm=T) 
nonfast<-as.matrix(med_non_fasting) 
fast2<-as.matrix(med_fasting) 
fast<-data.frame(nonfast,fast2, Row.names=rownames(nonfast)) 
annothitsck<-merge(annothits,fast, by="Row.names") 
fast$diff<-(fast$nonfast-fast$fast2) 
 
#Adding data from Price et al re-annotation file# 
reannot<-read.table("Price_450k_Reannotation.txt", sep="\t", header=TRUE) 
row.names(reannot)<-reannot$ID 
 
#Making large data frame with all data# 
methdiffs<-cbind(results, medianunfast4, medianfast4) 
methdiffs$diff<-methdiffs$medianunfast4-methdiffs$medianunfast4) 
row.names(reannot)<-reannot$ID 
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methdiffsreannot<-merge(methdiffs, reannot, by="row.names") 
methresults_annot<-merge(annot,methdiffs, by="row.names") 
meth_annot_reannot<-merge(methresults_annot,reannot, by="Row.names") 
methresults_sort<-meth_annot_reannot2[order(meth_annot_reannot2$q),] 
save(methresults_sort,file="methresults_070513.Rdata") 
 
##Restricting methresults_sort to q<0.05## 
hits2<-which(methresults_sort$q<0.05) 
methHITS<-methresults_sort[hits2,] 
write.table(methHITS, file = "methHITS.txt", sep="\t") 
 
#volcano plot for figure 4.12# 
plot(methHITS$diff1,-log(methHITS$q), main="450k loci significantly associated with fasting status", ylab="-log(q-
val)", xlab="methylation difference (fasting-non-fasting)") 
abline(v=0) 
abline(v=0.5,lty=2) 
abline(v=0.05,lty=2) 
abline(v=-0.05,lty=2) 
 
#screening out polymorphic CpG sites# 
xx<-which(methHITS$Target.CpG.SNP=="") 
methhitsxx<-methHITS[xx,] 
 
#making data-frame restricted to loci with median beta-value different >5 between fasting and non-fasting 
groups# 
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greatersdiff<-which(methresults_sort$diff1>0.05) 
b2diff<-methresults_sort[greatersdiffb2,] 
 
#Writing this to a table# 
write.table(b2diff, file = "b2diff.txt", sep="\t") 
 
#Finding p-value for Wilcoxon rank sum test for fasting analysis for all loci## 
FAST<-which(pd2$fasting==1) 
NONFAST<-which(pd2$fasting==0) 
 
#Applying Wilcoxon rank sum test across all probes on array to find probes significantly differentially methylated 
by fasting status# 
wilc<-rep(NA, nrow(mval)) 
for(i in 1:nrow(mval)) 
{ 
wilc[i]<-wilcox.test(bvalb3[i,FAST],bvalb3[i,NONFAST])$p.value 
} 
 
#FDR adjusting Wilcox p-values# 
wilc_fdr<-p.adjust(wilc, method="fdr") 
fdr_hits<-which(wilc_fdr<0.05) 
FDR_HITS<-wilc[fdr_hits,] 
 
#Make data frame with new hits (wilcoxon rank sum test) merged with annotation and re-annotation files# 
fdr_hits_annot<-merge(annot,fdr_hits, reannot, by="row.names") 
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#Removing polymorphic CpG sites# 
fdr_hits_annot$noSNP[fdr_hits_annot$Target.CpG.SNP==""]=0 
fdr_hits_annot$noSNP[fdr_hits_annot$Target.CpG.SNP!=""]=1 
fdr_hits_annot$noSNP<-as.factor(fdr_hits_annot$noSNP) 
nosingnucpol<-which(fdr_hits_annot$noSNP==0) 
br2c2b1_hits_noSNP<-fdr_hits_annot[nosingnucpol,] 
br2c2b1_hits_noSNP$unique[br2c2b1_hits_noSNP$AlleleA_Hits!=1]=0 
br2c2b1_hits_noSNP$unique[br2c2b1_hits_noSNP$AlleleA_Hits==1]=1 
promisc<-which(br2c2b1_hits_noSNP$unique==0) 
uni<-which(br2c2b1_hits_noSNP$unique==1) 
br2c2b1_hits<-br2c2b1_hits_noSNP[uni,] 
 
#Volcano plot for these hits# 
plot(br2c2b1_hits$diffbreast2C2, -log10(br2c2b1_hits$breast2C2_fdr), col=br2c2b1_hits$noSNP,main="450K 
methylation diff by significant p values",xlab="methylation difference", ylab="-Log10 P value") 
 
#Writing to a data frame# 
write.table(br2c2b1_hits, file = "br2c2b1_hits.txt", sep="\t") 
#plotting difference in methylation between fasting and non-fasting against gene locus for an individual gene (e.g. 
LGR6) (fig 4.15)# 
 
#First make index for gene  
LGR6<-which(annot$UCSC_RefGene_Name=="LGR6") 
png(file="LGR6.png",  width=960,height=480) 
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plot(annot$MAPINFO[LGR6], as.numeric(br2c2b1_hits $med_non_fasting[LGR6])-as.numeric(br2c2b1_hits 
$med_fasting[LGR6])) 
title("Plot Delta Beta Value- LGR6 by location") 
dev.off() 
 
 
 
 
 
 
